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General Introduction and Outline  
of the Thesis
12 CHAPTER 1
TYPES OF LEFT VALVULAR HEART DISEASE 
Prevalence and 
spectrum of the 
disease
  Left-sided significant valvular heart disease is a fast growing worldwide 
problem that expands proportionally to the increment of the life expectancy 
of the population and its prevalence is expected to double by 2050.1 In a large-
scale community screening cohort study that enrolled 2500 participants aged 
≥65 years, the prevalence of moderate or severe valvular heart disease was 
11.3%.1 According to the Euro-Heart survey II on valvular heart disease, aortic 
stenosis (AS) and mitral regurgitation (MR) are the two most common types 
of valvular heart disease in adults.2 Among those who suffer from moderate 
or severe valvular disease, AS is the most common cause with a prevalence 
of 41.2% followed by MR with a prevalence of 21.3%.2 The aetiology of the 
native valve disease is mainly degenerative in AS for about 90% of cases and 
in primary MR for about 60% of cases based on the recently reported Euro-
Heart survey II.2 However, 33% of the MR is categorized as secondary and 
51.6% of the secondary, as ischemic in origin.2  Degeneration as a cause of 
valvular heart disease is highly indicative of its association with the ageing 
of the population; as age increases from 55 to 75 year-old, the prevalence 
of AS and MR rises from 2% to 6% and 9% respectively.3 In a cohort with 
significant AS, patients older than70 years were 56% and the nonagenarians 
were 38%, whereas among patients with MR the prevalences were 44% and 
17%, respectively.4 Furthermore, in patients with multiple left-sided valvular 
heart disease, 33% were older than 80 years. 
Challenges  
in diagnosis
  Although it has been well established that left-sided valvular heart disease 
is a problem increasing with age, it is still underdiagnosed in about 10% of 
patients 75-84 year-old and 20% of patients aged ≥85 years.1 Thus there 
is an unmet need for accurate and timely diagnosis of the disease, so that 
appropriate treatment can be applied.
Aortic stenosis   AS is associated with adverse outcomes when there is imbalance between left 
ventricular hemodynamic load – mainly due to aortic valve obstruction and 
secondary due to increased arterial pressure- and left ventricular capacity to 
overcome the increased load.5 This pathophysiological imbalance in AS leads 
to left ventricular hypertrophy, concentric remodeling, myocardial fibrosis 
and heart failure.6 Hence, in a comprehensive approach of AS, apart from the 
aortic valve assessment (which is the cornerstone of the assessment), the 
afterload and the left ventricle have to be evaluated to define the disease 
severity and prognosis (Figure 1). 
AS is considered severe when the peak aortic jet velocity (Vmax) is ≥4m/s, 
mean pressure gradient (MPG) ≥40mmHg, aortic valve area (AVA) <1cm2 
and AVA index <0.6cm2/m2 assessed on echocardiography.7, 8 However the 
AVA and AVA index have to be evaluated because Vmax and MPG are flow 
dependent and in case of a high-flow condition such as anaemia, infection, 
hyperthyroidism, arteriovenous shunt they may overestimate severity.8 
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About 40% of patients with severe AS have low-gradient stenosis which 
has been recently endorsed by the guidelines as severe under specific 
circumstances.9 This type of AS, also called “discordant grading” (having 
Vmax<4m/s, MPG<40mmHg and concomitantly AVA <1cm2 and AVA 
index<0.6cm2/m2), is divided into three subgroups based on the forward 
flow and the left ventricular ejection fraction (LVEF): 1. Low-flow, low-
gradient with low ejection fraction <50% (classical low-flow low gradient), 
2. Low-flow, low-gradient with preserved ejection fraction (paradoxical low-
gradient) and 3.  Normal-flow, low-gradient.9-11 Flow is defined as low when 
the forward stroke volume index assessed by Doppler echocardiography 
is <35ml/m2.8 The classical low-gradient type is pathophysiologically 
attributed to low forward flow due to reduced LVEF.12 The paradoxical 
low-gradient type is attributed to low-flow due to pronounced concentric 
remodeling and small left ventricular cavity, to diastolic dysfunction, to atrial 
fibrillation, to increased afterload, to MR or mitral stenosis and to tricuspid 
regurgitation.13, 14 Among these low-gradient cases, about 30-70% are 
proven to be true severe stenosis after double-checking for possible Doppler 
echocardiography pitfalls underestimating the gradients or undersizing 
the left ventricular outflow tract area, after using stress echocardiography, 
Figure 1. Severe aortic stenosis is a disease of the valve that affects the myocardium and the 
symptoms begin when left ventricular capacity fails to overcome the imposed afterload by the 
valve and the aorta. Thus for a comprehensive evaluation of AS all three parts involved have to be 
evaluated: 1. The Valve: by aortic valve area (AVA), AVA index to body surface area (AVAi), mean 
pressure gradient (MPG), maximum velocity through the valve (Vmax), energy loss index (ELI), AVA 
planimetry on 3-dimentional (3D) imaging such as 3D echo and cardiac computed tomography, 
AVA and MPG on low-dose dobutamine stress echo in classical low-gradient AS and AVA projected 
at normal flow in paradoxical low-gradient AS, aortic valve calcium load in Agatston units on 
cardiac multidetector computed tomography (MDCT), fusion AVA by combining in the continuity 
equation Doppler haemodynamics with left ventricular outflow tract (LVOT) planimetry area on 
MDCT. 2. The Left Ventricle: remodeling by evaluating the size, the relative wall thickness (RWT) and 
the mass, function by evaluating the left ventricular ejection fraction (LVEF), the global longitudinal 
strain (GLS) as an estimation of intrinsic myocardial function and the forward stroke volume index 
(SVi), myocardiac fibrosis evaluated directly by late gadolinium enhancement (LGE) in cardiac 
magnetic resonance imaging (MRI) and indirectly by GLS with the echocardiographic method of 
speckle tracking. 3. The Afterload:  by measuring the blood pressure (systolic arterial pressure (SAP)/ 
diastolic arterial pressure) and estimating the global afterload with the valvuloarterial impedance 
(Zva) by the equation Zva = (SAP+MPG)/SVi. 
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advanced echo techniques or multidetector computed tomography (MDCT) 
cardiac analysis.10, 11  
Patients with high-gradient severe AS or with low-gradient AS proved to 
be severe, if (i) symptomatic with clinically relevant symptoms and (ii) really 
asymptomatic but with reduced LVEF <50% or aortic Vmax >5.5m/s or Vmax 
increase rate ≥0.3m/s/year, benefit from surgical or transcatheter aortic valve 
replacement (AVR).8, 10, 15, 16  Recently a study of 1678 asymptomatic patients 
with severe AS and preserved LVEF suggested that even patients with LVEF 
<55% benefit from AVR.17 The treatment modality, (transcatheter or surgical) 
is defined by the Heart Team taking into consideration the surgical risk 
(Euroscore II >4% or log Euroscore >10%), patient’s frailty, the type of stenosis 
(low-flow, low-gradient), left ventricular flow and systolic reserve (absence 
of reserve on dobutamine stress echocardiography) and other anatomical 
aspects (porcelain aorta on MDCT).8, 10 For the low-flow, low-gradient severe 
AS patients the preferred treatment option is the transcatheter approach, 
taking under consideration that these patients have small LV cavity and 
small annulus and many co-morbidities; in the case of low LVEF the preferred 
access site is the transfemoral.10
Defining the time and type of treatment in AS is mainly designated by the 
accurate diagnosis of AS type and severity, thus multimodality imaging is the 
cornerstone for the diagnosis and treatment.
Challenges  
in diagnosis
  Mitral regurgitation
MR is the second most common valvular heart disease according to EuroHeart 
Survey II leading to impaired quality of life and increased mortality.2 The 
mitral valve has a complex anatomy that includes the mitral annulus, the 
leaflets, the chorda (primary and secondary), the papillary muscles and the 
left ventricle.18 The proper diagnosis of regurgitation involves thorough 
assessment of all parts of the valvular apparatus. The quantification of the 
disease severity and the clarification of the regurgitant mechanism are 
mandatory to guide personalised patient care.19
MR moderate or severe (the trivial or mild is not further assessed) is classified 
as primary, secondary and mixed: 1. In primary type, the aetiology is the 
abnormal leaflet morphology (also called organic) associated with (i) normal 
leaflet motion (like in leaflet perforation, in endocarditis, in cleft), (ii) increased 
leaflet motion (leaflet prolapse or flail) or (iii) decreased leaflet motion in 
systole and diastole (restriction due to calcification or rheumatic valve). 2. 
In secondary type (also called functional), the leaflet morphology is normal 
(trivial leaflet thickening age-related is accepted) and the MR is attributed to 
pathology of the other parts of the apparatus, (i) with normal leaflet motion 
due to left atrial remodeling leading to mitral annulus dilatation (e.g. in atrial 
fibrillation) and (ii) with restricted leaflet motion only in systole due to left 
ventricular remodeling, ischemic or not, leading to papillary muscle apical 
dislocation and leaflet tethering (e.g. after myocardial infarction, dilated 
cardiomyopathy). 3. In mixed type, there is abnormal leaflet morphology, 
combined with left atrial or ventricular remodeling (e.g. hypertrophic 
obstructive cardiomyopathy, MR secondary to myocardial infarction and flail 
leaflet due to chorda rupture).18-20 
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Apart from the three types of MR described above, there is another 
classification proposed by Carpentier based merely on the leaflet motion 
that allows better communication between cardiologists and surgeons: Type 
I with normal leaflet motion, Type II with increased leaflet motion (prolapse 
or flail), Type IIIa with restricted leaflet motion in systole and diastole and 
Type IIIb with restricted leaflet motion only in systole.18 The three types of MR 
endorsing the Carpentier classification are presented in Figure 2.   
The impact of severe MR on survival is detrimental for all the disease types.20 
The treatment applied depends on the type of the MR.8 In the case of primary 
MR if the patient is symptomatic the best treatment option is surgical 
mitral valve repair. If the patient is asymptomatic the decision for mitral 
valve repair relies on the left ventricular function (LVEF ≤60%), size (LVESD 
≥45mm), the presence of new onset atrial fibrillation, elevated pulmonary 
pressures (>50mmHg), flail leaflet or severely dilated left atrium (≥60ml/m2) 
in the presence of dilated left ventricle (LVESD >40mm).8 The patients with 
secondary MR have worse survival than those with primary MR. However, 
the patients with secondary MR due to left atrial remodeling have better 
survival and lower incidence of heart failure compared to secondary MR 
due to left ventricular remodeling.20 For the former, the optimal treatment 
is usually surgical restrictive annuloplasty.21 Patients with secondary MR due 
to left ventricular remodeling have usually significantly dilated left ventricle 
and impaired LVEF, and if they are on optimal medical treatment for heart 
failure including cardiac resynchronisation, if indicated, the decision to 
operate is ambiguous, considering the lack of robust data demonstrating a 
survival benefit for surgery compared to medical management.22, 23 Losartan 
has been recommended as an option for secondary MR after myocardial 
infarction because it allows the adaptive leaflet growth and modulates their 
profibrotic changes.24 Cardiac resynchronization therapy is indicated not 
only for left ventricular functional improvement but it has been suggested to 
reduce functional ventricular MR by at least 1 grade.25 If the patient remains 
Figure 2. Mitral valve regurgitation classification based primarily on leaflet morphology (normal 
/ abnormal) and secondary on leaflet motion (normal / increased / restricted) and their matching 
with Carpentier classification for surgical use.
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symptomatic under medical treatment and resynchronisation, surgical repair 
has an indication IIb unless concomitant revascularization can be offered 
upgrading the indication to IIa, according to guidelines.8 
A community cohort study demonstrated that the patients with severe MR 
treated surgically are only few; 37% of those with primary MR and 7% of 
those with secondary MR.20 Thus there is an unmet need for new treatments 
of MR. The percutaneous mitral valve edge-to-edge repair with the MitraClip 
implantation has arisen as an alternative option. For the primary MR patients, 
MitraClip has been proven in a randomised trial (EVEREST II) to be a safe 
and effective alternative to surgical repair, with comparable outcomes.26 
Real world studies that followed the initial randomised trial, suggested in 
line that the short and long term clinical events and survival post MitraClip 
or surgery are comparable in-between and better than optimal medical 
treatment alone (including resynchronization).27, 28 However, these studies 
included mainly secondary MR population.27, 28 Randomised trials for patients 
with secondary MR and reduced systolic function have been performed with 
conflicting conclusions. MITRA-FR trial suggested no survival benefit and 
no reduction in heart failure related hospitalisations between MitraClip and 
medical treatment alone at 1-year follow-up.29 On the contrary, the COAPT 
trial demonstrated lower mortality and heart failure related hospitalizations 
at 2-years follow-up for the MitraClip group.30 Although the two trials 
included patients with secondary MR, the COAPT included patients with more 
severe MR and MITRA-FR with more diseased left ventricle with reference to 
its dilation and function which could be a reasonable explanation for the 
opposing results.31 Thus, is reasonable to perform MitraClip in symptomatic 
patients on optimal medical treatment who have severe MR (EROA >30mm2 
and/or regurgitant volume >45ml) and LVEF 20-50% with left ventricular 





  AS and MR are the 2 most common left heart valvulopathies and they may 
co-exist in about 20% of patients with severe AS.32 The two valvulopathies 
are interrelated to a different extent according to their type. From the 
cardiac pathophysiology perspective, severe AS is leading to left ventricular 
remodeling that may cause papillary muscles traction and displacement 
and leaflet tethering leading to secondary MR. Additionally, it increases left 
ventricular systolic pressure, leading to increased ventricular-atrial gradient, 
worsening all types of MR and dilates the left atrium, through diastolic 
dysfunction, leading to secondary MR (left atrial remodeling).33, 34 On the 
contrary, MR reduces the forward flow, by driving blood backwards to low-
pressure left atrium and by increasing the prevalence of atrial fibrillation, 
modifying AS to low-flow, low-gradient.33, 34  Thus, coinciding MR may be the 
reason of underestimation of AS and AS may be the reason of worsening MR 
especially if secondary. Hence, the type of each valvular disease is indicative 
of their interdependence, which is of paramount importance for the decision 
making of their treatment. It has been demonstrated that the double 
operation on both valves is high risk with 5-12.5% in-hospital mortality.35 To 
avoid this, the guidelines suggest that surgical intervention on mitral valve is 
in general not necessary and that secondary MR usually improves post AVR.8 
If the MR is secondary, after AVR the effective regurgitant orifice area and the 
regurgitant volume are reduced significantly more than in primary MR and 
17VASILEIOS KAMPERIDIS
at the same time left ventricular reverse remodeling with greater volume 
reduction occurs.36 Apart from the secondary type of MR, other parameters 
associated with MR reduction post AVR alone are: absence of mitral annular 
calcification, high gradient AS, dilated left ventricle (left ventricular end-
diastolic diameter ≥50mm, left ventricular end-systolic diameter ≥36mm), 
absence of atrial fibrillation, absence of pulmonary hypertension and 
successful AVR without aortic regurgitation and with left ventricular pressure 
reduction, especially if a balloon expandable transcatheter valve is implanted 
without prosthesis-patient mismatch.36-38  The reduced MR post-isolated 
TAVR, but not after surgical AVR, has a positive impact on survival compared 
with the stable or increased MR.39, 40 However, the decision of operating on 
mitral valve has to be taken without the a priori knowledge of the possible MR 
reduction. Although there are plenty of survival data regarding the impact of 
untreated significant MR on patients’ survival post AVR, they are controversial. 
Whereas isolated surgical AVR or TAVR is performed some studies support 
that untreated MR impacts on the survival and others not.37, 38, 41 It is of note 
that in low-gradient AS the prevalence of MR is higher compared to high-
gradient AS, the presence of significant MR has deleterious impact on survival 
and TAVR treatment improves survival compared with medical treatment 
alone.42 The final treatment decision, keeping in mind the interrelation of the 
valvular diseases and after a comprehensive evaluation of the AS and MR 
severity, depends on the type of the mitral valve disease: In primary MR with 
major anatomic lesions it is highly unlikely to experience MR reduction post 
AVR. Thus in low/intermediate risk patients, surgical replacement is proposed 
and in intermediate/high risk patients TAVR followed by transcatheter or 
minimally invasive surgical mitral repair. In secondary MR, isolated AVR is 
suggested, surgical AVR or TAVR according to Heart team, trying to avoid 
prosthesis-patient mismatch which is usually achieved in TAVR.37, 38    
MULTIMODALITY IMAGING for the DIAGNOSIS of AORTIC and MITRAL 
VALVE PATHOLOGY
Role of advanced 
echocardiography
  Aortic Stenosis
AS diagnosis is based mainly on echocardiography. Classically, 2-dimensional 
echocardiography and Doppler are used in every-day clinical practice to 
assess the severity of AS. Nowadays, with the endorsement of low-gradient 
stenosis in the spectrum of severe the classical measurements of aortic Vmax, 
MPG and AVA have to be done even more accurately and have been fortified 
by new parameters applying cutting-edge echocardiography techniques.
The Vmax and the MPG measured with continuous wave Doppler have to be 
estimated from the cardiac apex and additionally from the right parasternal 
side with a stand-alone probe and from subcostal and suprasternal site, 
wherever the Doppler beam is in line with the blood flow, to ensure that 
the highest possible Vmax and MPG is obtained, avoiding underestimation 
of the stenosis or pseudo-low-gradient stenosis.43  The acceleration time of 
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this signal is then measured AT>110msec and its ratio over ejection time 
AT/ET >0.36 are indicative of severe AS.9 The pulsed wave Doppler signal 
at the left ventricular outflow tract has to be representative of laminar flow 
and should be traced after reducing the gain and increasing the reject of 
the echocardiography device. Afterwards the Doppler velocity index can be 
estimated from the equation DVI=VTI LVOT / VTI aortic, <0.25 is indicative 
of severe stenosis.9 All the aforementioned measurements of transvalvular 
gradient have to be performed after normalization of the blood pressure, 
because arterial hypertension may lead to underestimation of the gradient, 
thus in a pseudo-low-gradient.44 The left ventricular outflow tract diameter 
has to be measured at the parasternal long axis at the hinge points or just 
below in mid-systole avoiding the presence of valve calcium. The area is then 
estimated from the equation 0.785xdiameter2 assuming that it is circular. 
However, it has been well demonstrated that LVOT is oval in shape. Thus it 
is more accurate to evaluate it by direct planimetry at 3-dimentional echo 
where the real short axis of the LVOT can be seen en-face and measured.45 This 
measurement is more accurate when transoesophageal echo is performed. 
The stroke volume is then estimated from the equation LVOT area x VTI LVOT. 
After indexing to BSA the flow state can be defined based on the SVi. AVA is 
estimated from the continuity equation (the flow that goes through LVOT 
in 1 beat is the same with the flow through aortic valve in 1 beat, preferably 
measured at stable heart rate) using all the measurements described above. 
This area corresponds to the effective orifice area, which is the area of the vena 
contracta of the forward flow jet, i.e. the narrowest area of the jet.  However, 
AVA can be measured with direct planimetry of the valve opening in a short 
axis view or more accurately at a 3D transoesophgeal short axis view tracing 
at the tips of the cusps, evaluating the anatomic valve area which is usually 
bigger, estimating the area at the tips of the cusps and not downstream at 
the narrowest point of the forward flow.46  In the case of a small aorta with 
diameter <3cm the AVA with continuity may overestimate the severity of 
the stenosis because it doesn’t account for the pressure recovery.47 For such 
patients the energy loss index = [(AVAxAortaArea)/(AortaArea-AVA)]/BSA 
is a better measure of the stenosis severity as it estimates the net pressure 
imposed to left ventricle after the kinetic energy partly convers to static. 
This pressure is comparable to the pressure measured with the wire in the 
catheterization laboratory and for this reason energy loss index improved 
the prediction of events due to AS compared to AVA.48 
Stress echocardiography is a modality applied in AS for severity assessment 
in low-gradient patients and for risk stratification in asymptomatic patients.49 
Low dose (till 20mg/Kg/min) dobutamine stress echo is performed in 
low-gradient patients with reduced ejection fraction for the assessment 
of severity and risk stratification.8 If during the test the MPG increases 
>40mmHg and AVA remains <1cm2 the test is indicative of severe stenosis, 
if the MPG remains <40mmHg and AVA increases >1cm2 the stenosis is 
moderate (pseudo-severe) and if MPG remains <40mmHg and AVA remains 
<1cm2 the test is inconclusive so far, due to lack of flow reserve and the next 
step is to calculate the AVA projected at normal flow conditions (250ml/
min), if the flow increases by 20%, and if AVA projects <1cm2 the stenosis is 
severe.50-52 A recent study suggests that AVA projected is the best parameter 
to clarify severity in dobutamine stress echo.53 The presence of flow reserve 
during the test, i.e. increase of the stroke volume >20%, is considered a sign 
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of good prognosis.52 However, even patients without flow reserve are doing 
better after surgical replacement compared to medical treatment and more 
recently after transcatheter replacement the survival was comparable in 
between the 2 groups of flow reserve.54-56 It is of note that after TAVR the LVEF 
improves independently of the flow reserve.54, 55 In low-flow, low-gradient 
patients with preserved ejection fraction, the low-dose stress echo has 
restricted application. It has been proposed to be used for the evaluation of 
the AVA projected at normal flow, indicating severe stenosis if AVA <1cm2, 
or AVA index < 0.55cm2/m2.57 In asymptomatic patients exercise stress 
echocardiography may reveal symptoms neglected by the patient or blood 
pressure fall below baseline indicative of bad prognosis urging to AVR besides 
the echocardiography findings.52, 58 An increase of the transaortic MPG by 
>18mmHg, a systolic pulmonary artery pressure >60mmHg or absence of 
contractile reserve during exercise defined as drop or increase less than 
4-5% of the LVEF are indicative of AS related events and valve replacement 
should be considered.52, 58 
 Mitral Regurgitation
Echocardiography is the cornerstone diagnostic method to assess all the 
parts of the mitral valve apparatus (left ventricle, papillary muscles, chorda, 
leaflets and annulus) and to evaluate MR severity and type in order to do 
a comprehensive assessment of MR. Transthoracic echocardiography 
is the first step in this approach for assessing mitral valve pathology on 
grey scale, left ventricular and atrial size and function and then perform 
qualitative and quantitative MR evaluation.59 Normal sized left ventricle and 
left atrium exclude chronic severe MR.59 MR is a dynamic phenomenon and 
as such before echo the heart rate, rhythm and blood pressure have to be 
monitored. In the qualitative assessment the type of MR has to be evaluated 
as described above (Figure 2) and MR jets have to be described by number, 
direction and duration in systole. The quantitative assessment is based on 
the Colour Doppler, continuous wave Doppler and pulsed wave Doppler. 
An area of the regurgitant jet >50% of the left atrium and a vena contracta 
width >7mm are indicative of severe MR.8, 18 Proximal isovelocity surface area 
(PISA) is used for evaluating the effective regurgitant orifice era >0.4cm2, the 
regurgitant volume >60ml, the regurgitant fraction >50% and radius >1cm 
at Nyquist limit 30-40cm/s. These cut-offs are endorsed by the European 
society of Cardiology for primary MR. For secondary MR the lower cut-offs of 
effective regurgitant orifice area >0.2cm2 and regurgitant volume >30ml are 
proposed.8 However, the American Heart Association/ American College of 
Cardiology approve the former cut-offs only for both primary and secondary 
MR.7 Vena contracta and PISA method may overestimate severity based on 
EROA in case of non-holosystolic MR, thus regurgitant volume has to be 
estimated. On the contrary PISA may underestimate severity in case of small 
size patient with small left ventricular cavity.18 The continuous wave Doppler 
used in PISA inform us about the duration of MR in systole and about the peak 
velocity, considering that the beam is aligned with the blood flow, which is 
indicative of the left atrial pressure (the lower the velocity the higher the 
atrial pressure).18 Pulsed wave Doppler should be used for the mitral inflow 
with E wave >1.2m/sec indicative of severe MR and for pulmonary vein signal 
with systolic flow reversal indicative of severe MR.59
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Transoesophageal echocardiography with the use of 3D imaging is necessary 
for better visualization of the complex mitral valve apparatus in case the 
findings on transthoracic are indeterminate or discordant and before 
any intervention, surgical or transcatheter repair. The 3D imaging enables 
the operator to specify the type of valve disease, to identify a leaflet cleft 
or perforation, to name the prolapsing scallop, to check the commissures, 
to apply PISA method more accurately.59 It has been demonstrated that 
3D echocardiography assesses the effective regurgitant orifice area more 
accurately than 2D and is comparable to MRI, by planimetry of the vena 
contracta area, perpendicular to the flow direction at the narrowest position.60 
Subsequently the regurgitant volume is more accurate too.60  Before the 
transcatheter repair with MitraClip, 3D transoesophageal echocardiography 
has to be performed to predict the feasibility of the method. If the segment 
2 prolapses, there is no calcification, the flail gap on 4 or 5 chamber view 
is <10mm, the flail width on short axis is <15mm, the mitral valve area is 
>4cm2 and the transmitral gradient is <4mmHg there is a  high chance of a 
successful MitraClip implantation.59  
Exercise stress echocardiography may be applied in primary MR. In 
asymptomatic patients it may reveal symptoms or systolic pulmonary 
pressure ≥60mmHg for risk stratification. In symptomatic primary MR that 
is at least moderate, an increase of MR severity by ≥1 grade, or systolic 
pulmonary pressure ≥60mmHg are indicative of worse prognosis. Moreover, 
absence of contractile reserve of left ventricle (LVEF increase <5%) or right 
ventricle (TAPSE <18mm) are associated with poor outcome.52, 61 In secondary 
MR, exercise stress echocardiography may predict worse prognosis if an 
increase of the effective regurgitant area by  ≥13mm2 is demonstrated or if 





  Aortic Stenosis
Cardiac computed tomography angiography, including a non-contrast 
acquisition as the first step of an exam, can be used to calculate the 
coronary artery calcium with the Agatston method. This technique has been 
extrapolated to aortic valve calcium. Thus, with a simple acquisition the aortic 
valve calcium can be estimated in arbitrary units.62 The more the calcium 
detected on the valve the more severe the stenosis grade is. This has been 
endorsed by the guidelines with a cut-off >3000AU for men and >1600AU for 
women indicating a high likelihood of severe stenosis.8 Aortic valve calcium 
evaluation is of paramount importance in the discordant low-gradient group 
of patients because it can discriminate severe from moderate stenosis after 
adjustment for the aortic annulus area and for the body surface area in a 
reproducible and personalized way.63 The clinical significance of the aortic 
valve calcium load has been well recognized because it has been associated 
with the mortality of AS patients beyond clinical parameters and Doppler 
echocardiographic criteria.64 
The contrast MDCT has the best spatial resolution among all other imaging 
modalities. Thus its role in evaluating the aortic valve is gradually evolving. 
The aortic valve can be seen “en-face” at a double oblique transverse view 
(the real short axis of the valve) and a complete anatomical analysis can be 
easily done.65 The type of valve, tricuspid or bicuspid, the extent of valve 
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calcification and its exact location (which cusp and where), the length of 
each leaflet, the left, right and non-coronary sinuses diameter and the AVA 
with planimetry can be estimated (of note this is the anatomical area not the 
hemodynamic) in diastole at 75% of the cardiac cycle and in systole at phase 
35%.65, 66 The aortic annulus area and perimeter can be accurately measured 
by planimetry at the real short axis, allowing accurate sizing of the prosthetic 
valve in severe AS patients in order to avoid prosthesis patient mismatch 
and paravalvular regurgitation after the implantation of a transcatheter 
valve.67 Then the aortic root can be evaluated, the diameter of sinotubular 
junction and the distance of the coronaries origin from the annulus in the 
pre-TAVR assessment to avoid obstruction of the coronaries.65, 66 An area 
that always has to be accurately measured for the diagnosis of severe AS 
is the left ventricular outflow tract. It has been demonstrated that this area 
is not circular but oval in shape and thus calculating it by one diameter 
as a circle instead of measuring the area by planimetry on 3-dimentional 
echocardiography imaging leads to overestimation of AS.68  The next step 
evolution is the introduction of the planimetered area on MDCT (Figure 3) in 
the continuity equation.
 Mitral Regurgitation
MDCT has been recently applied to illustrate based on its best spatial 
resolution the complex mitral valve. The quantification of MR by PISA 
method has been described above and the value of 3D imaging for the more 
accurate measurement of effective regurgitant area has been annotated. 
A study including primary and secondary MR proposed the integration of 
real cross-sectional mitral effective regurgitant area measured on the 3D 
volume dataset taken by MDCT in the PISA equation and proved that the 
fusion regurgitant volume estimated significantly reclassified 7/73 patients 
from severe MR according to echocardiography to non-severe MR and 
10/73 from non-severe to severe MR grade.69 Secondary MR due to atrial 
remodeling - type I Carpentier – has been studied and confirmed that 
mitral annulus area and perimeter measured by planimetry on short axis 
were independently associated with significant MR, shading light to the 
pathophysiology of atrial functional MR.70 In primary MR, MDCT can reliably 
detect the prolapsing scallop by cross-referencing long-axis views with 
short-axis views of the various scallops and can evaluate left ventricular and 
left atrial size.71 Moreover, the use of MDCT has been explored for annulus 
evaluation of size and calcifications (extent, location) which is important in 
planning percutaneous mitral prosthesis implantation.72 Another important 
role of MDCT is to predict the left ventricular outflow tract obstruction 
after the implantation of transcatheter prosthesis achieved by 2 means: 1. 
By evaluating the aorto-mitral angle created by the left ventricular outflow 
tract long-axis and the mitral annular trajectory line; the risk of obstruction is 
high at 90o and lowest when the two valves are almost parallel and the angle 
almost 0o. 2. By using the dedicated software created for evaluating the neo-
outflow tract.73 
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Figure 3. Cardiac multidetector 
computed tomography provides 
a 3-dimentional cardiac volume 
and by applying the tri-planar 
orthogonal system in the coronal 
(A) and saggital (B) view at the 
level of left ventricular outflow 
tract (LVOT) ie 5mm below aortic 
annulus, the double-oblique view 
is created (C) where the real LVOT 
short axis can be seen. Then, 
the LVOT area can be accurately 
measured by planimetry of the 
area. 
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  Global longitudinal strain (GLS) derived by speckle tracking 
echocardiography has emerged as an alternative way to assess LVEF. 
This technique is based on detecting and following the movement of 
myocardial speckles in the longitudinal way. Its advantage is that it is 
relatively independent of preload and afterload changes compared to 
LVEF and that it evaluates the intrinsic myocardial function and not on the 
volumetric changes of left ventricle which is the case in LVEF.74, 75 Moreover, 
the changes in pressure and volume loading conditions of the left ventricle 
may cause myocardial diffuse interstitial fibrosis and focal mid-wall fibrosis 
starting from the basal parts of the ventricle in AS or subendocardial 
interstitial fibrosis in MR, which can be indirectly detected by GLS.76, 77 In 
this regard, the clinical value of GLS in valvular heart disease should be 
appreciated.
 Aortic stenosis
AS is a disease of the valve and myocardium. The increased pressure overload 
causes left ventricular hypertrophy with excess mass, relative wall thickness 
increase and concentric hypertrophy. When the left ventricle cannot further 
compensate for the imbalance with the afterload, LVEF deteriorates, the 
haemodynamic consequences of the disease become obvious and symptoms 
become clinically apparent.78 It has been demonstrated that GLS worsens as 
the severity of the valve disease progresses, although LVEF remains stable.79 
GLS has been suggested as a more sensitive marker of subtle myocardial 
dysfunction before the LVEF is reduced and the symptoms appear.79, 80 This 
is of paramount importance as it could lead to AVR before any ischemic, 
systolic and diastolic damage is done to the myocardium and in advance 
of irreversible structural and functional myocardial changes.78, 80 Figure 4 
demonstrates such a case. The guidelines propose for the asymptomatic 
severe AS the cut-off 50% for LVEF as an indication to AVR. However, there 
are studies challenging this cut-off as too low by demonstrating that when 
LVEF is lower than 60% there is a decline to outcome.81, 82 Maybe it is time 
to incorporate in the formal assessment of asymptomatic AS the GLS as 
an expression of early endomyocardial dysfunction irrespective of left 
ventricular remodeling that may preserve the LVEF.78, 80 For such patients 
the GLS >-18% has been suggested for an integrate approach of stenosis 
severity, timely treatment decision and better clinical outcome.78, 83
AS has been categorised according to forward flow and gradient and the 
groups of low-flow low-gradient with reduced (classical) or preserved 
(paradoxical) LVEF have been recognised as severe AS. GLS has a prominent 
role in enlightening the pathophysiology of low-gradient severe AS with 
preserved LVEF. Left ventricular remodeling with thick walls and small cavity 
has a compensatory effect to intrinsic myocardial dysfunction and creates 
a supernormal LVEF, while the GLS is impaired.84 This impaired GLS is an 
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explanation of the low-flow and thus low-gradient condition although LVEF 
remains preserved.14  However, the prognostic value of GLS in these patients 
is not well elucidated. On the contrary for the patients with low-flow, low-
gradient with reduced LVEF, GLS prognostic value has been proven by 
studies from the TOPAS cohort.85 GLS is impaired alongside with LVEF but has 
independent prognostic value measured at rest and stress during the low-
dose dobutamine stress echo that the TOPAS patients undergone.86 Recently, 
the GLS cut-off of >-12% has been suggested to identify patients with lack of 
reverse remodeling after TAVR.87 
GLS not only detects the subtle myocardial changes and defines the 
prognosis in severe AS with high or low gradient; it has also the ability to elicit 
subtle changes in myocardial function post AVR when the pressure overload 
is retracted. After 1.5 years of surgical AVR, GLS improves although LVEF is 
still stable and this is due to afterload reduction rather than mass reduction 
or reverse remodeling.88 After TAVR in AS patients the GLS improved at 1-year 
follow-up and the greatest the improvement the lower the mortality rate.89 
However, there are scarce data about the left ventricular functional recovery 
after TAVR in low-gradient AS.
 Mitral regurgitation
In order to avoid the poor outcome of primary MR it has to be repaired at the 
proper time, which is defined by symptoms or by LVEF and left ventricular 
dilation in asymotomatic patients.8 In severe MR volume overload and 
emptying of the ventricle partly to a low pressure cavity, left atrium, leads 
to increased LVEF, because this is merely volume dependent. Thus LVEF may 
not accurately reflect myocardial performance or may mask myocardial 
dysfunction. Left ventricular GLS in such patients has been independently 
associated with survival after mitral valve repair and GLS <-20% has been 
proposed to define the appropriate timing of surgical repair (Figure 5).90 
Pre-operative GLS has increased prognostic value when added on top of 
the classical proposed by guidelines factors such as age, left atrial size, LVEF, 
atrial fibrillation.91 Thus in primary MR GLS enables early detection of subtle 
myocardial dysfunction designating the optimal surgical timing for better 
outcome. 
 
Figure 4. In an asymptomatic patient with severe aortic stenosis and preserved left ventricular 
ejection fraction (LVEF 76%), the global longitudinal strain GLS evaluated by speckle tracking 
echocardiography is impaired -11.6%, and worse in the basal segments of the left ventricular 
myocardium, indicating endomyocardial dysfunction.
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The clinical and prognostic value of GLS has been scarcely investigated 
in secondary MR. A study of 41 patients with secondary MR, treated with 
MitraClip demonstrated that GLS was the only independent predictor of 
cardiac events at 2-years follow-up. 
Clinical value  
of forward stroke 
volume
 Aortic Stenosis
The forward flow is a parameter of paramount importance in the assessment 
of AS severity. The low-flow defined as stroke volume index ≤35ml/m2 
may be the reason for low-gradient although the AS is severe. Thus, the 
forward stroke volume has been implemented in the guidelines for the 
assessment and categorization of AS.7, 8 The low-flow may be attributed to 
the low LVEF called “classical low-flow” or to the small left ventricular cavity 
due to remodeling or diastolic or intrinsic systolic dysfunction, despite the 
preserved LVEF called “paradoxical low-flow”. If the low-flow is associated 
with high gradient AS, this is indicative of super severe AS, implying that the 
aortic valve opening is so small that the pressure gradient is elevated even 
though the forward flow through the valve is low.14 
The forward stroke volume, having such a prominent role in diagnosis 
and classification of severe AS, has been inevitably studied for its clinical 
consequences. The patients with preserved LVEF and low-flow, low-gradient 
severe AS had worse survival compared with the high-gradient AS patients 
after AVR and when they followed conservative treatment their survival 
was as poor as or even worse than the high-gradient AS patients treated 
medically.92, 93 The normal-flow, low-gradient, preserved LVEF AS patients 
had survival comparable to the moderate AS and better that the low-flow, 
low-gradient.94 However, in another study, the normal-flow low-gradient AS 
patients who were treated medically had comparable outcome with the low-
flow low-gradient AS patients, creating a controversy.15 When all AS patients 
were treated with AVR the 10-year survival was worse for those with low-
flow (low-flow, low-gradient 37±10% and low-flow, high gradient 51±8%) 
and better for those with normal flow (normal-flow low-gradient 61±7% and 
normal-flow, high-gradient 68±4%).16
Patients with low LVEF that leads to low-flow (classical low-flow low-gradient 
AS) are at very high surgical risk. However, these patients if left untreated 
(under medical care without AVR), have poor prognosis and very high 
Figure 5. A case of an asymptomatic patient with primary organic mitral regurgitation due to 
posterior leaflet prolapse and preserved left ventricular ejection fraction (LVEF 78%) who has 
impaired global longitudinal strain by speckle tracking echocardiography (GLS -19.2%). According 
to the impaired GLS that was worse than -20% the patient was considered for surgical mitral valve 
repair.
26 CHAPTER 1
mortality rate.11, 56 On the other hand their survival is significantly improved 
with surgical AVR especially if there is flow-reserve, i.e. stroke volume increase 
by >20%, during the low-dose dobutamine stress echocardiography. 
Otherwise, there is high operative mortality.56 This obstacle of the peri-
operative mortality for those patients has been surpassed nowadays by 
treating them with TAVR; the presence or absence of forward flow reserve 
had no impact on the survival post-TAVR and furthermore, LVEF improved in 
both patient groups.54 
When all AS patients were treated with TAVR the low-flow was an independent 
predictor of poor survival.95, 96 However, the outcome was significantly better 
for the low-flow patients if treated with TAVR, which is the preferred method 
of treatment, compared to medical care alone.95 Even the patients with 
heart failure and low-flow with moderate AS may be considered for TAVR, 
to unload the left ventricle and increase the forward flow, but the answer to 
these triggering thoughts will be given after the completion of the UNLOAD 
trial.97 
In case this low-flow state is not improving after TAVR and remains low at 
discharge, it is indicative of poor outcome.98 
 Mitral Regurgitation
In MR patients LVEF may be increased without corresponding to good left 
ventricular function, because it merely represents a change in total left 
ventricular volume from diastole to systole without taking into consideration 
where the blood goes. In MR the left ventricle partially empties into the low-
pressure left atrium, instead of the high-pressure aorta. Thus the forward left 
ventricular flow and the blood supply to the periphery is reduced.  Thus, the 
forward stoke volume and forward ejection fraction (forward stroke volume 
expressed as a percentage of left ventricular end-diastolic volume) may be 
better predictors of left ventricular function and more clinically relevant. 
Comparing with AS, in MR the patients with preserved LVEF and low-flow 
state can be identified. Although the impact of forward flow on AS prognosis 
has been extensively studied and the low-flow has been recognized to be 
deleterious on survival, its role in MR has not been yet elucidated. 
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OBJECTIVES AND OUTLINE OF THE THESIS
The current thesis explores the most common left-sided valvular heart diseases: AS and MR. By 
applying novel techniques such as deformation imaging by echocardiography and 3-dimentional 
imaging with excellent spatial resolution by MDCT the diagnosis of left-sided valvular heart disease 
and its prognosis after surgical or novel transcatheter treatment, is enlightened through this thesis.
Part I focuses on aortic valve stenosis diagnosis and management. Chapter 
2, explores the use of fusion AVA for reclassification of AS severity in patients 
with low-gradient AS and preserved LVEF, by implementing the planimetered 
left ventricular outflow tract area on MDCT in the continuity equation. In 
chapter 3 the diagnosis and management of AS in patients with heart failure 
and reduced ejection fraction are reviewed. Chapter 4, aims to prove that 
left ventricular functional recovery and reverse remodeling occurs after TAVR 
in patients with low-flow and low-gradient AS with reduced or preserved 
ejection fraction. Chapter 5 refers to the management of severe AS with 
surgical sutureless or transcatheter aortic valves and aims to compare the 
hemodynamic performance of the two different valve types and the impact 
clinical outcomes in propensity score-matched high-risk populations.  
Part II focuses on secondary mitral valve regurgitation diagnosis and 
management. Chapter 6 aims to investigate whether in patients with 
secondary MR, speckle tracking GLS is an alternative and better, than LVEF, 
way to assess left ventricular systolic function.  Chapter 7 studies patients 
with non-ischemic dilated cardiomyopathy and secondary MR and evaluates 
left ventricular reverse remodeling and increase of forward flow after mitral 
valve repair. 
 Part III studies the prognosis of AS and MR. Chapter 8, evaluates the calcium 
of aortic and mitral valve detected on contrast-enhanced MDCT and its 
association with the outcome in patients with suspected coronary artery 
disease. Chapter 9 studies the impact of left ventricular forward flow and GLS 
on outcome post AVR in patients with low-gradient severe AS and preserved 
LVEF. In chapter 10, patients with severe secondary MR are evaluated with 
the aim to identify the prognostic implications of left ventricular forward 
flow after surgical mitral valve repair.
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ABSTRACT
Aims    Low gradient severe aortic stenosis (AS) with preserved left ventricular 
ejection fraction (LVEF) may be attributed to aortic valve area index (AVAi) 
underestimation due to the assumption of a circular shape of the left ventric-
ular outflow tract (LVOT) with 2-dimensional echocardiography. The current 
study evaluated whether fusing Doppler and multi-detector computed to-
mography (MDCT) data to calculate AVAi results in significant reclassification 
of inconsistently graded severe AS.
Methods and 
results
   In total, 191 patients with AVAi <0.6cm2/m2 and LVEF ≥50%, (mean age 80±7 
years, 48% male) were included in the current analysis. Patients were classi-
fied according to flow (stroke volume index <35 or ≥35 ml/m2) and gradient 
(mean transaortic pressure gradient ≤40 or >40 mmHg) into 4 groups: normal 
flow - high gradient (n=72), low flow - high gradient (n=31), normal flow - low 
gradient (n=46) and low flow - low gradient (n=42). LVOT area was measured 
by planimetry on MDCT and combined with Doppler hemodynamics on con-
tinuity equation to obtain the fusion AVAi. The group of patients with normal 
flow - low gradient had significantly larger AVAi and LVOT area index com-
pared with the other groups. Although MDCT-derived LVOT area index was 
comparable among the 4 groups, the fusion AVAi was significantly larger in 
the normal flow - low gradient group. By using the fusion AVAi, 52% (n=24) of 
patients with normal flow - low gradient and 12% (n=5) of patients with low 
flow - low gradient would have been reclassified into moderate AS due to AVAi 
≥0.6cm2/m2. 
Conclusion    The fusion AVAi reclassifies 52% of normal flow - low gradient and 12% of low 
flow - low gradient severe AS into true moderate AS, by providing true cross-
sectional LVOT area. 
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INTRODUCTION
Patients with inconsistently graded severe aortic stenosis (AS), defined by an aortic valve area index 
(AVAi) <0.6cm2/m2 and low mean transaortic pressure gradient (≤40mmHg), pose a diagnostic and 
therapeutic challenge.1 Particularly, in patients with preserved left ventricular (LV) ejection fraction 
(LVEF), severe AS with discordant gradient may be observed in 30% of patients.2 One of the factors 
underlying this inconsistent grading of AS severity is the assumption of a circular geometry of the 
LV outflow tract (LVOT) when using 2-dimensional echocardiography, introducing in the continuity 
equation a squared error.3 Initial studies in AS patients, using 3-dimensional imaging techniques 
(3-dimensional echocardiography or multi-detector computed tomography [MDCT]) have shown 
that the introduction of the planimetered LVOT area in the continuity equation leads to a signifi-
cantly larger aortic valve area compared with the use of 2-dimensional echocardiography derived 
LVOT diameter.4, 5 However, the inclusion of patients with low flow due to systolic LV dysfunction 
may introduce another error in the evaluation of AS severity which can be unmasked by performing 
dobutamine stress echocardiography. By including patients with low gradient AS and preserved LVEF, 
this confounding factor is obviated.6 The present evaluation fused MDCT and echocardiography 
data to derive aortic valve area and assessed the impact of MDCT-derived LVOT area on AS severity 
grading in patients with low gradient severe AS and preserved LVEF.
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METHODS
Patients   Patients with severe AS (AVAi <0.6cm2/m2) and preserved LVEF (≥50%) who 
underwent transcatheter aortic valve replacement were evaluated with 
transthoracic echocardiography and MDCT prior to the procedure. Patients 
with more than moderate aortic or mitral regurgitation, or prosthetic aortic 
valves were excluded.  
  Clinical, echocardiographic and MDCT data were prospectively collected and 
stored on a dedicated departmental Cardiology Information System (EPD-Vi-
sion®, Leiden University Medical Center, Leiden, The Netherlands) and were 
retrospectively analyzed. The Institutional Review Board approved this retro-




  Comprehensive 2-dimensional and Doppler transthoracic echocardiography 
was performed with a commercially available ultrasound system (Vivid-7 
and E9, General Electric, Horten, Norway) equipped with 3.5 MHz or M5S 
transducers. Data were stored digitally and analyzed offline on a dedicated 
workstation (EchoPac 112.0.1, GE Medical Systems, Horten, Norway). Aortic 
valve area was estimated by the continuity equation according to current 
echocardiography guidelines and then indexed to body surface area.3, 7 From 
the LV apical long-axis or 5-chamber views, continuous wave Doppler spectral 
recordings through the aortic valve were obtained and the mean pressure 
gradient was estimated with the modified Bernoulli equation.3 The highest 
aortic valve velocity was obtained systematically in all patients and was found 
in non-apical locations in 16 (35%) of patients. The LVOT area was derived 
from the LVOT diameter measured on a zoomed parasternal long-axis view, 
5 mm below the aortic annulus. The velocity time integral was measured on 
the spectral pulsed wave Doppler recordings of the LVOT obtained from the 
LV apical long-axis or 5-chamber views with the sample volume located 5 
mm below the aortic annulus. Stroke volume index (SVi) was then calculated 
as previously described and indexed to body surface area.8, 9 From the LV 
apical 4- and 2-chamber views, the LV volumes and LVEF were assessed using 
the Simpson’s biplane method.10 From the parasternal long-axis views, using 
M-mode recordings of the LV, the LV mass was calculated with the Devereux 
formula and then indexed to body surface area.10 The global LV afterload 
was assessed by calculating the valvulo-arterial impedance according to the 
formula Zva= (systolic arterial pressure + mean pressure gradient) / SVi and 
the pulsatile arterial load by the systemic arterial compliance from the formula 
SAC= SVi x (systolic – diastolic arterial pressure).8, 9, 11
  Based on SVi, patients with low gradient severe AS were classified into 4 groups: 
1. Normal flow - high gradient (SVi >35 ml/m2 and mean pressure gradient 
>40mmHg), 2. Low flow - high gradient (SVi ≤ 35 ml/m2 and mean pressure 
gradient >40mmHg), 3. Normal flow - low gradient (SVi >35 ml/m2 and mean 
pressure gradient ≤40mmHg), 4. Low flow - low gradient (SVi ≤ 35 ml/m2 and 





  MDCT scans were performed using a 64- or a 320-detector row computed 
tomography scanner (Aquilion 64; Toshiba Medical Systems, Otawara, Japan 
and Aquilion ONE; Toshiba Medical Systems, Tochigi-ken, Japan, respectively). 
With the 64-detector row system, the data were acquired with a collimation 
of 64 x 0.5 mm, a gantry rotation time of 400 ms and a tube current set of 
300-400 mA. With the 320-detector row system, the collimation was set at 
320 x 0.5mm, the gantry rotation time was 350 ms and the tube current was 
400 to 580 mA. The voltage was 100, 120, or 135 kV, depending on body mass 
index of the patients. A prospectively ECG-triggered coronary calcium com-
puted tomography data set was obtained. Then, a contrast-enhanced scan 
was performed and the dataset was reconstructed at 75% (diastolic phase) and 
30-40% (systolic phase) of the RR interval, according to the local protocol.13 All 
the reconstructed datasets were stored to a remote dedicated workstation for 
off-line analysis (Vitrea 2, Vital Images, Plymouth, Minnesota). 
  From the coronary calcium computed tomography dataset, the aortic valve 
calcium burden was evaluated using the Agatston method.14 In order to adjust 
for patients’ body size the aortic valve calcium density and the aortic valve 
calcium index were calculated by indexing calcium to MDCT-measured aortic 
annulus area and body surface area, respectively.15 From the contrast-enhanced 
dataset, the 3 multiplanar reformation planes were aligned on the standard 
orthogonal coronal and sagittal views to obtain the double oblique transverse 
view of the aortic valve. On systolic phase, the LVOT area was measured by 
planimetry, 5 mm below the predefined aortic annulus level. LVOT area was 
then indexed to body surface area. 

















Age, years 80±7 81±7 81±7 79±7 0.67
Male, n (%) 33 (45.8) 14 (45.2) 20 (43.5) 25 (59.5) 0.42
Body surface area, 
m2
1.87±0.21 1.86±0.23 1.83±0.21 1.90±0.20 0.56
Hypertension, n 
(%)
54 (75.0) 26 (83.9) 39 (84.8) 36 (85.7) 0.41
Diabetes,  
n (%)
19 (26.4) 10 (32.3) 13 (28.3) 13 (31.0) 0.92
Hyperlipidemia, 
n (%)
43 (59.7) 18 (58.1) 32 (69.6) 31 (73.8) 0.36
Coronary artery 
disease, n (%)
42 (58.3) ¥ 22 (71.0) 35 (76.1) 36 (85.7) † 0.01
Systolic arterial 
pressure, mmHg
143±22 142±20 142±24 135±23 0.37
Diastolic arterial 
pressure, mmHg
69±11 72±12 70±12 71±12 0.54
* ANOVA or Chi-square overall comparison within the four groups. 
† vs Normal Flow - High Gradient group. 
¥ vs Low Flow - Low Gradient group
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Fusion of Doppler  
with MDCT data
  By combining hemodynamic echocardiographic data and LVOT area measured 
on contrast-enhanced MDCT, the fusion AVAi was calculated introducing the 




  where VTI is the velocity time integral, PW is pulse wave Doppler and CW is 
continuous wave Doppler. An example demonstrating the evaluation of echo-
cardiographic and fusion AVAi in a patient with normal flow - low gradient 
severe AS is shown in Figure 1.
Figure 1. Aortic valve area index (AVAi) evaluated by echocardiography (Echo) and by fusion 
of multi-detector computed tomography (MDCT) and Doppler-echocardiographic data. By 
echocardiography, the left ventricular outflow tract (LVOT) diameter was measured 5 mm below the 
aortic annulus and the LVOT area was estimated (A). Using MDCT, the LVOT area was planimetered 
at the reconstructed double-oblique transverse view in systole, 5 mm below the annulus (B). The 
velocity time integral (VTI) of the flow at the LVOT was measured on pulsed wave (PW) Doppler 
recordings obtained from the apical 5-chamber view with the sample volume located 5 mm 
below the aortic annulus (C). The VTI of the flow at the aortic valve was measured on continuous 
wave (CW) Doppler recordings (D). By applying the continuity equation, the echo and the fusion 
AVAi were evaluated by using the echo-estimated LVOT area and the MDCT-derived LVOT area 




  Categorical variables are expressed as frequencies (percentage) and were 
compared with the X2 test. Continuous variables are expressed as mean±-
standard deviation, if normally distributed and as median and interquartile 
range if non-normally distributed. Comparisons between normally distributed 
continuous variables were performed with the one-way ANOVA test using 
the Bonferroni’s post-hoc analysis. The Kruskal-Wallis test was performed to 
compare non-normally distributed continuous data. Correlations between 
continuous variables were performed with the Pearson test. Bland-Altman plots 
were used to evaluate the agreement between MDCT and echocardiography to 
measure LVOT and AVA areas. Univariable analysis was performed with binary 
logistic regression analysis and the variables with a p<0.1 were introduced in 
the multivariable model. The odds ratio and 95% confidence interval were 
reported. Aortic valve calcium, aortic valve calcium index and aortic valve 
calcium density were not-normally distributed and were introduced in the 
uni- and multivariable analysis after log-transformation. The statistical analysis 
was performed with the SPSS version 20.0 (SPSS, Chicago, Illinois). A p-value 
<0.05 was considered statistically significant. 
RESULTS
A total of 191 patients (mean age 80±7 years, 48% male) with severe AS (AVAi <0.6cm2/m2) and 
preserved LVEF (≥50%) who had echocardiographic and MDCT evaluation prior to TAVI were includ-
ed in the current analysis. Echocardiographic AVAi was 0.38±0.10cm2/m2, mean pressure gradient 
45±16mmHg, SVi 38±10ml/m2 and LVEF 63±7%. Patients were classified into 4 groups according to 
flow and transaortic gradient: normal flow - high gradient (n=72, 38%); low flow - high gradient (n=31, 




  Table 1 presents the demographic and clinical characteristics of the 4 groups 
of patients. The 4 groups were comparable in terms of body surface area, 
cardiovascular risk factors and blood pressure. In the low flow - low gradient 
group the prevalence of coronary artery disease was higher compared to the 
normal flow - high gradient.
  Table 2 shows the comparison of the hemodynamic and anatomic echocar-
diographic characteristics among the 4 groups. By definition, SVi and mean 
gradient were significantly different across the groups. Despite AVAi was less 
than 0.6cm2/m2 in all patients, those with normal flow - low gradient severe AS 
had significantly larger AVAi, larger LVOT area index and more concentrically 
hypertrophied LV compared with their counterparts. In addition, the global LV 
afterload was significantly lower in patients with normal flow - low gradient 
severe AS compared with the other groups.
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Table 2. Hemodynamic and anatomic data evaluated by echocardiography among the four groups 


















44.91±8.38 ‡‡,¥¥ 30.32±3.51 ††,§§ 43.17±6.28 ‡‡,¥¥ 26.66±4.71 ††,§§ <0.001
MPG,  
mmHg
56.85±10.87 §§,¥¥ 55.83±11.45 §§,¥¥ 31.99±5.83 ††,‡‡ 29.71±6.28 ††,‡‡ <0.001
Vmax,  
m/sec
4.79±0.47 §§,¥¥ 4.70±0.46 §§,¥¥ 3.71±0.37 ††,‡‡ 3.51±0.41 ††,‡‡ <0.001
AVA,  
cm2
0.70±0.15 ‡‡,§§ 0.50±0.12 ††,§§,¥¥ 0.89±0.15 ††,‡‡,¥¥ 0.64±0.15 ‡‡,§§ <0.001
AVAi,  
cm2/m2
0.37±0.08 ‡‡,§§,¥ 0.27±0.05 ††,§§,¥¥ 0.49±0.06 ††,‡‡,¥¥ 0.34±0.07 †,‡‡,§§ <0.001
LVEF, % 64.76±7.48 ¥ 62.16±8.14 62.61±6.94 60.24±6.81 † 0.02
LVEDVi,  
ml/m2
48.74±15.96 44.15±15.55 51.26±18.52 ¥ 38.22±12.80 †,§ 0.001
LVESVi,  
ml/m2
18.55±8.89 17.05±8.57 21.05±10.02 ¥ 15.47±6.17 § 0.02
LV mass index,  
gr/m2
136.58±36.05 127.80±27.42 130.24±38.40 120.61±33.85 0.11
RWT, % 65.04±13.67 62.84±16.06 59.72±14.18 67.56±16.62 0.08
Zva,  
mmHg/ml/m2
4.58±1.00 ‡‡,¥¥ 6.59±1.11 ††,§§ 4.10±0.74 ‡‡,¥¥ 6.38±1.47 ††,§§ <0.001
SAC,  
ml/mmHg/m2
0.65±0.19 ‡‡,¥¥ 0.46±0.11 ††,§§ 0.65±0.21 ‡‡,¥¥ 0.45±0.15 ††,§§ <0.001
LVOT area,  
cm2
3.11±0.63 2.79±0.62 §§ 3.37±0.60 ‡‡,¥ 2.96±0.65 § <0.001
LVOT area index, 
cm2/m2
1.67±0.31 ‡,§ 1.49±0.27 †,§§ 1.84±0.26 †,‡‡,¥¥ 1.56±0.31 §§ <0.001
AVAi, aortic valve area index;  
LV, left ventricular;  
LVEDVi, left ventricular end-diastolic volume index;  
LVEF, left ventricular ejection fraction;  
LVESVi, left ventricular end-systolic volume index;  
LVOT, left ventricular outflow tract;  
MPG, mean pressure gradient;  
RWT, relative wall thickness;  
SAC, systemic arterial compliance;  
SVi, stroke volume index;  
Vmax, maximum transvalvular velocity;  
Zva, valvulo-arterial impedance.
* ANOVA overall comparison within the four groups. 
† vs Normal Flow - High Gradient group 
‡ vs Low Flow - High Gradient group 
§ vs Normal Flow - Low Gradient group 
¥ vs Low Flow - Low Gradient group 
1 symbol: p<0.05 and 2 symbols: p<0.001
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Figure 2. Correlation and Bland-Altman plots comparing echocardiography (Echo), multi-detector 
computed tomography (MDCT) and fusion measurements of the left ventricular outflow tract (LVOT) 
area and aortic valve area (AVA). Pearson correlation showed fair agreement between MDCT and Echo 
measurements of the LVOT area (panel A). The Bland-Altman plot demonstrates that LVOT area is 
underestimated by Echo compared with MDCT (panel B). On average, Echo underestimated the LVOT 
area by 25% compared with MDCT. The fusion AVA had good linear correlation with Echo AVA (panel 
C). However, the Bland-Altman plot shows that Echo underestimates the AVA compared with fusion 
AVA (panel D). On average, Echo underestimated the AVA by 25% compared to fusion technique.
Fusion of MDCT 
anatomy and Doppler 
hemodynamics
  The MDCT-derived LVOT area and LVOT area index were comparable among 
the 4 groups, in contrast to the echocardiographic evaluation. However, fusion 
AVA and AVAi were significantly larger in the normal flow - low gradient group 
(Table 3). The LVOT area measured on MDCT showed good correlation with the 
LVOT area measured with echocardiography (Figure 2A) with a mean bias of 
1.16±0.92cm2 (Figure 2B) and the fusion AVA showed a good correlation with 
echocardiographic AVA (Figure 2C) with a mean bias of 0.23±0.20cm2 resulting 
in a larger fusion AVA area (Figure 2D).
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Table 3. Anatomic data evaluated by multi-detector row computed tomography and their fusion 























2143 (1246–3067)  
††,‡
2310 (1586–3352)  
†
<0.001






















MDCT LVOT area, 
cm2
4.14±0.98 4.33±0.77 4.40±0.78 4.26±0.79 0.46
MDCT LVOT area 
index, cm2/m2
2.21±0.51 2.33±0.31 2.39±0.40 2.25±0.43 0.16






















AU, arbitrary units; AVC, aortic valve calcium; AVA, aortic valve area; LVOT, left ventricular outflow 
tract; MDCT, multi-detector computed tomography.
* Kruskal-Wallis or ANOVA overall comparison within the four groups. 
† vs Normal Flow - High Gradient group 
‡ vs Low Flow - High Gradient group  
§ vs Normal Flow - Low Gradient group 
¥ vs Low Flow - Low Gradient group 
1 symbol: p<0.05 and 2 symbols: p<0.001
  The aortic valve calcium, calcium density and calcium index were significantly 
different among the 4 groups, but the calcium load was comparable in-be-
tween the 2 low gradient groups and in-between the 2 high gradient groups 
(Table 3). 
  The aortic valve calcium load was independently associated to low gradient 
severe aortic stenosis (odds ratio 0.02, 95% confidence interval 0.003-0.13, 
p<0.001) (Table 4). However, aortic valve calcium load was not associated with 
flow (odds ratio 1.01, 95% confidence interval 0.31-3.32, p=0.99) (Table 5), indi-
cating that aortic valve calcium load may not be able to discriminate between 
normal and low flow severe aortic stenosis patients who have comparable 
gradient.
  By using the fusion AVAi, 52% (n=24) of patients with normal flow - low gradi-
ent AS and 12% (n=5) of patients with low flow - low gradient AS would have 
been reclassified into true moderate AS due to low gradient and AVAi≥0.6cm2/
m2 (Figure 3). Those patients reclassified to true moderate AS had comparable 
aortic valve calcium burden to that of patients with low gradient severe AS 
(2226 [1467-3342] versus 2227 [1543-3098] AU, respectively; p=0.73).
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Table 4. Uni- and multivariable associates of low gradient (≤40mmHg), severe aortic stenosis with 
preserved ejection fraction
Univariable Multivariable
OR 95% CI p-value OR 95% CI p-value
Clinical Parameters
Age, years 0.98 0.94-1.03 0.49
Male 1.25 0.70-2.20 0.45
Body surface area, m2 1.01 0.26-3.90 0.98
Coronary artery disease 2.54 1.31-4.94 0.006 5.09 1.80-14.39 0.002
Diabetes 1.07 0.57-2.00 0.83
Hypertension 1.66 0.78-3.51 0.19
Hemodynamic Parameters
ECHO AVAi, mm2/m2 1.07 1.03-1.10 <0.001 - - -
Fusion AVAi, mm2/m2 1.09 1.06-1.13 <0.001 1.09 1.05-1.14 <0.001
LV Ejection fraction, % 0.95 0.92-0.99 0.02 0.96 0.91-1.01 0.15
SVi, ml/m2 0.99 0.99-1.00 <0.001 - - -
Zva, mmHg/ml/m2 1.00 0.82-1.21 0.98
SAC, ml/mmHg/m2 0.40 0.09-1.72 0.22
LV mass index, gr/m2 0.99 0.98-1.00 0.10
Relative wall thickness, % 0.99 0.98-1.01 0.67
Anatomical Parameters
ECHO LVOTa index, cm2/m2 2.55 1.00-6.47 0.048 2.89 0.75-11.13 0.12
MDCT LVOTa index, cm2/m2 1.52 0.77-3.01 0.23
Aortic valve calcium 0.04 0.01-0.17 <0.001 - - -
Aortic valve calcium index 0.04 0.009-0.16 <0.001 0.02 0.003-0.13 <0.001
Aortic valve calcium density 0.02 0.003-0.09 <0.001 - - -
Aortic valve calcium, Aortic valve calcium index and Aortic valve calcium density were introduced in 
the uni- and multivariable analysis as log transformation
AVAi, aortic valve area index;  
ECHO, echocardiography;  
LV, left ventricular;  
LVOTa, left ventricular outflow tract area;  
MDCT, multi-detector computed tomography;  
SAC, systemic vascular compliance;  
SVi, stroke volume index;  
Zva, valvulo-arterial impedance.
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Table 5. Uni- and multivariable associates of low flow (stroke volume index ≤35ml/m2), severe 
aortic stenosis with preserved ejection fraction
Univariable Multivariable
OR 95%CI p-value OR 95%CI p-value
Clinical Parameters
Age, years 1.00 0.96-1.04 0.98
Male 1.41 0.78-2.53 0.25
Body surface area, m2 1.95 0.49-7.78 0.35
Coronary artery disease 2.06 1.04-4.07 0.04 2.37 0.80 – 6.99 0.12
Diabetes 1.24 0.65-2.34 0.51
Hypertension 1.51 0.69-3.30 0.29
Hemodynamic Parameters
LV ejection fraction, % 0.95 0.91-0.99 0.01 0.94 0.88–1.00 0.07
Zva, mmHg/ml/m2 6.43 3.77-10.94 <0.001 6.50 2.87–14.70 <0.001
SAC, ml/mmHg/m2 0.001 0.001-0.007 <0.001 1.87 0.03-106 0.76
LV mass index, gr/m2 0.99 0.98-1.00 0.04 0.99 0.97-1.00 0.20
Relative wall thickness, % 1.01 0.99-1.03 0.25
ECHO AVAi, mm2/m2 0.84 0.79-0.88 <0.001 - - -
Fusion AVAi, mm2/m2 0.93 0.90-0.96 <0.001 0.83 0.005-145 0.94
Anatomical Parameters
ECHO LVOTa index, cm2/m2 0.10 0.04-0.30 <0.001 0.53 0.09 – 2.94 0.47
MDCT LVOTa index, cm2/m2 1.01 0.50-2.03 0.98
Aortic valve calcium 1.13 0.35-3.67 0.84
Aortic valve calcium index 1.01 0.31-3.32 0.99
Aortic valve calcium density 0.97 0.27-3.54 0.97
Aortic valve calcium, Aortic valve calcium index and Aortic valve calcium density were introduced in 
the uni- and multivariable analysis as log transformation
AVAi, aortic valve area index; ECHO, echocardiography;  
LV, left ventricular;  
LVOTa, left ventricular outflow tract area;  
MDCT, multi-detector computed tomography;  
SAC, systemic vascular compliance;  
Zva, valvulo-arterial impedance.
Figure 3. Reclassification of aortic stenosis severity in patients with echocardiographic severe 
aortic stenosis and preserved ejection fraction. AVAi, aortic valve area index. 
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DISCUSSION
The present study demonstrated that in patients with low gradient severe AS and preserved LVEF, the 
evaluation of fusion AVAi, by incorporating the MDCT-derived LVOT area in the continuity equation, 
reclassified 52% of the normal flow - low gradient and 12% of the low flow - low gradient severe AS 
patients to true moderate AS.  
Prevalence of low 
gradient severe AS 
with preserved LVEF
  Inconsistently graded severe AS, defined as an AVAi <0.6cm2/m2 and low gra-
dient (<40 mmHg) is rather common in clinical practice and poses a diagnostic 
and therapeutic challenge. Low stroke volume, inaccurate measurements of the 
LVOT dimensions with 2-dimensional echocardiography and the presence of a 
small ascending aorta (which enhances the pressure recovery phenomenon) 
have been identified as the main reasons for the inconsistently graded severe 
AS. However, Minners et al have shown that 26% of patients undergoing cardiac 
catheterization to calculate AVAi by applying the Gorlin formulae may also show 
inconsistently graded severe AS.2 The Gorlin formulae provides the anatomic 
aortic valve area, which may be larger than the effective orifice area calculated 
with echocardiography. In addition, during catheterization the pressure recovery 
phenomenon may also overestimate the aortic valve area leading to a lower 
percentage of inconsistently graded severe AS compared with echocardiogra-
phy (26% vs. 34%, respectively). An important factor that may also cause this 
discrepant severe AS grading is the presence of low flow despite preserved LVEF. 
The prevalence of low flow - low gradient severe AS ranges between 13% and 
28% whereas the prevalence of normal flow - low gradient severe AS is 23%.16, 
17 The present study observed similar prevalence with 22% and 24% of severe 
AS patients with preserved LVEF having low flow - low gradient and normal 
flow - low gradient AS, respectively. Accurate assessment of the cross sectional 
area of the LVOT is crucial to minimize the inaccurate measurement of AVAi. 
Reclassification of 
low gradient severe 
AS with preserved 
LVEF according to 
fusion AVAi
  Incorporation of the true cross sectional area of the LVOT in the calculation 
of the AVAi may reduce the prevalence of inconsistently graded severe AS by 
reclassifying patients into moderate AS.3 The true cross sectional LVOT area 
can be evaluated by 3-dimensional echocardiography, MDCT and cardiac 
magnetic resonance imaging.4, 18, 19 MDCT provides accurate visualization of 
the elliptical shape of the LVOT. Several studies have demonstrated that the 
LVOT diameter measured on 2-dimensional echocardiography corresponds to 
the diameter of the minor axis of the ellipse measured on MDCT, leading to 
underestimation of the LVOT area and subsequently of the AVAi.4, 18, 20 A typical 
example of the oval LVOT true cross-sectional area at a 3-plane reconstructed 
MDCT view is depicted in Figure 1B. In routine clinical practice, by using the 
2-dimensional echocardiography data the short diameter of the oval-shaped 
LVOT is measured (Figure 1A) and by assuming a circular-shaped LVOT the AVAi 
is underestimated (Figure 1E). This could be avoided by applying the true LVOT 
cross-sectional area assessed with 3-dimensional imaging in the continuity 
equation (Figures 2B and 2E). The LVOT area (independently of the modality 
used for measuring it) should be evaluated at a level 5mm apical to the aortic 
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annulus level in correspondence to the Doppler pulse wave sampling that 
provides hemodynamic information at the specific level.3, 21  
  MDCT permits calculation of AVAi either by direct planimetry of the aortic an-
atomic orifice area or by fusing the MDCT-derived LVOT area with echocardio-
graphic Doppler data of the aortic valve in the continuity equation, obtaining 
the aortic effective orifice area.5, 18, 22 In contrast to the anatomic aortic valve 
area, the effective orifice area of the aortic valve represents the workload that 
the LV has to overcome due to AS and therefore provides a more physiological 
evaluation of AS severity.23, 24
  The aortic effective orifice area has been previously evaluated by applying the 
MDCT-derived aortic annulus or LVOT area in the continuity equation.4,5 In 53 
patients with severe AS undergoing transcatheter aortic valve implantation, Ng 
et al showed that the aortic annulus area was significantly underestimated by 
2-dimensional echocardiography compared with 3-dimensional echocardiogra-
phy and MDCT resulting in reclassification of 25% of patients into moderate AS.4, 
5 Similarly, Clavel et al evaluated the distribution of patients with inconsistently 
graded AS based on AVA with echocardiography and with MDCT.25 Among 205 
patients with preserved LVEF, 13% had low mean gradient and an echocardio-
graphic AVA ≤1cm2 while the percentage of patients with low mean gradient 
and tight AVA based on MDCT (≤1.2 cm2) was 12%. In contrast to the present 
study, the authors used a higher cut-off value to define severe AS based on 
MDCT measurements of AVA explaining the discrepant results. In addition, it is 
important to note that, previous studies did not take into consideration the LV 
stroke volume, another important determinant of inconsistently graded severe 
AS. The impact of MDCT-derived LVOT area in the calculation of the AVAi in pa-
tients with low or normal flow may differ significantly. In the present study, 52% 
of the echocardiographic normal flow - low gradient severe AS patients could be 
reclassified to true moderate AS whereas only 12% of the low flow - low gradient 
severe AS patients should be reclassified to true moderate AS. Therefore, the 
evaluation of SVi should be incorporated in routine clinical practice to improve 
hemodynamic characterization of low gradient AS severity.   
  This reclassification may have important therapeutic implications since previous 
studies have shown that patients with normal flow - low gradient severe AS 
and preserved LVEF had comparable survival to that of patients with moderate 
AS whereas patients with low flow - low gradient severe AS and preserved 
LVEF have worse survival than patients with moderate AS (3-year survival 
58% vs. 85%, respectively; p=0.002).9,26,27 Furthermore, Maes et al showed that 
patients with low flow - low gradient severe AS and preserved LVEF represent 
an earlier stage of the disease since almost 40% of those patients developed 
high gradients on subsequent echocardiography and showed better survival 
than patients with high gradient severe AS.28
Proposed 
reclassification of low 
gradient severe AS 
with preserved LVEF
  The present evaluation proposes a novel method to reclassify patients with low 
gradient severe AS, with normal or low flow, and preserved LVEF. Implementation 
of fusion AVAi may be the first discriminatory method between true severe and 
true moderate AS. By applying the fusion AVAi, 52% of the normal flow and 12% 
of the low flow - low gradient severe AS patients would be reclassified to true 
moderate AS. Eventually, in the group with low flow - low gradient severe AS, 
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the projected AVAi on stress echocardiography could be used to correct for the 
potential error caused by the low flow and discriminate between true severe 
and pseudo-severe AS.29 This algorithm, for low gradient severe AS assessment, 
eliminates the potential errors in AVAi calculation due to anatomical assumptions 
in 2-dimensional echocardiography or low flow effect. 
  Additionally, assessment of aortic valve calcium burden using coronary calcium 
computed tomography data has been recently proposed to identify patients 
with true severe AS among patients with inconsistently graded severe AS.14 
Operative data have shown that the weight of the excised aortic valve of 
patients with paradoxical low flow - low gradient severe AS was significantly 
lower than that of patients with normal flow - high gradient severe AS, despite 
a significant overlap between the groups (1.9 [1.63-2.50] g versus 2.60 [1.66-
3.32] g, respectively; p=0.03).30 In addition, Clavel et al confirmed that patients 
with low gradient severe AS had significantly lower aortic valve calcium on 
coronary calcium computed tomography (1926 [1214-2695] AU for men and 
1145 [854-1743] AU for women) compared with patients with high gradient 
severe AS (2617 [1819-2819] AU for men and 1320 [747-1429] AU for women) but 
significantly higher compared with patients with moderate AS (1240 [720-1833] 
AU for men and 487 [251-890] AU for women).14 However, differences in aortic 
valve calcium burden between patients with normal flow - low gradient and 
low flow - low gradient severe AS have not been reported so far. The present 
study showed no differences in aortic valve calcium load between these two 
groups, suggesting a relatively homogeneous aortic valve calcium load in these 
two patient groups, but significantly lower compared with the high gradient 
groups. Noteworthy, the aortic valve calcium load could differentiate between 
the different gradient groups but not between the different flow groups. 
This finding suggests that in patients with low gradient severe AS, accurate 
assessment of true cross sectional LVOT area (using 3-dimensional imaging 
techniques) may play a more relevant role on the aortic stenosis grading rather 
than assessing the aortic valve calcium load.
Limitations   The current retrospective analysis of prospectively collected data is an 
observational study. The prognostic implications of fusion AVAi need to be 
demonstrated in prospective studies. In the current analysis the AVA was 
indexed to body surface area. However, in obese patients, the grade of 
underestimation of the AVA may be larger.  
CONCLUSION
In patients with low gradient severe AS with echocardiographic AVAi <0.6cm2/m2 and preserved LVEF, 
fusion AVAi evaluation (by combining the true cross-sectional LVOT area from 3-dimensional MDCT 
imaging and Doppler hemodynamics in the continuity equation) permits reclassification to true 
moderate AS in 52% of the normal flow and 12% of the low flow - low gradient severe AS patients. 
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Abstract
Aortic stenosis (AS) is the most frequent degenerative valvular heart disease in Western countries 
and its prevalence increases parallel to the ageing process of the population. Heart failure (HF) 
may be present in up to a quarter of patients with severe AS posing diagnostic and management 
challenges. The present article reviews the prevalence of HF in severe AS patients, discusses the 
diagnostic challenges and the advances in multimodality imaging to identify the patients that 
may benefit from surgical or transcatheter aortic valve replacement and summarizes the current 
evidence on management for this group of patients.
 Keywords    Aortic stenosis;  
Heart failure;  
Stress echocardiography;  
Multi-detector computed tomography;  
Transcatheter aortic valve replacement
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INTRODUCTION 
Aortic stenosis (AS) is the most frequent degenerative valvular heart disease in Western countries 
and its prevalence increases with the ageing of the population.1, 2 While the development of 
symptoms (angina, syncope or dyspnea) demarks an inflexion point in the survival of the patients 
with AS, the correlation between severity of AS and onset of symptoms is poor and depends largely 
on the hypertrophic response of the left ventricle (LV) to the pressure overload.3 LV hypertrophy is 
a compensatory mechanism to restore wall stress and maintain cardiac output under increasing 
pressure afterload caused by the stenotic valve. However, progressive cardiomyocyte death and 
consequent fibrosis that accompany LV hypertrophy may lead to the development of LV dysfunction 
and heart failure (HF) symptoms. The onset of symptoms is not the only determinant of the timing 
for intervention in severe AS. Reduction of LV ejection fraction (LVEF) <50% even in asymptomatic 
patients with severe AS is also considered as class I indication (level of evidence B) for aortic valve 
replacement.4, 5 However, the co-existence of severe AS, reduced LVEF and HF is complex and poses 
diagnostic and clinical decision-making dilemmas.
In HF patients with low LVEF, aortic valve area (AVA) ≤1.0cm2 and low mean transaortic pressure 
gradient (<40mmHg) frequently co-exist challenging the diagnosis of severe AS.6 In this 
circumstance, differentiation between true severe AS and pseudosevere AS is mandatory. In true 
severe AS, the compensatory mechanism of LV hypertrophy is exhausted with cardiomyocyte death 
and myocardial fibrosis that lead to reduced LVEF and low stroke volume and transaortic gradient. 
This entity is known as “classical” low-flow low-gradient severe AS. In contrast, in pseudosevere AS, 
reduced LVEF is caused by a primary dysfunction of the myocardium leading to reduced stroke 
volume, reduced opening forces of the valve and underestimation of AVA. 
Besides the “classical” low-flow low-gradient severe AS, another circumstance characterized by 
inconsistent grading of severe AS is the “paradoxical” low-flow low-gradient severe AS, where LVEF 
is preserved (≥50%) and the reason of low-flow and consequently low-gradient AS is other than 
systolic HF. This condition is characterized by a small LV chamber size due to pronounced concentric 
remodeling in response to increased global afterload and reduced systemic arterial compliance 
which cause impaired LV mechanics (despite preserved LVEF) and diastolic filling.6 
The decision making for patients with severe AS, reduced LVEF and HF is an important clinical 
dilemma. Currently the therapeutic options are conservative medical treatment, surgical aortic valve 
replacement (SAVR) and transcatheter aortic valve implantation (TAVI).4, 5 Data from randomized 
clinical trials and observational registries have provided important evidence on the benefits 
and risks of SAVR versus TAVI.7, 8 However, there remain areas of uncertainty in the treatment of 
patients with severe AS and HF (i.e. patients with LVEF<30%, treatment options for patients with 
pseudosevere AS and patients with preserved LVEF and inconsistently graded severe AS).
The present review article provides an overview of current literature on the prevalence of HF 
(defined as reduced LVEF) in patients with severe AS, focusing on the diagnostic challenges and the 
various therapeutic options.
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PREVALENCE OF HF IN SEVERE AS PATIENTS 
In AS the left ventricle responds to the increased pressure load with adaptive 
concentric wall hypertrophy that maintains wall stress and LVEF. However, 
at this point, LV diastolic filling and LV longitudinal shortening are already 
impaired.3, 9 In more advanced stages of AS, the pressure overload cannot 
be counterbalanced by the LV hypertrophy leading to reduced LVEF and HF 
symptoms and poor outcomes.3, 9 
  The prevalence of HF among severe AS patients varies largely based on the 
definition of HF (i.e. LVEF<50%, presence of symptoms) and the characteristics 
of patients included in the studies (Figure 1).7, 10-13 In a large retrospective 
series of 9940 patients with severe AS, the prevalence of symptomatic LV 
dysfunction (LVEF<50%) was 24% whereas the prevalence of asymptomatic 
LV dysfunction was 0.4%.10 In addition, in a retrospective population-level 
epidemiological study of hospitalized care in Scotland, among 13 200 
patients diagnosed with AS (mean age 76±11 years old, 47% male), 25.1% 
were admitted with concomitant HF and 10.5% had at least one episode of 
previous HF hospitalization.14 This prevalence was higher in a retrospective 
study including 453 patients with severe AS (mean age 75±13 years old, 48% 
male) who were conservatively treated during 1.5 years of follow-up: 35% of 
patients had an LVEF<40%.11 
  Reduced LVEF is associated with increased operative mortality risk and up to 
30% of the patients with severe AS and reduced LVEF were deemed inoperable 
according to the EuroHeart Survey.15 The advent of TAVI has changed the 
management of patients with severe AS and data from randomized clinical 
trials and registries on TAVI may provide more information on the prevalence 
of HF in severe AS patients. For example, among the 971 patients with 
severe AS included in the Placement of Aortic Transcatheter Valve (PARTNER) 
trial cohorts A and B, 23% had LVEF<50%.7 In the US CoreValve trial, which 
randomized 795 patients with severe AS and high operative risk to TAVI 
or SAVR, 19% of patients reported NYHA functional class IV HF symptoms 
while the prevalence of LVEF<50% was not reported.16 These randomized 
clinical trials excluded patients with LVEF<20% and, therefore may not 
represent the real-world patients treated with TAVI. In the the Society of 
Thoracic Surgeons/American College of Cardiology Transcatheter Valve 
Therapy registry, including 7710 patients treated with TAVI, the prevalence 
of LVEF<30% was 7%.13 Similar prevalence has been reported across several 
European registries of patients with severe AS treated with SAVR or TAVI.12, 
17-20 The largest European registry so far is the German Aortic Valve Registry 
(GARY) including 15 964 patients treated with TAVI;12 in this registry the 
prevalence of LVEF<30% was 9.5%. 
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Figure 1. Prevalence of heart failure based on left ventricular ejection fraction (LVEF) in patients 
with severe aortic stenosis. 
  Besides failure of LV concentric hypertrophic remodeling to match the 
increased pressure overload, concomitant underlying coronary artery 
disease (CAD) is an important cause of HF in AS patients and has important 
therapeutic and prognostic implications.21 Calcific AS and CAD share common 
pathophysiologic mechanisms and therefore frequently coexist.22 In patients 
undergoing SAVR, coronary artery bypass grafting was performed in >50% 
of patients aged over 70 years.23 In a recent observational analysis comparing 
2286 patients with severe AS undergoing SAVR and coronary artery bypass 
grafting versus 1637 patients undergoing isolated SAVR, the short- and long-
term prognosis of the former group was worse (survival rates at respective 
30 days and 10 years: 97.6% versus 98.7% and 43% versus 59%).24 The study 
showed that the increased mortality of patients undergoing combined 
SAVR and coronary artery bypass grafting was associated with the effects 
of pre-existing ischemic myocardial damage and co-morbidities. Therefore, 
evaluation of the presence of significant coronary artery disease and its 
consequences on LV performance is relevant for appropriate timing of SAVR.
  In the randomized clinical trials on TAVI, the reported prevalence of coronary 
artery disease ranged between 74-76%7, 16 whereas this prevalence is lower 
in the TAVI registries ranging from 31% to 69%.12, 13, 17, 18, 20 In this specific 
group of patients, management of concomitant significant coronary artery 
disease remains controversial. In elderly patients, complete revascularization 
in patients undergoing TAVI seems less paramount.25, 26 However, similarly to 
surgical series, some observational studies have suggested that the presence 
of myocardial ischemic damage (myocardial scar) is associated with worse 
outcome after TAVI.27, 28 
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DIAGNOSTIC CHALLENGES IN PATIENTS WITH SEVERE AS AND HF 
 In patients with reduced LVEF, inconsistently graded severe AS (tight AVA with low transvalvular 
gradients/velocity) can be observed in 5-10% of patients with severe AS posing a diagnostic 
dilemma.29, 30 Differentiation between true severe AS and pseudosevere AS is crucial to decide the 





  The outcome of patients with low flow low gradient severe AS and reduced 
LVEF is dismal under medical therapy but the operative mortality is high 
and therefore accurate assessment of the AS grade and the severity of 
LV myocardial damage is crucial to select the appropriate treatment.29, 
30 Calculation of AVA in this subgroup of patients is challenging since it is 
directly proportional to the cardiac output. Therefore, increasing the cardiac 
output (improving myocardial contractility and increasing stroke volume) 
with intravenous administration of dobutamine may help to assess the 
AVA in different flow status and differentiate between fix severe AS and 
pseudosevere AS.31, 32 During intravenous administration of dobutamine at 
5mcg/kg/min increase every 3-5 minutes until a maximum doses of 20 mcg/
kg/min, the mean transvalvular gradient and the stroke volume are measured 
keeping constant the LV outflow tract diameter. The AVA is then calculated 
by continuity equation. An increase in ≥20% in wall motion score and in 
≥20% in stroke volume relative to baseline define LV contractile32 and flow 
reserve,31 respectively. In true severe AS, LV wall motion score, stroke volume 
and transvalvular gradients increase (>30 mmHg) at low dose dobutamine 
whereas AVA remains fixed (≤1.0 cm2). In contrast, in pseudosevere AS, the 
improvement in LV contractility and stroke volume leads to an increase in AVA 
(>1.0 cm2 or absolute increase >0.3 cm2) while the transvalvular gradients 
remain low.  
Assessment of 
AS severity in 
patients without 
LV contractile or 
flow reserve
  However, one third of the patients with low flow low gradient severe AS and 
reduced LVEF may not show LV contractile or flow reserve during dobutamine 
stress echocardiography.31, 32 In this situation, definition of the severity of 
AS remains difficult. Several series have demonstrated that these patients 
have the highest operative mortality and the worst prognosis if medically 
treated.31, 33 The lack of LV contractile or flow reserve can be due to increased 
afterload that blunts the myocardial response to dobutamine, the presence 
of significant coronary artery disease that reduces myocardial blood flow or 
the presence of extensive myocardial scar. To overcome the limitations of 
dobutamine stress echocardiography, several additional echocardiographic 
variables and imaging techniques have been proposed to identify patients 
with true severe AS.34, 35
  In the multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study, 
including 46 patients with low flow low gradient severe AS (AVA≤1.2 cm2 
or indexed AVA≤0.6 cm2/m2, mean gradient <40 mmHg and LVEF≤40%), 
the accuracy of the projected AVA to differentiate between true severe AS 
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and pseudosevere AS was investigated.34 Twenty-three patients underwent 
SAVR and the severity of the AS was assessed by the surgeon. The projected 
AVA is defined as the AVA calculated at standardized flow rate (250 ml/s 
which corresponds to the normal flow rate observed in patients with severe 









 is the AVA at baseline, Q
rest
 is the mean transvalvular flow 
rate and VC is the valve compliance which corresponds to the slope of the 
relationship between AVA and flow and represents the rate of change in AVA 
in relation to the flow during stress. A cut-off value of indexed AVA
proj
≤0.55 
cm2/m2 correctly classified true severe AS in 91% of patients who underwent 
SAVR.34 In contrast, the percentage of correct classification of patients with 
true severe AS reduced to 71%, 65% and 61% when an increase in mean 
transvalvular gradient >30 mmHg, and AVA at peak stress <1.0 cm2 or an 
increase in AVA <0.3 cm2 were applied (Figure 2). With larger number of 
included patients (n=142, 52 patients undergoing SAVR), the investigators 
of the TOPAS study could confirm and extend these results.36 However, this 
technique remains inaccurate in patients with increase in mean transvalvular 
flow rate <15%.36
  Furthermore, simple evaluation of the aortic valve morphology and amount 
of calcifications causing restriction of the aortic cusps suggest the presence 
of severe AS. Computed tomography permits accurate evaluation of the 
aortic valve calcification burden (Figure 3). Using this imaging modality, 
Cueff et al. demonstrated in 49 patients with severe AS and LVEF≤40% (20 
of them with an AVA<1cm2 and mean transvalvular gradient≤40 mmHg) 
that an aortic valve calcification burden of 1651 AU or more identified the 
patients with true severe AS with an sensitivity, specificity, negative and 




  Despite a significant reduction in operative mortality from 20% to 10% in the 
last years,33 accurate risk stratification of patients with severe AS and reduced 
LVEF remains challenging. Patients with true severe AS, regardless the 
presence or absence of LV contractile and flow reserve during dobutamine 
stress echocardiography, have better prognosis when treated surgically 
rather than medically 31, 37 whereas patients with pseudosevere AS have 
better prognosis when medically treated.38 Therefore, the definition of the 
severity of AS is the first step in risk stratification of patients with low flow 
low gradient severe AS and reduced LVEF. The presence of LV contractile 
or flow reserve has been associated with better prognosis in patients 
undergoing SAVR.31 In a multicenter study including 136 patients with low 
flow low gradient severe AS and reduced LVEF, patients with LV flow reserve 
defined by an increase in LV stroke volume of ≥20% had lower perioperative 
mortality compared with patients without LV flow reserve (5% versus 32%, 
p=0.0002).31 The presence of LV flow reserve was associated with better 
perioperative survival (odds ratio 0.091, 95% confidence interval 0.023-0.38; 
p=0.001) and long-term prognosis (hazard ratio 0.4, 95% confidence interval 
0.23-0.69; p=0.001).31 However, a subsequent study showed that in terms of 
LVEF recovery, patients with LV flow reserve had similar improvement in LVEF 
after SAVR as compared to patients without flow reserve.39 Furthermore, data 
from the French multicenter registry demonstrated that in patients with 
64 CHAPTER 3
Figure 2. Low dose dobutamine stress echocardiography to differentiate true severe 
(TS) from pseudosevere (PS) aortic stenosis. The panels indicate the individual data of 
several echocardiographic parameters across each aortic stenosis category. The percentage of 
correctly classified true severe or pseudosevere AS was higher using the indexed projected aortic 
valve area. The arrows in E indicate the 3 patients who had <15% increase in mean flow rate with 
dobutamine stress. Reproduced with permission from Blais et al.34
Abbreviations:  
CC: correct classification;  
EOA: effective orifice area;  
MG: mean gradient;  
PS: pseudosevere;  
Qmean: mean flow rate;  
TS: true severe.
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low flow low gradient severe AS and reduced LVEF (n=81) and no LV flow 
reserve on dobutamine stress echocardiography, the long-term prognosis 
was better after SAVR compared with medical treatment.37 Therefore, in 
this specific group of patients other factors should be considered to decide 
whether SAVR may be a safe and feasible therapeutic option. 
  Assessment of LV systolic function with conventional echocardiographic 
parameters such as LVEF or stroke volume in patients with low flow low 
gradient severe AS and reduced LVEF has several limitations since these 
parameters are highly influenced by LV geometry and preload conditions. 
The advent of novel echocardiographic techniques such as speckle tracking 
echocardiography has permitted detection of early myocardial damage in the 
left ventricle, and have proven good correlations with extent of myocardial 
scar assessed with LGE-MRI.40, 41 By evaluating active myocardial deformation 
of the LV, speckle tracking echocardiography has shown that patients with 
aortic stenosis have impaired multidirectional deformation that may improve 
after SAVR (Figure 4).42, 43 Particularly in the group of patients with low flow 
low gradient severe AS, investigators from the TOPAS study demonstrated 
the prognostic value of LV longitudinal strain in 47 patients (16 of them 
undergoing SAVR).44 Peak longitudinal strain (rate) was measured at rest and 
following peak dose dobutamine infusion. Although peak longitudinal strain 
did not change (from -7.56±2.34% to -7.41±2.89%, p=0.7), peak longitudinal 
strain rate improved significantly at peak stress suggesting an improvement 
in LV contractility (from -0.38±0.12 s-1 to -0.53±0.18 s-1, p<0.001). Peak stress 
longitudinal strain rate had incremental prognostic value over the STS-
r
Figure 3. Aortic valve calcification burden assessed with computed tomography to 
differentiate between true and pseudosevere aortic stenosis. The left panel shows the 
example of an 85 year old patient with severe aortic stenosis and reduced left ventricular ejection 
fraction. During low dose dobutamine stress echocardiography, the mean gradient increased 
to 36 mmHg and the aortic valve area (AVA) remained <0.6 cm2/m2. On computed tomography, 
the calcium score of the valve was 1858 AU (above the cut-off value proposed to define severe 
AS; see main text). The right panel shows the example of a 79 year old woman with severe aortic 
stenosis and reduced left ventricular ejection fraction. During low dose dobutamine stress 
echocardiography, the AVA increased >0.6cm2/m2 suggesting the diagnosis of pseudosevere AS. On 
computed tomography, the calcium score of the aortic valve was below the proposed cut-off value). 
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PROM  (Society of Thoracic Surgeons Predicted Risk of Mortality score) and 
NT-proBNP (area under the curve 0.89, p=0.034).44 In a subsequent sub-
analysis of the TOPAS trial, including 202 patients with low gradient severe 
AS and LVEF≤40%, global LV longitudinal strain at rest and at peak stress was 
independently associated with outcome: a value of global LV longitudinal 
strain at rest of -9% or higher (indicating more impaired LV shortening) was 
associated with a two-fold increased mortality risk after correction for age, 
coronary artery disease, AVA
proj
 and type of treatment (SAVR versus medical 
treatment).45 In addition, the lack of LV contractile reserve during dobutamine 
stress echocardiography (defined by a global LV longitudinal strain value at 
stress of -10% or higher) had incremental prognostic value over rest global 
LV longitudinal strain. 
  The underlying LV substrate is characterized by increasing amounts of 
myocardial fibrosis, which explains the impaired LV myocardial deformation 
and lack of LV contractile or flow reserve.40, 46 The increased afterload imposed 
by the stenotic valve and associated factors such as hypertension and 
increased valvulo-arterial impedance lead to development of LV hypertrophy, 
which may eventually lead to HF if aortic stenosis (and arterial hypertension) 
is left untreated. This transition is characterized by increased apoptosis 
and fibrosis (scar) formation. The patterns of replacement fibrosis (scar) in 
AS patients assessed with late gadolinium contrast-enhanced magnetic 
resonance imaging (LGE-MRI) can be divided in midwall fibrosis and infarct-
like fibrosis (subendocardial or transmural)(Figure 5).47 In patients with low 
gradient severe AS, Herrmann et al showed that the amount of replacement 
Figure 4. Improvement in left ventricular systolic function after transcatheter aortic valve 
implantation in an 83 year old female with severe aortic stenosis. Panel A shows the baseline left 
ventricular systolic function measured with conventional transthoracic echocardiography (LVEF 
31%) and speckle tracking echocardiography (global longitudinal strain -5.9%). At 6 months follow-
up, LVEF normalized and global longitudinal strain improved to -14.6% (panel B).  
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fibrosis (scar) was significantly larger compared with patients with high 
gradient severe AS, and was associated with more impaired LV longitudinal 
shortening.46 In 143 patients with at least moderate AS undergoing LG-MRI, 
the presence of myocardial scar was observed in 64% (38% midwall scar; 
28% infarct-like scar).47 The presence of midwall and infarct-like scar was 
associated with 8- and 6-fold increase in all-cause mortality, respectively. On 
multivariate analysis, lower LVEF (HR: 0.96, 95% CI 0.94-0.99; p=0.009) and 
midwall fibrosis (HR: 5.35, 95% CI 1.16-24.56; p=0.003) were independently 
associated with all-cause mortality. In patients undergoing SAVR, the 
presence of LGE was also shown independently associated with worse 
postoperative mortality (HR:2.8, 95% CI 1.3-6.9; p=0.025).28
  However, LGE identifies only regional differences in macroscopic replace-
ment fibrosis (scar) and does not detect diffuse interstitial fibrosis, which 
is the predominant form of fibrosis at earlier stages of AS. MRI T1 mapping 
techniques have allowed quantifying this interstitial diffuse fibrosis (which 
can be considered as a precursor of HF). Flett et al applied
  T1 mapping in patients with severe AS, and demonstrated that diffuse myo-
cardial fibrosis correlated with clinical symptoms and LV systolic function 
parameters.48 Six months after SAVR, LV mass reduced but the amount of 
diffuse myocardial fibrosis remained unchanged suggesting that regression 
in LV hypertrophy occurred due to reduction in cell volume rather than re-
gression in diffuse fibrosis.
  These studies demonstrate the clinical value of advanced assessment of LV 
function (beyond LVEF) using strain (rate) imaging or advanced anatomical 
imaging using MRI T1 mapping to assess myocardial tissue characteristics 
(fibrosis). These functional and anatomical imaging techniques may help to 
understand the outcome after SAVR, TAVI and medical treatment of patients 
with severe AS and reduced LVEF.  
Figure 5. Late gadolinium contrast-enhanced magnetic resonance imaging in aortic 
stenosis. Panel A shows midwall focal fibrosis at the junction between the right and the left 
ventricle (arrow). Panel B shows infarct-like myocardial fibrosis with transmural hyperenhacement 
of the septum (arrows).
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TREATMENT AND OUTCOMES 
Aortic valve replacement is the definitive treatment of severe calcific AS. Recent registries have 
shown significant declines in 30-day mortality risks after SAVR (from 0.83 in 1992-1994 to 0.64 
in 2007-2009).49 The operative mortality rates for isolated SAVR in patients aged <70 years are 
1-3% whereas for older patients the mortality rates range between 4-8%.4 One of the factors 
independently associated with increased operative mortality is the presence of HF and reduced 
LVEF.11, 50, 51 In a contemporary observational analysis including 114,135 patients aged ≥65 years old 
who underwent  isolated aortic valve replacement, the presence of HF was associated with increased 
operative mortality and worse long-term survival.50 In addition, longer duration of HF symptoms 
before aortic valve replacement was significantly associated with worse outcome.50 Therefore, 
management of patients with severe AS and HF requires careful weighing of the operative risks and 
the clinical benefits. 
Medical treatment and percutaneous balloon valvuloplasty may be appropriate therapeutic bridges 
to definitive aortic valve replacement in specific circumstances such as patients with hemodynamic 
instability. Indication for SAVR or TAVI relies on Heart Team discussion evaluating the individual’s 
operative risk, frailty and comorbidities as well as the technical suitability for TAVI. Finally, patients 
with pseudosevere AS represent a specific subgroup with better outcomes under medical therapy 
than patients with true severe low flow low gradient AS and comparable survival to that of HF 
patients without AS.38
Figure 6. Long-term survival of patients with severe aortic stenosis undergoing 
balloon aortic valvuloplasty. Reproduced with permission from Eltchaninoff et al. Am Heart J. 
2014;167(2):235-40.54
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Severe AS and 
decompensated 
HF. 
  This high risk situation urges prompt hemodynamic stabilization that 
cannot be delayed by the screening process to decide suitability for SAVR 
or TAVI. Few studies have reported on the role of medical treatment in 
critically ill patients with severe AS and LV systolic dysfunction.52, 53 Although 
vasodilators are traditionally contraindicated in this group of patients, 
small studies have demonstrated that nitroprusside and levosimendan can 
improve cardiac output and stabilize the hemodynamic condition allowing 
later referral to SAVR.52, 53 Of note, patients with hypotension (mean arterial 
systolic pressure <60 mmHg) or under inotropic treatment were excluded 
from these trials52, 53 and therefore, such a therapeutic option would not 
be indicated in those specific patients. More experience has accumulated 
with the use of percutaneous balloon aortic valvuloplasty as alternative to 
inotropic treatment.54 This technique permits decreases in mean transaortic 
pressure gradient >50% and improvement in AVA >1.0cm2 in 80% of the 
patients. Reductions of the arterial sheaths and development of vascular 
closure devices have improved the safety of this procedure with significant 
decreases in vascular complication rates. In 323 patients with severe AS and 
high operative risk (logistic EuroSCORE 28.7±12.5%) who underwent balloon 
aortic valvuloplasty, the rate of major inhospital complications was 6.8% 
and inhospital mortality was 2.5%.54 After this treatment, 65% of patients 
continued medical treatment while the remaining patients were bridged to 
SAVR or TAVI. Single balloon aortic valvuloplasty was associated with worse 




  In patients with low flow low gradient severe AS and reduced LVEF and 
presence of contractile/flow reserve, current guidelines recommend SAVR.4 
Studies comparing the outcomes of SAVR versus medical treatment of 
patients with classical low flow low gradient severe AS demonstrated that 
SAVR was associated with better survival at follow-up.29, 55 Similar results have 
been reported for patients with classical low flow low gradient severe AS 
without contractile/flow reserve on dobutamine stress echocardiography.37 
In addition, SAVR was associated with improvement in LVEF at follow-up 
in patients with classical low flow low gradient severe AS independently 
of the presence of contractile/flow reserve.39 The French multicentre study 
including 66 patients with classical low flow low gradient severe AS (46 with 
contractile/flow reserve and 20 patients without) showed that after SAVR 
the increment in LVEF was comparable between patients with and without 
contractile/flow reserve (19±10% versus 17±11%, p=0.54).39 The advent of 
TAVI has altered the management of such high-risk patients. The Placement 
of Aortic Transcatheter Valves (PARTNER) trial included a large cohort of 
patients with severe AS who were randomized to TAVI or medical treatment 
(including balloon aortic valvuloplasty) for patients with contraindications 
for SAVR (cohort B) and to TAVI or SAVR for patients with increased surgical 
risk (cohort A).56, 57 The prevalence of classical low flow low gradient severe 
AS was 15% (n=147). Low flow status was associated with increased 2-year 
mortality compared with normal flow status (for both cohorts) (47.1% versus 
33.7%; hazard ratio 1.58, 95% confidence interval 1.28-1.95; p<0.001).7 
However, the presence of reduced LVEF (<50%) was not associated with 
further increase in mortality. Compared with medical treatment, TAVI 
was associated with significant reductions in 2-year mortality of patients 
70 CHAPTER 3
with classical low flow low gradient severe AS (80% versus 47.1%, p=0.04) 
whereas there were no differences between SAVR and TAVI (37.1% versus 
42.9%, p=0.5).7 In addition, subanalysis of the PARTNER cohort A showed that 
SAVR and TAVI lead to comparable improvements in LVEF at follow-up (from 
38.0±8.0% to 50.1±10.8% and from 35.7±8.5% to 48.6±11.3%, respectively). 
Importantly, right ventricular pacing or induction of left bundle branch 
block (LBBB) after TAVI have been associated with lack of improvement in LV 
systolic function.58, 59 Recent series including 3726 patients treated with TAVI 
showed that, after a mean follow-up of 22 months, 15% and 5.6% of deaths 
were caused by advanced HF and sudden cardiac, respectively.60 LVEF≤40% 
was independently associated with death from advanced HF and sudden 
cardiac death whereas persistent LBBB following TAVI was associated with 
increased risk of sudden cardiac death. These findings have important clinical 
implications and fuel the discussion on the use of cardiac resynchronization 
therapy with or without defibrillator capabilities in these patients.
Pseudosevere AS.   In this subgroup of patients, optimal medical treatment provides similar 
survival than that of patients with HF and normal aortic valve function.38 
Cardiac resynchronization therapy, an established HF therapy indicated 
in patients who remain symptomatic despite optimal medical treatment, 
reduced LVEF and wide QRS,61 may be one of the therapies underutilized in 
this specific group of patients. A recent analysis including 88 patients with 
classical low flow low gradient severe AS showed that the prevalence of 
QRS duration ≥130 ms was 56%. 62 In addition, QRS duration was strongly 
associated with worse outcome (hazard ratio 2.20, 95% confidence interval 
1.15-4.24; P = 0.027). Whether treatment with cardiac resynchronization 
therapy would have resulted in better outcomes remains unknown.
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FUTURE DIRECTIONS 
Severe AS and HF are common conditions that may coincide having 
important clinical and prognostic implications. The development of TAVI 
has shifted the attention to this subgroup of patients who were considered 
inoperable a decade ago. However, there are still uncertainties regarding 
the treatment of specific subgroups of patients with severe AS and HF. 
For example, patients with LVEF<20% have been excluded from recent 
randomized trials on TAVI.16, 56, 57 Currently few case reports have shown the 
safety and feasibility of performing TAVI under extracorporeal membrane 
oxygenation. Whether patients with such reduced LVEF may benefit from 
TAVI remains to be elucidated. Probably, accurate assessment of the LV 
structure and function using late gadolinium contrast enhanced MRI may 
help to identify the patients with limited amount of scar that can lead to 
functional recovery after TAVI and better prognosis.28 Another question is the 
role of cardiac resynchronization therapy in these patients. Upgrade of right 
ventricular pacing to cardiac resynchronization therapy or implantation of 
cardiac resynchronization therapy in patients with LBBB prior or after TAVI may 
further improve LVEF and improve the prognosis. Finally, afterload reduction 
with medical therapy is the mainstay of HF therapy.  Bearing in mind the 
increasing prevalence of HF and degenerative AS along with the ageing of 
the population, additional afterload reduction by TAVI on top of established 
HF therapy seems an attractive new concept. The Transcatheter Aortic Valve 
Replacement to UNload the Left ventricle in patients with ADvanced heart 
failure (TAVR UNLOAD) is a newly designed international randomized trial to 
assess whether TAVI on top of optimized HF therapy affects the composite 
hierarchical endpoint of all-cause death, disabling stroke, hospitalization for 
HF or aortic valve disease and change in quality of life in patients with HF and 
proven moderate AS. Additional randomized clinical studies are needed to 
better define the management of HF patients with aortic stenosis. 
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CHAPTER 4
Left Ventricular Functional Recovery and 
Remodeling in Low-Flow Low-Gradient 
Severe Aortic Stenosis After Transcatheter 
Aortic Valve Implantation
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Philippe Debonnaire, MD; Spyridon Katsanos, MD; Philippe J. van 
Rosendael, MD; Frank van der Kley, MD; Georgios Sianos, MD, PhD; 
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ABSTRACT
 Background   Speckle-tracking derived global longitudinal strain (GLS) is a more 
sensitive method of detecting left ventricular (LV) functional recovery after 
transcatheter aortic valve implantation (TAVI) in patients with severe aortic 
stenosis. However it remains unknown whether LV function improves in low 
flow, low gradient severe aortic stenosis (LFLGSAS) patients after TAVI. The 
current study aims to evaluate LV functional recovery and remodeling after 
TAVI in LFLGSAS patients.
 Methods   68 patients (men 57%, mean age 79.1±7.1 years) with LFLGSAS treated with 
TAVI were evaluated. LV function and remodeling, were investigated pre-TAVI, 
at 6 and 12 months after TAVI. All echocardiography data were prospectively 
collected and GLS was retrospectively analyzed.
 Results   Among LFLGSAS patients, 35 (52%) had low LV ejection fraction (LVEF<50%) 
and 33 (48%) had preserved LVEF (≥50%). The low LVEF group had significantly 
more impaired GLS than the group with preserved LVEF (-8.3±2.6 vs. -13.3±3.5 
%; p<0.001). LV systolic function improved after TAVI in both groups. While 
in the group of patients with low LVEF all functional parameters improved, 
in the group of patients with preserved LVEF only strain derived parameters 
significantly improved. There was a significant decrease in absolute LV wall 
thickness and relative wall thickness and a trend to decrease in LV mass index 
in both LVEF groups.  LV volumes decreased significantly in those with low 
LVEF but not in those with preserved LVEF. Baseline GLS but not LVEF group 
was independently associated to GLS improvement at 12 months post-TAVI.
 Conclusions   LFLGSAS patients with low and preserved LVEF had a significant improvement 
in LV function after TAVR, as assessed by GLS.  Absolute and relative LV wall 
thickness decreased in both groups of patients, but only those with low LVEF 
had a reduction in LV chamber volumes.
 Keywords   Aortic valve stenosis,  
Low-flow low-gradient,  
Speckle tracking, Strain,  
Transcatheter aortic valve implantation
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INTRODUCTION
The prevalence of low flow low gradient severe aortic stenosis (LFLGSAS) among patients referred for 
aortic valve replacement is relatively high. Pooled data from the Placement of Aortic Transcatheter 
Valves (PARTNER) trials (including the inoperable and high-risk cohorts) showed a prevalence of 
29% of LFLGSAS.1 Transcatheter aortic valve implantation (TAVI) in this group of patients leads to a 
better prognosis than medical treatment.1-3 The associated factors that may determine an improved 
outcome remain unknown. Probably, an improvement in LV mechanics and remodeling after relief 
of pressure overload may influence positively the prognosis of the patients. However, changes in LV 
function and remodeling after TAVI in this particular group of patients have not been investigated. 
In addition, it remains unknown when exactly these changes do occur, either early after reducing 
the pressure overload or later at follow-up. 
Left ventricular ejection fraction (LVEF) is the most frequently used parameter to assess LV function 
although it may not be sensitive enough to detect significant improvement in left ventricular (LV) 
mechanics after TAVI, particularly in the subgroup of patients with LFLGSAS and preserved LVEF. 
Recently it has been suggested that speckle tracking global longitudinal strain (GLS) is a more 
sensitive method than LVEF in detecting LV myocardial recovery after TAVI.4,5 Therefore, the aim 
of the present evaluation was to characterize LV functional recovery, estimated by LVEF and GLS, 
and LV remodeling, estimated by LV mass and volumes, after TAVI in LFLGSAS patients, with special 
focus on subpopulations with reduced (<50%), known as “classical LFLGSAS”, and preserved LVEF 
(≥50%), known as “paradoxical LFLGSAS”, according to ESC/EACTS guidelines.6 In addition, the time 
course of these changes was investigated.
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METHODS
Patients   From a cohort of 253 patients with symptomatic severe aortic stenosis 
who underwent TAVI at the Leiden University Medical Center, 68 (27%) 
patients were identified as having LFLGSAS according the baseline Doppler 
echocardiography estimation of aortic valve area index (AVAi ≤0.6 cm2/m2), 
mean pressure gradient across the aortic valve (MPG ≤40mmHg) and stroke 
volume index (SVi ≤35 ml/m2).6,7 LV remodeling and functional recovery 
was evaluated at follow-up after successful TAVI. LV mass index (LVMi) and 
indexed LV volumes were measured at baseline, 6 and 12 months after TAVI. 
In addition, LVEF and speckle tracking derived GLS and strain rate were 
assessed. Further analysis by dividing the population into low LVEF (<50%) 
and preserved LVEF (≥50%) groups at baseline was performed. Patients who 
had high gradient aortic stenosis, patients who underwent “valve in valve” 
procedures or had more than mild aortic regurgitation before TAVI were 
excluded from the analysis. For this retrospective evaluation the Institutional 
Review Board waived the need of patient written informed consent. 
TAVI procedure   TAVI was performed at the catheterization laboratory under general 
anesthesia and the 23, 26 or 29-mm Edwards SAPIEN and SAPIEN XT 
(Edwards Lifesciences, Irvine, California) or the 26, 29, 31-mm Medtronic 
CoreValve (Medtronic, Minneapolis, Minnesota) were implanted. The 
preferred approach was transfemoral. The transapical approach was used 
in patients with unfavourable iliofemoral anatomy or in patients in whom a 
29-mm Edwards SAPIEN XT valve was implanted.8 Successful TAVI procedure 
was defined as implantation of a well-functioning valve in the aortic annulus, 
without intraprocedural death.9 
2D Transthoracic 
echocardiography
  Transthoracic echocardiography was performed before TAVI and at 6 and 12 
months after TAVI using commercially available ultrasound system (Vivid-7 
and E9, General Electric, Horten, Norway) equipped with 3.5MHz or M5S 
transducers. Two-dimensional grey-scale images and colour, continuous 
and pulsed wave Doppler data were acquired from parasternal, apical and 
subcostal acoustic windows. Data were stored digitally and analyzed offline 
on a dedicated workstation (EchoPac 112.0.1, GE Medical Systems, Horten, 
Norway). 
  The aortic stenosis severity was quantified by measuring the maximum 
velocity through the aortic valve with the use of continuous wave Doppler. 
Mean pressure gradient (MPG) was estimated using the modified Bernoulli 
equation.10 Left ventricular outflow tract was measured on 2D transthoracic 
echocardiography and subsequently, aortic valve area (AVA) was calculated 
with the continuity equation and indexed to body surface area (BSA).10 







: aortic cross sectional area at the level of sino-
tubular junction).10,11 LV dimensions were measured on the parasternal 
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long-axis view on 2-dimensional grey-scale images. LV mass (LVM) was then 
estimated according to the formula by Devereux et al (0.8x {1.04 [(LVEDD 
+PWTd+ SWTd)3 -(LVEDD)3]} +0.6 g; where LVEDD is left ventricular end-
diastolic diameter, PWTd is posterior wall thickness in diastole, SWTd is 
septal wall thickness in diastole and indexed to BSA.12 Relative wall thickness 
[RWT=(2xPWTd)/LVEDD]13 and the ratio of LVM to LVEDV were then 
estimated.13 LV end-diastolic (LVEDV) and end-systolic volume (LVESV) were 
calculated from the apical four- and two-chamber views and then indexed 
to BSA.12 LVEF was derived with the biplane Simpson method.12 Stroke 
volume (SV) was calculated by multiplying the LV outflow tract (LVOT) cross 
sectional area by the velocity time integral derived from the pulsed wave 
Doppler recordings acquired at the LVOT. Cardiac output (CO) was estimated 
by multiplying SV by heart rate (HR) and cardiac index by indexing CO for 





  LV systolic function was assessed with 2D speckle tracking echocardiography 
(STE) derived global longitudinal strain (GLS) and strain rate (GLSr). In order to 
estimate GLS, the three-, four- and two-chamber apical views were optimized 
to achieve a frame rate of at least 40 frames per second, recorded on 2D grey-
scale and then analyzed offline at a workstation with commercially available 
software (EchoPac 112.0.1, GE Medical Systems, Horten, Norway). The aortic 
valve closure timing was first defined at the apical LV long-axis view and then 
the LV endocardial border was traced at each apical view at an end-systolic 
frame. A region of interest was automatically defined and adapted not to 
extend beyond the epicardial border. Finally, GLS and GLSr were calculated 
as the average from all 3 apical views. GLS was expressed as % and GLSr as 1/s. 
Two representative examples of GLS evaluation at the three time points (pre-
TAVI, 6 months and 12 months post-TAVI) for a patient with low and a patient 
with preserved LVEF are presented at Figure 1 and Figure 2 respectively.
Figure 1.  
Illustrative case of left ventricular global longitudinal strain (GLS) evaluation in a patient with 
low left ventricular ejection fraction and low-flow low-gradient severe aortic stenosis: GLS 




  Statistical analyses were performed with the SPSS software version 20 (SPSS, 
Chicago, IL). All categorical values are expressed as frequency (percentage) 
and continuous variables as mean ± standard deviation. Continuous variables 
were compared between the 2 groups at baseline with the Student-t test or 
Mann Whitney U test, as appropriate, and categorical variables with the x2 test.
  The modeling approach for assessing the overall change of LVEF, GLS, 
GLSr, LVMi, LVEDVi and LVESVi over the 12-month period after TAVI, was 
linear mixed modeling with these variables as the dependent variables and 
time (baseline, 6 and 12 months after TAVI) and LVEF category at baseline 
(<50% vs. ≥50%) as the main fixed effects. Main effects were compared with 
Bonferroni confidence interval adjustment. Parameter estimates and tests 
for covariance estimates were tested with 95% confidence interval. Post 
hoc testing was done to determine the time points at which the dependent 
variables differed between the 2 LVEF groups. Clinical and echocardiographic 
parameters were then tested as covariates to assess their influence on LV 
function and remodeling over time. Improvement in GLS or GLSr over 
time was defined by the amplitude of increase in GLS / GLSr regardless of 
whether these are expressed in positive or negative numbers. In order to 
identify baseline parameters associated with LV mass regression and GLS 
improvement, binary logistic regression was performed by defining at 12 
months the improvement in GLS as 10% increase of absolute amplitude,15 
and the LV mass regression as 10% reduction.16




  Table 1 summarizes the demographic characteristics of the patients (39 
men, mean age 79.1±7.1 years). The mean logistic Euroscore was 26.6±16.3 
%. Baseline echocardiographic characteristics are presented in Table 2. The 
mean AVAi was 0.4±0.1 cm2/m2, mean transaortic pressure gradient was 
28.1±8.1 mmHg and mean SVi was 26.6±4.6 ml/m2. Mean LVEF was 45.8±16.2 
%. 
  There were 35 patients with LFLGSAS and low LVEF, whereas the remaining 33 
patients had preserved LVEF. Patients with preserved LVEF had significantly 
smaller LV volumes and more concentrically remodeled LV compared to 
patients with reduced LVEF. In addition, patients with preserved LVEF had 
more preserved LV GLS and GLSr (-13.3±3.5 vs. -8.3±2.6 %; p<0.001 and 
-0.7±0.1 vs. -0.4±0.1 1/s; p<0.001, respectively) compared to patients with 
reduced LVEF (Tables 1 and 2). Prosthesis-patient mismatch was observed in 
14 (20%) patients and paravalvular regurgitation in 32 (47%) of patients.
LV functional recovery 
and remodeling in 
LFLGSAS patients after 
TAVI
  LV systolic function significantly improved over 12 months after TAVI in 
the overall cohort of LFLGSAS patients. Although LVEF had no significant 
change over time (from 45.8±16.2 % pre-TAVI to 49.7±15.9 % 6 months after 
TAVI and 49.8±15.2 % at 12 months; p=0.08), LV GLS and GLSr improved 
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Table 1. Baseline clinical and TAVI characteristics of the LFLGSAS patients
Overall   
(N=68)






Age (years) 79.1±7.1 79.2±6.8 78.8±7.5 0.80
Male gender, n (%) 39 (57) 22 (63) 17 (52) 0.34
BSA (m2) 1.8±0.1 1.8±0.1 1.8±0.1 0.90
Sinus Heart Rhythm, n (%) 40 (59) 18 (51) 22 (67) 0.38
CVD Risk Factors
Hypertension, n (%) 54 (79) 25 (71) 29 (88) 0.09
Diabetes, n (%) 22 (32) 10 (29) 12 (36) 0.49
Hyperlipidemia, n (%) 43 (63) 21 (60) 22 (67) 0.56
Smoking ever, n (%) 34 (50) 18 (51) 16 (49) 0.80
Medical History
PVD, n(%) 38 (60) 22 (63) 16 (49) 0.32
Stroke prior to TAVI, n(%) 10 (15) 4 (12) 6 (18) 0.51
CAD, n(%) 52 (77) 26 (74) 26 (79) 0.77
Revascularization, n(%) 45 (67) 22 (65) 23 (70) 0.66
Renal Failure, n(%) 15 (22) 9 (26) 6 (18) 0.56
Symptoms
Angina, n (%) 24 (35) 9 (26) 15 (46) 0.08
Dyspnea, n (%) 67 (99) 34 (97) 33 (100) 0.32
Syncope, n (%) 9 (13) 3 (90 6 (18) 0.24
Medication
Beta-blockers, n (%) 50 (74) 24 (69) 26 (79) 0.41
ACEi / ARBs, n (%) 43 (63) 25 (71) 18 (55) 0.20
Surgical Risk
Logistic EuroSCORE (%) 26.6±16.3 32.7±17.2 20.2±12.8 0.001
TAVI procedure
Approach-Transfemoral, n(%) 28 (41) 13 (37) 15 (46) 0.4
Valve type-SAPIEN, n(%) 66 (97) 34 (97) 32 (97) 0.9
Values are mean ± standard deviation or n (%) 
*p-value for comparison between LFLG, low LVEF and LFLG, preserved LVEF 
ACEi, angiotensin converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BSA, 
Body surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVD, 
cardiovascular disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; 
STS, society of thoracic surgeons; TAVI, transcatheter aortic valve implantation.
Figure 2. Illustrative case of left ventricular global longitudinal strain (GLS) evaluation in a patient 
with preserved left ventricular ejection fraction and low-flow low-gradient severe aortic stenosis: 
GLS assessed A. pre-TAVI, B. 6 months post and C. 12 months post-TAVI.
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Table 2. Baseline echocardiographic assessment of the LFLGSAS patients





Bicuspid valve, n (%) 2 (3) 1 (3) 1 (3) 0.96
Vmax (m/s) 3.4±0.5 3.3±0.5 3.5±0.5 0.07
MPG (mmHg) 28.1±8.1 26.4±8.2 30.0±7.5 0.06
AVAi (cm2/m2) 0.38±0.1 0.37±0.1 0.38±0.1 0.64
ELI (cm2/m2) 0.44±0.1 0.44±0.1 0.45±0.1 0.73
LV Geometry
SWTd (cm) 1.4±0.2 1.3±0.2 1.5±0.1 0.002
PWTd (cm) 1.3±0.2 1.2±0.2 1.3±0.1 0.07
LVEDDi (cm/m2) 2.6±0.5 2.9±0.5 2.3±0.3 <0.001
LVESDi (cm/m2) 1.9±0.6 2.3±0.5 1.4±0.3 <0.001
LVMi (g/m2) 138.8±40.3 152.5±46.8 124.2±25.6 0.003
RWT (%) 55.1±16.7 47.6±14.1 63.0±15.8 <0.001
LVEDVi (ml/m2) 54.1±28.2 68.1±31.1 39.2±14.2 <0.001
LVESVi (ml/m2) 31.5±23.9 46.8±24.4 15.2±5.7 <0.001
LVM/LVEDV ratio (g/ml) 3.1±1.6 2.64±1.4 3.63±1.5 0.01
LV Systolic Function  
LVEF (%) 45.8±16.2 31.9±8.6 60.6±6.0 <0.001
SVi (ml/m2) 26.6±4.6 26.2±4.3 27.0±4.9 0.45
CO (l/min) 3.7±0.8 3.7±0.7 3.7±0.9 0.78
 CI (l/min/m2) 1.9±0.4 1.9±0.4 2.0±0.4 0.82
LV GLS (%) -10.7±3.9 -8.3±2.6 -13.3±3.5 <0.001
LV GLSr (%) -0.5±0.1 -0.4±0.1 -0.7±0.1 <0.001
Values are mean ± standard deviation or n (%)
*p-value for comparison between LFLG, low LVEF and LFLG, preserved LVEF.
AVAi, Aortic valve area indexed; 
CI, cardiac index; 
CO, cardiac output; 
ELI, energy loss index; 
LV, left ventricular; 
LVEDDi, left ventricular end-diastolic diameter indexed; 
LVEDVi, left ventricular end-diastolic volume indexed; 
LVEF, left ventricular ejection fraction; 
LVESDi, left ventricular end-systolic diameter indexed; 
LVESVi, left ventricular end-systolic volume indexed; 
LV GLS, left ventricular global longitudinal strain; 
LV GLSr, left ventricular global longitudinal strain rate; 
LVMi, left ventricular mass indexed; 
MPG, mean pressure gradient; 
PWTd, posterior wall thickness at end-diastole; 
RWT, relative wall thickness; 
SVi, stroke volume indexed; 
SWTd, septal wall thickness at end-diastole; 
Vmax, transaortic valve maximal velocity.
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significantly during the 12 months of follow-up (-10.7±3.9 vs. -11.9±4.5 vs. 
-12.6±4.5 %; p=0.002; and -0.5±0.1 vs. -0.6±0.2 vs. -0.7±0.2 1/s; p<0.001; 
respectively for the same time period) (Figure 3). This improvement in GLS 
and GLSr occurred mainly during the first 6 months after TAVI. No significant 
changes were observed in these variables between 6 and 12 months after 
TAVI. The improvement in GLS over time remained significant after adjusting 
for age, gender, diabetes, hypertension, coronary artery disease, logistic 
Euroscore, use of beta-blockers, angiotensin converter enzyme inhibitors / 
angiotensin receptor blockers, TAVI valve type (self-expandable vs. balloon-
expandable), TAVI access (transfemoral vs. transapical), LVMi as well as LVEF 
category at baseline (adjusted coefficient -1.82, confidence interval -0.51 to 
-3.13, p=0.007). The extent of improvement in GLS was comparable between 
patients who underwent transfemoral vs. transapical TAVI (coefficient -1.01, 
confidence interval 0.81 to -2.84, p=0.27). GLS improvement over time was 
influenced by the presence of prosthesis-patient mismatch (coefficient 
3.29, confidence interval 0.97 – 5.60, p=0.006) but not by the presence of 
paravalvular regurgitation (coefficient 0.33, confidence interval -2.03 – 
2.70, p=0.78) at 6 months post-TAVI. From the baseline variables, GLS was 
independently associated (OR 1.69, confidence interval 1.18 – 2.42, p=0.004) 
to a 10% GLS improvement after adjusting for LVEF category at baseline. 
  Over a 12-month period after TAVI, there were no significant changes in LV 
volumes. However, relative wall thickness was significantly reduced during 
the first 6 months after TAVI and remained stable for the next 6 months 
(from 55.1±16.7 to 48.2±12.8 and 48.7±14.3, p=0.003). Additionally, there 
was a significant reduction in LVMi during the first 6 months after TAVI that 
remained stable for the next 6 months (from 138.8±40.3 to 125.5±35.0 
and 126.1±32.4 g/m2; p=0.01) (Figure 4). The reduction in LVMi over time 
remained significant after adjusting for age, gender, diabetes, hypertension, 
coronary artery disease, logistic Euroscore, use of beta-blockers, angiotensin 
converter enzyme inhibitors / angiotensin receptor blockers, TAVI valve type, 
TAVI access, GLS as well as LVEF category at baseline in the LFLGSAS patients 
Figure 3. Changes in left ventricular systolic function assessed by (A) left ventricular ejection 
fraction (LVEF), (B) left ventricular global longitudinal strain (GLS) and (C) left ventricular global 
longitudinal strain rate (GLSr) in the total low-flow low-gradient severe aortic stenosis population 
(black line), in the low left ventricular ejection fraction group (red line) and in the preserved left 
ventricular ejection fraction group (green line) over a 12-month period after transcatheter aortic 
valve implantation. GLS and GLSr improved over time in the total cohort and in both groups, 
regarding that GLS and GLSr improvement is expressed by more negative numbers, i.e. the lower 
the value, the better the systolic function. All parameters are expressed as mean ± standard 
deviation. P-values for the change of the parameter over the total 12-month follow-up period after 
TAVI.
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(adjusted coefficient -12.04, confidence interval -1.28 to -22.79, p=0.02). LV 
mass regression over time was neither affected by the presence of prosthesis-
patient mismatch (coefficient 9.28, confidence interval -10.86 – 29.44, 
p=0.36) nor by the presence of paravalvular regurgitation (coefficient 9.46, 
confidence interval -9.51 – 28.44, p=0.32). Any of the baseline parameters 
was not significantly associated to LV mass regression at follow-up.
Comparison of 
1-year LV functional 
recovery and 
remodeling between 
the low LVEF and 
the preserved LVEF 
group of LFLGSAS 
  LVEF improved significantly in the group of patients with low LVEF, but not 
in the group with preserved LVEF (Table 3). However, in terms of LV GLS and 
GLSr, both groups of patients significantly improved in LV systolic function 
over 12 months after TAVI (table 3). Although GLS improvement over time 
was significant in both groups, it was more prominent in the low LVEF group 
(coefficient -5.18, 95% confidence interval -3.86 – -6.48, p<0.001).  However, 
LV GLS and GLSr, at each time point, were significantly better in the group 
of patients with preserved LVEF (coefficient -5.18, confidence interval -3.88 
to -6.47, p<0.001 and coefficient -0.27, confidence interval -0.21 to -0.32, 
p<0.001 respectively) (Figure 3).
  LV reverse remodeling in both groups was led by the significant reduction 
of posterior and septal wall thickness and subsequently reduction of relative 
wall thickness. LVESVi reduction over time was significant only in the low 
LVEF group. In the group of patients with preserved LVEF there was no 
significant change in LV volumes over time. Although LVMi regression 
over time occurred in both groups, it was more prominent in the low LVEF 
category (coefficient 25.18, 95% confidence interval 10.20 – 40.17, p=0.001) 
(Table 3) (Figure 4). 
DISCUSSION
The present study demonstrates that TAVI is associated with significant improvement in LV 
performance and reduction in LV mass in patients with LFLGSAS. LV functional recovery and mass 
reduction occurred during the first 6 months after TAVI and remained stable for the following 6 
months. In contrast to conventional LVEF, LV GLS and GLSr improved significantly in both groups 
of LFLGSAS patients, with baseline LVEF ≥50% and <50%. Changes in LV GLS and GLSr were 
independent of LVEF at baseline, LVMi and procedural approach (transfemoral or transapical), 
among other relevant clinical variables. 
In the contemporary era, treatment of patients with LFLGSAS still remains controversial. While 
medically treated patients with LFLGSAS have a poor prognosis, the operative risk of these patients 
is also high, with mortality rates significantly higher compared to patients with normal flow and 
high gradient severe AS.17,18 TAVI has emerged as a feasible and safe alternative for patients with 
severe AS and very high operative risk or contraindications for surgery.19-21 According to the sub 
analysis of the PARTNER trial, the prevalence of LFLGSAS was 29% (including cohort A, patients with 
high operative risk, and cohort B, inoperable patients).1 This subgroup of patients had higher 2-year 
mortality rates than patients with normal flow AS (47% vs. 34%, hazard ratio 1.5, 95% confidence 
interval 1.25-1.89, p=0.006). However, the 2-year mortality rates of patients with LFLGSAS who 
underwent TAVI were significantly lower than the group of patients who was medically treated (46% 
vs. 76%, p<0.001). Furthermore, in the subgroup of patients with paradoxical LFLGSAS (preserved 
87VASILEIOS KAMPERIDIS
Figure 4. Changes in left ventricular remodeling assessed by (A) left ventricular end-diastolic 
volume index (LVEDVi), (B) left ventricular end-systolic volume index (LVESVi), (C) left ventricular 
mass index (LVMi) and (D) relative wall thickness (RWT) in the total low-flow low-gradient severe 
aortic stenosis population (black line), in the low left ventricular ejection fraction group (red line) 
and in the preserved left ventricular ejection fraction group (green line) over a 12-month period 
after transcatheter aortic valve implantation.
All parameters are expressed as mean ± standard deviation. P-values for the change of the 
parameter over the total 12-month follow-up period after TAVI.
Table 3. Change of the LV systolic function and remodeling in each LFLGSAS group separately, over a 12-month period after TAVI
LFLGSAS total population (N=68)
LFLG, Low LVEF LFLG, Preserved LVEF
Pre- TAVI 6-month FU 12-month FU p* value Pre-TAVI 6-month FU 12-month FU p† value
N=35 N=23 N=18 N=33 N=26 N=23
LVEF (%) 31.9±8.6 38.9±12.6 40.0±13.3 0.02 60.6 ±6.0 60.7±9.8 58.7±12.0 0.4
LV GLS (%) -8.2±2.7 -9.1±2.9 -10.2±3.6 0.02 -13.2±3.5 -15.0±3.4 -15.1±3.8 0.04
LV basal LS (%) -5.6±3.9 -7.1±4.5 -8.4±4.1 0.02 -8.5±4.7 -9.2±5.7 -12.4±4.9 0.005
LV GLSr (1/s) -0.4±0.1 -0.5±0.1 -0.5±0.1 0.001 -0.6±0.1 -0.8±0.2 -0.8±0.2 0.002
LVMi (g/m2) 152.5±46.8 138.0±36.8 136.8±39.3 0.09 124.2±25.6 112.5±28.8 115.5±21.8 0.1
LVEDVi ml/m2) 68.1±31.1 64.0±26.3 61.8±29.3 0.1 39.2±14.2 42.6±14.5 37.8±13.2 0.5
LVESVi (ml/m2) 46.8±24.5 39.2±22.2 37.7±21.9 0.02 15.2±5.7 17.0±7.8 16.6±8.9 0.4
RWT (%) 47.7±14.1 42.6±10.9 41.5±7.9 0.02 63.1±15.8 54.1±11.9 54.8±15.2 0.01
SWTd (cm) 1.3±0.2 1.2±0.2 1.1±0.2 0.006 1.5±0.2 1.2±0.1 1.2±0.2 <0.001
PWTd (cm) 1.2±0.2 1.1±0.2 1.1±0.2 0.06 1.3±0.2 1.2±0.1 1.2±0.2 0.02
All values are expressed as mean ± standard deviation.
p*   for total change of the parameter over the total FU time in LFLGSAS, low LVEF group
p†   for total change of the parameter over the total FU time in LFLGSAS, preserved LVEF group
LVEDVi, left ventricular end-diastolic volume index;  
LVEF, left ventricular ejection fraction;  
LVESVi, left ventricular end-systolic volume index;  
LV GLS, left ventricular global longitudinal strain;  
LV GLSr, left ventricular global longitudinal strain rate; 
 LVMi, left ventricular mass index;  
LS, longitudinal strain;  
PWTd, posterior wall thickness at end-diastole;  
RWT, relative wall thickness;  
SWTd, septal wall thickness at end-diastole.
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LVEF), TAVI was associated with a significant reduction of the 1-year mortality rates (from 66% to 
35%, p=0.02). Changes in LV remodeling and performance after TAVI may be one of the mechanisms 
underlying the improvement of outcome in these patients. However, data on changes over time in 
LV dimensions and function after TAVI in this particular subgroup of patients are scarce. 






  Several studies have demonstrated LV systolic function improvement and LV 
hypertrophy regression after TAVI.4,5,16,22-24 LVEF is the most frequently used 
method to assess LV systolic function. However, accumulating evidence 
shows that LVEF may not be the ideal parameter to characterize LV systolic 
function in patients with severe AS.7,17,25-27 The compensatory LV hypertrophy 
that accompanies AS leads to an increase in radial wall thickness which 
preserves LVEF.25,28-30 However, LV longitudinal shortening may be impaired 
at this early stage.7,25,29 Therefore, assessment of changes in LVEF after TAVI 
may not be sensitive enough to detect changes in LV function. In contrast, 
the use of more sensitive parameters such as GLS and strain rate may identify 
the patients that benefit from TAVI and show significant improvements in 
LV systolic function. Recently, in 101 consecutive patients undergoing TAVI, 
Kempny et al showed no significant changes in LVEF at 3 months follow-
up whereas GLS and strain rate improved significantly (from -14.0±4.4 to 
-15.5±4.0% and from -0.68±0.24 to -0.78±0.23 1/s respectively).4 Similarly, 
the present study provides more insight into the field by evaluating changes 
in LV systolic function in patients with LFLGSAS treated with TAVI. While 
LVEF did not change significantly over time, GLS and strain rate improved 
significantly at 6 months follow-up. This improvement was sustained at 12 
months follow-up.  
  These changes in LV systolic function are not only related to relief of pressure 
overload but also associated with LV remodeling. Data from the PARTNER 
trials showed a significant reduction in LVMi at 2 years follow-up without 
significant changes in LV volumes.31 However, data on LV remodeling in 
LFLGSAS patients after TAVI are very limited. Gotzmann et al demonstrated a 
significant reduction in LVMi in 10 LFLGSAS with low LVEF patients at 6 months 
after TAVI.3 The present study expands those results and also demonstrates 
that patients with LFLGSAS benefit from TAVI with significant reductions in 
LV mass and improvement in LV systolic function. These improvements were 
independent of TAVI access (transfemoral or transapical), baseline LVEF and 
LVMi and other clinical variables. 
Changes in LV 
performance 
and remodeling 
in LFLGSAS with 
LVEF<50% vs. 
≥50%
  Among patients with LFLGSAS, two different groups can be identified: 
patients with low LVEF and patients with preserved LVEF (or so-called 
paradoxical LFLGSAS).17,32,33 Patients with LFLGSAS and reduced LVEF show 
significantly larger LV volumes at baseline and more eccentric hypertrophy 
than patients with paradoxical LFLGSAS. In addition, based on 2-dimensional 
speckle tracking analysis, patients with LFLGSAS and reduced LVEF have 
more impaired GLS and strain rate compared to patients with paradoxical 
LFLGSAS. However, the time course of LVEF, GLS and strain rate and LVMi 
and LV volumes after TAVI has not been elucidated in these two groups of 
patients.   
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  The present study shows that LV systolic function improves after TAVI in both 
groups of LFLGSAS patients. This improvement was detected by LVEF and 
GLS in the low LVEF group but only by GLS in the preserved LVEF group. 
Using 3D transthoracic echocardiography, Schueler et al reported similar 
findings.5 In 44 patients treated with TAVI, a significant improvement in 
LVEF and GLS was observed in patients with baseline LVEF<37%. In contrast, 
the group of patients with baseline LVEF ≥37% showed a significant 
improvement in GLS but not in LVEF.5 However, the study by Schuler et al did 
not specifically focused on the group of patients with LFLGSAS. In the group 
of patients with paradoxical LFLGSAS, improvement in GLS may reflect an 
intrinsic improvement of myocardial contractility.17,32 In contrast, LVEF may 
only reflect changes in LV volumes and this particular group of patients did 
not show any significant change in these parameters. It remains unknown 
whether this functional improvement is an independent determinant of 
better prognosis in patients with LFLGSAS.
Limitations   The present evaluation is a single center study and the analysis of the data 
was retrospective, although prospectively collected. The number of patients 
included is low, however, this group of patients with LFLG SAS is not common 
in TAVI studies, representing 15 and 14 % of patients with preserved or low 
LVEF, respectively.1 Dobutamine stress echocardiography was not performed 
systematically before TAVI and therefore data on myocardial contractile 
reserve were not available. However, all the patients underwent CT scan with 
an estimated Agatston score of >1650 units from the aortic valve calcification 
which is suggested to distinguish pseudo- from true- severe AS.17,34 The loss 
of patients at follow-up is another limitation. Our results may have been 
influenced by a survival bias considering that patients who died before 6 or 
12 months (perhaps with worse LV function and increased LV hypertrophy) 
had no echocardiographic measurements included in the 6 and 12 months 
data analysis.
CONCLUSION
LFLGSAS patients after TAVI significantly improved LV function, regardless of baseline LVEF category. 
This improvement, which occurred during the first 6 months after TAVI and remained stable for the 
subsequent 6 months, was detected by LV GLS but not by LVEF change, especially in the preserved 
LVEF group. In addition, absolute and relative wall thickness decreased in both groups of patients, 
but only those with low LVEF had a reduction in LV chamber volumes. Overall, TAVI had a positive 
impact on the LFLGSAS patients, providing LV functional recovery and reverse remodeling.
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ABSTRACT
 Objectives   In propensity-score matched patients with severe aortic stenosis treated 
with surgical aortic valve replacement (AVR) with the 3f Enable sutureless 
prosthesis (Medtronic) or transcathter aortic valve replacement (TAVR), the 
hemodynamic performance of both valves and mid-term survival of patients 
were evaluated.  
Background   Data on hemodynamic performance of surgical sutureless bioprostheses in 
high operative risk patients with aortic stenosis are scarce.
 Methods   Of 258 patients undergoing TAVR or surgical AVR with the 3f Enable valve, 
80 (79±5 years old, 100% men) were included in the current analysis based 
on propensity score 1:1 matching for baseline clinical and hemodynamic 
characteristics. All patients had hemodynamic echocardiographic evaluation 
at baseline and discharge. Mid-term survival was analyzed. 
 Results   Compared with the 3f Enable valve, TAVR prostheses (Edwards SAPIEN XT 
[Edwards Lifesciences, Irvine, CA] and CoreValve [Medtronic, Minneapolis, 
MN]) had larger effective orifice area index (1.00±0.30 vs 0.76±0.22cm2/
m2, p<0.001), lower pressure gradient (8.14±4.21 vs 10.72±4.01mmHg, 
p=0.006), less frequent prosthesis-patient mismatch (PPM) (30.0 vs 67.5%, 
p=0.001) and low-flow (46.2 vs 72.5%, p=0.02), but more frequent aortic 
regurgitation (AR) (87.5 vs 20.0%, p<0.001). The presence of PPM was 
independently associated to low-flow state at discharge (OR 4.70, p=0.004) 
and independently associated with the use of the sutureless prosthesis (OR 
3.90, p=0.02). However, the survival of the two groups was comparable after 
1.5 (interquartile range 0.79 to 2.01) years follow-up (log-rank p=0.95).   
 Conclusions   TAVR prostheses showed better hemodynamics than the 3f Enable valve but 
showed higher incidence of AR. However, these differences did not influence 
mid-term survival of patients.
Key Words   aortic stenosis;  
sutureless prosthesis;  
transcatheter prosthesis;  




  The present report highlights the different hemodynamic performance of 
surgical sutureless and transcatheter aortic valve prostheses, by studying a 
propensity-score 1:1 matched population who underwent successful sur-
gical sutureless or transcatheter aortic valve replacement (TAVR) for severe 
aortic stenosis. Compared with sutureless valves, TAVR prostheses had larger 
effective orifice area index, lower pressure gradient, less frequent prosthe-
sis-patient mismatch (PPM) and low-flow state, but more frequent aortic re-
gurgitation. The presence of PPM was independently associated to low-flow 
state at discharge and independently determined by sutureless prostheses. 




 Objectives   In propensity-score matched patients with severe aortic stenosis treated 
with surgical aortic valve replacement (AVR) with the 3f Enable sutureless 
prosthesis (Medtronic) or transcathter aortic valve replacement (TAVR), the 
hemodynamic performance of both valves and mid-term survival of patients 
were evaluated.  
Background   Data on hemodynamic performance of surgical sutureless bioprostheses in 
high operative risk patients with aortic stenosis are scarce.
 Methods   Of 258 patients undergoing TAVR or surgical AVR with the 3f Enable valve, 
80 (79±5 years old, 100% men) were included in the current analysis based 
on propensity score 1:1 matching for baseline clinical and hemodynamic 
characteristics. All patients had hemodynamic echocardiographic evaluation 
at baseline and discharge. Mid-term survival was analyzed. 
 Results   Compared with the 3f Enable valve, TAVR prostheses (Edwards SAPIEN XT 
[Edwards Lifesciences, Irvine, CA] and CoreValve [Medtronic, Minneapolis, 
MN]) had larger effective orifice area index (1.00±0.30 vs 0.76±0.22cm2/
m2, p<0.001), lower pressure gradient (8.14±4.21 vs 10.72±4.01mmHg, 
p=0.006), less frequent prosthesis-patient mismatch (PPM) (30.0 vs 67.5%, 
p=0.001) and low-flow (46.2 vs 72.5%, p=0.02), but more frequent aortic 
regurgitation (AR) (87.5 vs 20.0%, p<0.001). The presence of PPM was 
independently associated to low-flow state at discharge (OR 4.70, p=0.004) 
and independently associated with the use of the sutureless prosthesis (OR 
3.90, p=0.02). However, the survival of the two groups was comparable after 
1.5 (interquartile range 0.79 to 2.01) years follow-up (log-rank p=0.95).   
 Conclusions   TAVR prostheses showed better hemodynamics than the 3f Enable valve but 
showed higher incidence of AR. However, these differences did not influence 
mid-term survival of patients.
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surgical sutureless and transcatheter aortic valve prostheses, by studying a 
propensity-score 1:1 matched population who underwent successful sur-
gical sutureless or transcatheter aortic valve replacement (TAVR) for severe 
aortic stenosis. Compared with sutureless valves, TAVR prostheses had larger 
effective orifice area index, lower pressure gradient, less frequent prosthe-
sis-patient mismatch (PPM) and low-flow state, but more frequent aortic re-
gurgitation. The presence of PPM was independently associated to low-flow 
state at discharge and independently determined by sutureless prostheses. 





 AR: aortic regurgitation 
AVR: aortic valve replacement 
CI: confidence interval 
OR: odds ratio 
PARTNER: placement of aortic transcatheter valves  
PPM: patient-prosthesis mismatch 
SVi: stroke volume index  
TAVR: transcatheter aortic valve replacement
INTRODUCTION
In patients with severe aortic stenosis and high operative risk, transcatheter aortic valve replacement 
(TAVR) has demonstrated to be non-inferior to conventional surgical aortic valve replacement (AVR) 
when using the balloon-expandable Edwards SAPIEN (Edwards Lifesciences, Inc. Irvine, CA) and 
superior to surgical AVR when using the self-expandable device CoreValve (Medtronic, Minneapolis, 
MN) (1-3). Recently, surgical AVR with sutureless prostheses offers minimal surgical access, 
reduced aortic cross-clamping and cardiopulmonary by-pass times compared to classical surgical 
replacement and, in contrast to TAVR, the native calcified valve is removed (4-6). In patients with 
severe aortic stenosis and high operative risk, perioperative complications and in-hospital mortality 
associated with surgical AVR using sutureless valves are comparable to TAVR (4,6,7). Compared 
with stentless aortic bioprostheses, TAVR prostheses have demonstrated superior hemodynamics 
(8). However, little is known about the hemodynamics of sutureless valves in comparison with 
TAVR prostheses. In propensity-score matched populations, the present evaluation compared the 
hemodynamic performance of the sutureless 3f Enable valve (Medtronic, Minneapolis, MN) (Figure 
1) and transcatheter valves (Edwards SAPIEN XT, Edwards Lifesciences, Inc. Irvine, CA and CoreValve, 
Medtronic, Minneapolis, MN). In addition, the mid-term survival of patients undergoing surgical 
sutureless AVR and patients treated with TAVR was evaluated.  
Figure 1.  
3f Enable® Aortic Root Bioprosthesis. 
©Medtronic, Inc. Printed with 
permission. The valve consists of 
a self-expanding Nitilol frame and 
3 equine pericardial leaflets that 
form a tube, preserving the aortic 






  Patients with symptomatic severe aortic stenosis (aortic valve area index <0.6 
cm2/m2) (9), who were treated according to the Heart Team (10) with surgical 
AVR using the 3f Enable valve or with TAVR at the Leiden University Medical 
Centre between November 2007 and February 2013 were evaluated. Only 
patients with a successful procedure, defined as no immediate procedural 
mortality within 72h post-procedure (11), were considered eligible for the 
current analysis. The immediate procedural mortality was 2% for surgical 
aortic valve replacement using the 3f Enable and 4.5% for TAVR. The 
Institutional Review Board approved this retrospective analysis of clinically 




  TAVR was performed according to current recommendations (12). The 
type of valve, Edwards SAPIEN XT or CoreValve, the size of valve and the 
access of implantation (transfemoral or transapical) were selected prior to 
the procedure based on the multi-detector row computed tomography 
measurements (13). 
  Surgical sutureless AVR was performed as recently described (4). The 3f 
Enable sutureless bioprosthesis was implanted and deployed after medial 
sternotomy, through transverse aortotomy and after excision of the native 
valve and decalcification of the aortic annulus (5,14,15). The size of the valve 
(19, 21, 23, 25 or 27 mm) was selected during the procedure, based on aortic 
annulus direct observation and measurement with surgical callipers of 




  Transthoracic echocardiography was performed at baseline (pre-AVR) and 
at hospital discharge. Using continuous wave Doppler, the peak velocity 
through the valve (native and bioprosthesis) and the mean transvalvular 
pressure gradient were obtained and the aortic valve area of the native 
valve and the effective orifice area of the bioprosthesis were derived with 
the continuity equation and indexed to body surface area (9). Moderate 
and severe prosthesis-patient mismatch (PPM) was defined by an estimated 
effective orifice area index <0.85cm2/m2 and <0.65cm2/m2, respectively (16-
19). Aortic valve regurgitation (AR) and mitral regurgitation were assessed 
using colour Doppler data and classified as I-IV (16). The forward flow through 
the aortic valve, native or bioprosthesis, was evaluated by the stroke volume 
index (SVi) calculated as the cross sectional area of the left ventricular outflow 
tract multiplied by the velocity time integral of the left ventricular outflow 
tract pulsed wave Doppler spectral signal and divided by the body surface 
area. Subsequently, low-flow state was defined as SVi≤35ml/m2 (20,21). 
The ratio of the prosthesis diameter relative to the aortic annulus diameter, 
measured on the parasternal long-axis view, was estimated to assess the 
grade of under- or oversizing of the prosthesis (8,22). Left ventricular ejection 
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measurements (13). 
  Surgical sutureless AVR was performed as recently described (4). The 3f 
Enable sutureless bioprosthesis was implanted and deployed after medial 
sternotomy, through transverse aortotomy and after excision of the native 
valve and decalcification of the aortic annulus (5,14,15). The size of the valve 
(19, 21, 23, 25 or 27 mm) was selected during the procedure, based on aortic 
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  Transthoracic echocardiography was performed at baseline (pre-AVR) and 
at hospital discharge. Using continuous wave Doppler, the peak velocity 
through the valve (native and bioprosthesis) and the mean transvalvular 
pressure gradient were obtained and the aortic valve area of the native 
valve and the effective orifice area of the bioprosthesis were derived with 
the continuity equation and indexed to body surface area (9). Moderate 
and severe prosthesis-patient mismatch (PPM) was defined by an estimated 
effective orifice area index <0.85cm2/m2 and <0.65cm2/m2, respectively (16-
19). Aortic valve regurgitation (AR) and mitral regurgitation were assessed 
using colour Doppler data and classified as I-IV (16). The forward flow through 
the aortic valve, native or bioprosthesis, was evaluated by the stroke volume 
index (SVi) calculated as the cross sectional area of the left ventricular outflow 
tract multiplied by the velocity time integral of the left ventricular outflow 
tract pulsed wave Doppler spectral signal and divided by the body surface 
area. Subsequently, low-flow state was defined as SVi≤35ml/m2 (20,21). 
The ratio of the prosthesis diameter relative to the aortic annulus diameter, 
measured on the parasternal long-axis view, was estimated to assess the 
grade of under- or oversizing of the prosthesis (8,22). Left ventricular ejection 
fraction was evaluated with the Simpson’s biplane method (22).
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Clinical outcome   The procedural outcome and the periprocedural complications were recorded 
according to Valve Academic Research Consortium-2 definitions (11). All 
patients were followed-up after surgical AVR or TAVR and all-cause mortality 
data were recorded in the Cardiology Department Information System (EPD-
Vision®, Leiden University Medical Center, Leiden, the Netherlands) or the 




  To control the selection bias, propensity score matching was performed. 
The propensity score was created from a multivariate binary logistic 
regression model, in which the type of procedure (AVR with sutureless 
valve or TAVR) was the dependent variable. The covariates in this model 
were clinical parameters that had affected our choice of procedure and the 
echocardiographic variables that would affect the hemodynamics of the 
bioprosthesis: age, gender, body surface area, logistic EuroSCORE I, aortic 
annulus, mean transvalvular pressure gradient, aortic valve area index, SVi 
and left ventricular ejection fraction at baseline. The Hosmer-Lemeshow 
goodness-of-fit test was used to check the accuracy of the model (p=0.98). 
Subsequently, propensity score 1:1 matching was performed without 
replacement (23).
  Continuous variables are expressed as mean ± standard deviation or as 
median (interquartile range) if not normally distributed and categorical 
variables as frequencies (percentage %). For comparison of continuous 
variables, the Student-t test, 1-way ANOVA test (with Bonferroni post-hoc 
analysis) or Mann-Whitney U test were used, as appropriate. For comparison 
of categorical variables, the Chi-square test or Fisher’s exact test were 
used, as appropriate. Univariate and multivariate binary logistic regression 
analysis were performed to identify variables that were associated with 
low-flow state or PPM after surgical AVR or TAVR. Variables with univariate 
p-value<0.10 were entered in the multivariate models. Odds ratios (OR) and 
95% confidence intervals (CI) were reported. The cumulative survival curves 
were calculated based on Kaplan-Meier method and comparison between 
surgical AVR and TAVR groups was evaluated by log-rank test.
  Statistical analysis was performed using the SPSS software version 20 (SPSS, 
Chicago, IL). A p-value<0.05 defined statistical significance. 
RESULTS
Patients   Of the 258 patients with severe aortic stenosis successfully treated with 
surgical AVR using the sutureless prosthesis or with TAVR, 80 patients were 
included in the current analysis after propensity score 1:1 matching. The 
baseline clinical and echocardiographic data used for propensity score 







  The hemodynamics of the transcatheter and sutureless bioprostheses are 
shown in Table 2. The TAVR group had significantly lower mean transvalvular 
pressure gradient (8.14±4.21 vs. 10.72±4.01 mmHg, p=0.006), higher 
effective orifice area index (1.00±0.30 vs. 0.76±0.22 cm2, p<0.001), less 
frequent presence of PPM, higher SVi and less frequent presence of low-flow 
state, but higher frequency of AR compared with the patients who received 
a sutureless bioprosthesis (Figure 2). 
Table 1. Baseline characteristics included in the propensity score, for the total and 1:1 propensity 
score matched population









Age, years 78.5 ± 4.6 80.9 ± 7.1 0.03 79 ± 4.5 79 ± 5.9 0.96
Male, n (%) 47 (100) 105 (50) <0.001 40 (100) 40 (100) 1
BSA, m
2
1.9 ± 0.36 1.8 ± 0.2 0.17 1.9 ± 0.4 1.9 ± 0.2 0.69
Log EuroScore, % 14.9 ± 10.1 22.8 ± 13.2 <0.001 15.9 ± 10.6 15.5 ± 8.4 0.85
LVEF, % 61.2 ± 10.4 54.8 ± 14.5 0.004 59.9 ± 10.5 59.7 ± 10.7 0.93
MPG, mmHg 43.2 ± 18.1 42.2 ± 17.2 0.74 42.9 ± 18.7 44.7 ± 17.5 0.65





0.37 ± 0.14 0.39 ± 0.10 0.26 0.38 ± 0.14 0.38 ± 0.09 0.72
SVi, ml/m
2
36.3 ± 10.9 37.1 ± 11.5 0.68 35.8 ± 11.0 35.9 ± 10.8 0.96
Low flow, n (%) 24 (51.1) 102 (48.3) 0.74 21 (52.5) 21 (52.5) 1
Values are mean ± SD or n (%).
AVAi=aortic valve area index, A 
VR= aortic valve replacement,  
BSA=body surface area,  
LVEF=left ventricular systolic function,  
MPG=mean pressure gradient,  
SVi=stroke volume index,  
TAVR=transcatheter aortic valve replacement
Figure 2. Frequency of prosthesis patient mismatch (PPM) and aortic valve prosthesis regurgitation 
(AR) after transcatheter (TAVR) or surgical sutureless (SU-AVR) aortic valve replacement. No AR 










  The patient population was divided into 4 groups based on the type of 
prosthesis and the presence of PPM at discharge: surgical sutureless AVR 
with PPM, surgical sutureless AVR with no-PPM, TAVR with PPM, TAVR with 
no-PPM. The forward flow was significantly different among the 4 groups (SVi 
24.63±7.32 vs. 40.89±6.86 vs. 30.94±9.15 vs. 37.61±13.36 ml/m2, respectively, 
ANOVA p<0.001). Patients treated with sutureless AVR who showed PPM 
had significantly lower SVi than patients without PMM or treated with TAVR 
(Bonferroni p<0.001 for both). Additionally, PPM patients have significantly 
lower SVi than the no-PPM patients (38.68±11.66 vs. 26.57±8.35 ml/m2, 
p<0.001) (Figure 3A).
Table 2. Comparison of the hemodynamic profile of the sutureless versus transcatheter aortic 





Maximum transaortic velocity, m/s 2.32 ± 0.44 1.88 ± 0.41 <0.001
Mean pressure gradient, mmHg 10.72 ± 4.01 8.14 ± 4.21 0.006
Effective orifice area index, cm2/m2 0.76 ± 0.22 1.00 ± 0.30 <0.001
Prosthesis patient mismatch, n (%) 27 (67.5) 12 (30.0) 0.001
Doppler Velocity Index 0.46 ± 0.11 0.57 ± 0.15 0.001
Prosthesis size/Annulus diameter 0.97 ± 0.08 1.12 ± 0.11 <0.001
AR grade I, n (%) 6 (15) 26 (65)
<0.001
AR grade II, n (%) 2 (5) 9 (22.5)
MR grade I-II, n (%) 27 (69.3) 30 (76.9) 0.45
Left ventricular ejection fraction, % 63.50 ± 12.63 59.57 ± 10.46 0.15
Stroke volume index, ml/m2 29.91 ± 10.47 35.56 ± 12.50 0.03
Low-flow, n (%) 29 (72.5) 18 (46.2) 0.02
Values are mean ± SD or n (%).
AR=aortic valve prosthesis regurgitation,  
AVR= aortic valve replacement,  
MR=mitral regurgitation,  
TAVR=transcatheter aortic valve replacement
Figure 3. Association between prosthesis patient mismatch (PPM) and aortic regurgitation 
(AR) and forward flow after surgical sutureless (SU-AVR) and transcatheter (TAVR) aortic valve 
replacement (AVR). A. Patients treated with surgical aortic valve replacement and who showed 
PPM had significantly lower stroke volume compared with the other groups. B. There were no 
differences in stroke volume between patients with and without significant AR after surgical or 
transcatheter aortic valve replacement.
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Table 3. Uni- and multivariate binary logistic regression analysis to identify factors that define low-
flow state post sutureless and transcatheter aortic valve replacement.
Univariate Multivariate 
OR 95% CI p-value OR 95% CI p-value
Age, years 1.06 0.97-1.16 0.18
Sutureless-AVR 3.08 1.21-7.85 0.02 1.29 0.23-7.26 0.77
PPM 5.81 2.13-15.83 0.001 4.70 1.64-13.48 0.004
AR 0.42 0.17-1.07 0.07 0.70 0.17-2.85 0.62
post LVEF, % 1.04 0.99-1.08 0.12
AVP size/ Annulus 0.03 0.001-1.55 0.08 0.33 0.002-64.03 0.68
Propensity score 0.69 0.06-8.06 0.77
AVP size/Annulus=aortic valve prosthesis size/aortic annulus diameter,  
AR=aortic valve prosthesis regurgitation,  
CI=confidence interval,  
LVEF=left ventricular systolic function,  
PPM=prosthesis patient mismatch,  
OR=odds ratio
Table 4. Uni- and multivariate binary logistic regression analysis to identify factors that define 
prosthesis patient mismatch post sutureless and transcatheter aortic valve replacement.
Univariate Multivariate 
OR 95% CI p-value OR 95% CI p-value
Sutureless-AVR 4.67 1.81-12.07 0.001 3.90 1.22-12.50 0.02
Annulus, cm 1.37 0.19-9.73 0.76
AVP size/ Annulus 0.01 0.001-0.56 0.03 0.28 0.002-37.61 0.61
Propensity score 0.29 0.03-3.37 0.32
AVP size/Annulus=aortic valve prosthesis size/aortic annulus diameter,  
CI=confidence interval,  
OR=odds ratio
Figure 4.  Kaplan-Meier estimates of time to death in patients treated with TAVR and patients 
treated with surgical aortic valve replacement suing the sutureless 3f Enable valve (SU-AVR). 
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  Subsequently, the patient population was divided into 4 groups based on 
type of prosthesis and the presence of AR at discharge: surgical sutureless 
AVR with AR, surgical sutureless AVR without AR, TAVR with AR, TAVR without 
AR. The forward flow was not significantly different among these 4 groups 
(SVi 29.92±11.83 vs. 29.91±10.32 vs. 35.19±12.60 vs. 38.11±12.85 ml/m2, 
respectively, ANOVA p=0.19). Additionally, patients with AR at discharge 
have not significantly higher SVi than the patients with no-AR (34.18±12.49 
vs. 31.02±10.87 ml/m2, p=0.24) (Figure 3B).
  A low-flow state at discharge was present in 79.5% of the patients with PPM 
vs. 40% of patients without PPM (p<0.001). However, low-flow state was 
observed in 70% of patients with AR vs. 50% of patients without AR (p=0.07). 
The presence of PPM was independently associated with low-flow state 
at discharge (OR 4.70, 95% CI 1.64-13.48, p=0.004) (Table 3). Surgical AVR 
with sutureless bioprosthesis was independently associated with PPM at 
discharge (OR 3.90, 95% CI 1.22-12.50, p=0.02) (Table 4).
 
Clinical outcome   Although the hemodynamic characteristics of the TAVR prosthesis were more 
favourable compared with the sutureless prosthesis, the survival during a 
median follow-up of 1.5 years (interquartile range from 0.79 to 2.01) was 
comparable between the two groups (log rank p=0.95) (Figure 4). The 2-year 
survival rate for patients treated with a sutureless bioprosthesis was 92.5% 
compared with 87.3% for patients undergoing TAVR. The periprocedural 
complications were comparable between the 2 groups, although there 
was a trend towards more vascular complications in TAVR group and more 
bleeding complications in the surgical sutureless group (Table 5). 






Stroke, n (%) 2 (5) 1 (2.5) 0.31
Transient ischemic attack, n (%) 1 (2.5) 0
Bleeding
Minor, n (%) 4 (10) 1 (2.5) 0.07
Major, n (%) 3 (7.5) 0
Conduction disturbances
Transient complete AV block, n (%) 3 (7.5) 0 0.69
Pacemaker implantation, n (%) 1 (2.5) 3 (7.5)
Acute kidney injury
Stage 1, n (%) 5 (12.5) 6 (15) 0.28
Stage 2, n (%) 0 2 (5)
Vascular injury
Major, n (%) 0 0 0.08
Minor, n (%) 0 3 (7.5)
AV=atrioventricular,  
AVR=aortic valve replacement,  
TAVR=transcatheter aortic valve replacement
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DISCUSSION
The present study demonstrated that transcatheter bioprostheses have better hemodynamic 
profile than surgical sutureless 3f Enable valve in terms of effective orifice area index, mean 
transvalvular pressure gradient and PPM. However, AR was more often present after TAVR. The 
sutureless bioproshtesis was independently associated with PPM at discharge. Although the two 
types of valves have significant differences in the hemodynamic performance at discharge, the 





  The improved hemodynamics of transcatheter aortic bioprostheses 
compared with stentless or stented surgical aortic bioprostheses have 
been demonstrated (8,24). Clavel et al. (8) reported larger effective orifice 
area index (0.90±0.26 cm2/m2), lower mean pressure gradient (10±4 
mmHg) and less percentage of severe PPM (11%) in transcatheter aortic 
bioprosthesis compared with stentless (0.80±0.21 cm2/m2, 14±6 mmHg and 
28%, respectively) and stented (0.76±0.16 cm2/m2, 13±5mmHg and 26%, 
respectively) bioprostheses. However, the presence of AR grade I or more 
after TAVR was more frequently observed compared with surgical AVR using 
stentless or stented bioprostheses (50% vs. 12% and 10%, respectively) (8). 
  Few studies have compared the hemodynamics of transcatheter aortic 
bioprostheses and surgical sutureless bioprostheses (7,25). In 37 patients, 
Santarpino et al. (7) reported comparable mean pressure gradients between 
transcatheter and sutureless bioprostheses (14.2±5.8 versus 13.3±3.9 mmHg, 
respectively) and higher incidence of AR among patients undergoing TAVR 
(13.5 versus 0 %, respectively). The present study confirms previous results 
and provides additional data in terms of incidence of PPM which was lower 
among patients treated with transcatheter aortic bioprostheses compared 
with patients receiving a sutureless bioprosthesis. PPM was independently 
associated with forward low-flow status, which was more prevalent among 
patients receiving a sutureless bioprosthesis. Additionally, in TAVR the 
prevalence of low-flow status was low despite having a higher incidence 
of AR, as compared with sutureless bioprosthesis. These findings are in 
agreement with the substudy of the Placement of AoRTic TraNscathetER 
valves (PARTNER) trial showing no association of low-flow status after TAVR 
with AR (24). 
  More importantly, current results were reported in a propensity score 
matched population based on baseline clinical, hemodynamic and anatomic 
parameters that are known to influence the hemodynamics and the survival. 
This would have resulted in similar aortic bioprosthesis hemodynamics. 
However, the observed higher incidence of PPM after sutureless AVR 
could be explained by relative prosthesis undersizing compared to TAVR 
bioprostheses (prosthesis size/annulus diameter ratio was 0.97±0.08 
versus 1.12±0.11, respectively, p<0.001). While cardiac multi-detector row 
computed tomography was used to select the TAVR bioprosthesis size 
and generally the selected prosthesis is oversized by 10-15% to minimize 
paravalvular AR (13,26), sizing of the sutureless bioprosthesis was performed 
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at the operating theatre by using the pre-sized callipers which may lead to 
a smaller prosthesis size and effective orifice area (5). On the other hand, AR 
after surgical AVR with sutureless bioprosthesis was less frequent maybe due 
to the decalcification of the aortic annulus performed during the procedure 
(5,14,15), while after TAVR the annular calcium may lead to gaps between the 
bioprostheses and the native aortic annulus from where the paravalvular AR 





  Presence of residual AR, low-flow state and PPM have been associated 
with the prognosis of patients undergoing TAVR or surgical AVR for aortic 
stenosis (24). In several registries and the randomized PARTNER trial, AR 
grade I or more after TAVR has been associated with poor outcome (2,27-
29). However, AR was not a predictor of outcome among patients treated 
with surgical AVR (24). In contrast, low-flow state at follow-up was associated 
with poor prognosis after surgical AVR but not after TAVR (24). Furthermore, 
the association between PPM and survival after TAVR or surgical AVR remains 
controversial (19,24,30). Ewe et al. (19) and Chacko et al. (30) suggested that 
PPM was not associated with survival after TAVR or surgical AVR while Hahn 
et al. (24) concluded that PPM was a predictor of mortality after both TAVR or 
surgical AVR.
  Studies comparing the impact of hemodynamics of transcatheter and 
sutureless bioprostheses on survival are scarce. Santarpino et al. (7) reported 
better survival after surgical AVR with sutureless bioprosthesis compared 
to TAVR and the only difference between patient groups was the higher 
incidence of AR after TAVR as compared with surgical sutureless AVR. The 
present analysis showed comparable survival between patients treated with 
TAVR and patients treated with surgical AVR using sutureless bioprosthesis. 
The low number of patients and the propensity score matching process 
may have reduced the power of the study to observe significant differences 
in survival and has precluded us to investigate independent associates of 
survival. 
Limitations   The main limitation is the limited number of patients included in the analysis. 
However, the two groups of 40 patients were 1:1 propensity score matched. 
The inclusion of only men is another limitation since the results of the 
present study may not be applicable to female patients with smaller body 
surface areas and aortic annulus. Moreover, systematic echocardiographic 
follow-up data after discharge were not available for patients treated with a 
sutureless bioprosthesis. Additionally, the limited number of patients in each 
group matched for hemodynamic parameters mainly, may bias the survival 
analysis and a Cox-regression analysis was not performed to explore the 
independent impact of bioprosthesis hemodynamics on survival, due to the 
very few events (n=13) during the median follow-up of 1.5 years. 
Conclusions   In high operative risk patients with severe aortic stenosis treated with 
valve replacement, TAVR prostheses have better hemodynamic profile 
at discharge, in terms of higher effective orifice area index, lower mean 
transvalvular pressure gradient, lower prevalence of forward low-flow and 
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PPM, compared to the sutureless 3f Enable valve. However, the incidence 
of AR is significantly higher among patients treated with TAVR than patients 
receiving a sutureless bioprosthesis. Nevertheless, these differences did not 
have prognostic implications since patients treated with sutureless AVR had 
comparable mid-term survival with those treated with TAVR.
Acknowledgements:   None
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ABSTRACT
 Aims   Left ventricular (LV) ejection fraction (LVEF) is currently considered for the 
decision making of patients with mitral regurgitation (MR). However, LVEF 
represents change in LV volume between end-diastole and end-systole but 
does not characterize the intrinsic function of the myocardium. In contrast, 
speckle tracking global longitudinal strain (GLS) characterizes myocardial 
deformation. The present study evaluated whether LV GLS may detect further 
impairment in LV systolic function in dilated cardiomyopathy patients with 
and without severe secondary MR matched based on LVEF.
 Methods and 
results
  Patients with non-ischemic dilated cardiomyopathy (N=150, 59±12 years 
old, 58% male) were included: 75 patients with severe secondary MR and 
75 patients with none or less than mild MR matched 1:1 according to 
LVEF. The LV systolic function was evaluated by LVEF (following Simpsons 
biplane method), forward ejection fraction (forward stroke volume relative 
to LV end-diastolic volume) and speckle tracking GLS. By definition, LVEF 
was comparable between the two groups (patients with severe MR 31±10 vs. 
patients with no/mild MR 31±10%, p=0.93). However, patients with severe 
MR had significantly lower forward ejection fraction (29±14 vs. 40±18%, 
p<0.001) and more impaired GLS (-8.08±3.33 vs. -9.78±3.78%, p=0.004) 
compared to their counterparts. The presence of severe secondary MR was 
independently associated with worse LV GLS (beta 1.32, 95% confidence 
interval 0.14  2.49, p=0.03). 
 Conclusion   In patients with severe secondary MR, speckle tracking GLS shows more 
deteriorated LV systolic function than LVEF. 
 Keywords   Severe secondary mitral regurgitation; Left ventricular ejection fraction; 
Global longitudinal strain 
Abbreviations  GLS, global longitudinal strain 
 LV, left ventricular 
 LVEF, left ventricular ejection fraction 
 MR, mitral regurgitation
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INTRODUCTION
In routine clinical practice, left ventricular (LV) ejection fraction (LVEF) is currently one of the 
most requested parameters for the decision making of patients with mitral regurgitation (MR).1, 2 
However, LVEF represents the change in LV volume from end-diastole to end-systole without taking 
into consideration the direction of the blood flow and the intrinsic properties of the myocardium. 
In patients with MR, LVEF may not truly represent the LV systolic function since the left ventricle 
partly empties in the low pressure left atrium and does not reflect the effective stroke volume 
pumped into the aorta. This may lead to an overestimation of the LV systolic function although 
the myocardial contraction may be already impaired by the volume overload. Previous studies 
showed that circumferential myocardial fibre shortening assessed with LV angiography was 
significantly reduced in patients with chronic MR compared with patients without MR despite 
comparable LVEF.3, 4 The American Heart Association/American College of Cardiology guidelines for 
the management of patients with valvular heart disease have recently introduced the concept of 
stages of progression of valvular heart disease which takes into account the response of the LV to 
the volume overload.2 Characterization of LV structural changes and function using 2-dimensional 
speckle tracking echocardiography or magnetic resonance imaging techniques may help in refining 
and personalizing treatment options for patients with MR.5, 6  
LV global longitudinal strain (GLS), assessed with 2-dimensional speckle tracking echocardiography, 
has been demonstrated to detect subtle LV systolic dysfunction in patients with organic MR and 
preserved LVEF.7 However, in patients with dilated cardiomyopathy and severe secondary MR it has 
not been demonstrated if LV GLS may show more impaired LV systolic function than LVEF. In this 
subset of patients, LVEF may overestimate LV systolic function by emptying part of the LV volume 
into the left atrium, whereas LV GLS may be more impaired than that of patients with dilated 
cardiomyopathy, similar LVEF and competent mitral valve. Accordingly, the present study evaluated 
whether LV GLS may detect further impairment in LV systolic function in dilated cardiomyopathy 
patients with and without severe secondary MR matched based on LVEF. 
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METHODS
Patients   Patients with non-ischemic dilated cardiomyopathy and chronic severe 
secondary MR (n=145) were selected from a clinical database (EPD-vision 
8.3.3.6; Leiden University Medical Center, Leiden, The Netherlands). Patients 
with dilated cardiomyopathy due to congenital heart disease, ischemic 
cardiomyopathy or hypertrophic cardiomyopathy were excluded. In addition, 
patients with preserved LVEF (≥50%), mitral stenosis, significant aortic valve 
disease, previous cardiac surgery, or endocarditis were excluded leading 
to 108 patients with severe MR. Furthermore, patients with non-ischemic 
dilated cardiomyopathy with less than mild MR (n=220) were selected. After 
excluding the patients with concomitant other valvular disease or treated 
with aortic valve replacement / transcatheter aortic valve implantation, 136 
patients were eligible for inclusion. Patients with and without significant 
MR were matched 1:1 based on LVEF. In all patients, invasive coronary 
angiography was performed and the presence of significant coronary artery 
stenosis was excluded.  
  Demographics, clinical characteristics, symptoms and medication of these 
patients were prospectively collected in the departmental electronic files 
(EPD-vision 8.3.3.6; Leiden, The Netherlands). All the patients had a complete 
transthoracic echocardiographic study digitally stored for off-line analysis 
(EchoPAC 112.0.0, GE Medical Systems, Horten, Norway). 
  The Institutional Ethics Committee approved this retrospective analysis of 




  The echocardiograms were performed in hemodynamically stable 
patients during a scheduled outpatient visit with commercially available 
ultrasound systems (Vivid-7, and E9, GE-Vingmed, Milwaukee, WI, USA). Two-
dimensional grey scale, continuous, pulsed and colour Doppler images were 
retrospectively analysed for LV function and dimensions as well as grade 
of MR assessment according to the current recommendations.8 Various 
parameters were used for LV systolic function, including LVEF, forward 
ejection fraction and LV GLS. LVEF was calculated according to the Simpson’s 
biplane method. From the apical 4- and 2-chamber views, the LV end-systolic 
and end-diastolic volumes were measured and LVEF was derived. In addition, 
the forward ejection fraction was measured. The LV outflow tract area was 
derived from the LVOT diameter measured on the parasternal long-axis 
view of the left ventricle and multiplied by the LV outflow tract velocity-time 
integral on pulsed wave Doppler recordings obtaining the LV stroke volume. 
The cardiac output was obtained from the product of stroke volume and 
heart rate. Finally the forward ejection fraction was calculated by dividing 
stroke volume by LV end-diastolic volume and expressed as a percentage.9 
Moreover, from the grey scale apical 3-, 4- and 2-chamber views, GLS was 
measured using 2-dimensional speckle tracking echocardiography.10 The 
aortic valve closure was first defined at the apical 3-chamber view. Then the 
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LV endocardium was traced at each apical view at the end-systolic frame. A 
region of interest was automatically defined between the endocardial and 
epicardial borders and manually adjusted to include the LV myocardium. In 
patients with atrial fibrillation, GLS was repeatedly measured from 3 cardiac 
cycles and averaged. GLS was then corrected for LV end-diastolic volume 
and end-systolic volume.
  In addition, the wall thickness and the LV end-diastolic diameter were 
measured at the parasternal long-axis view. LV mass was evaluated by the 
formula (0.8 x {1.04[(LV end-diastolic diameter + posterior wall thickness in 
diastole + septal wall thickness in diastole)3 - (LV end-diastolic diameter)3]} 
+ 0.6g) and indexed to BSA.8 In addition, the relative wall thickness ([2 x 
posterior wall thickness in diastole] / LV end-diastolic diameter) and the 
ratio of LV mass to LV end-diastolic volume were evaluated.8 LV volumes and 
dimensions were indexed to body surface area.
  MR grade was assessed using a multiparametric integrated approach as 
recommended,11 including vena contracta width and, when feasible, effective 
regurgitant orifice area and regurgitant volume calculated according to the 
proximal isovelocity surface area method. Severe functional MR was defined 
by vena contracta width ≥0.4cm, effective regurgitant orifice area ≥0.2cm2 
and regurgitant volume ≥30ml taking into account the hemodynamic status 
of the patient and the LV end-diastolic volume as recommended.11 
Statistical 
analysis
  Continuous variables are expressed as mean ± standard deviation and 
categorical variables as frequency (percentage). Continuous variables were 
compared between the groups using the Student’s t test or the Mann-
Whitney U test, as appropriate, whereas categorical variables were compared 
using the x2 test or Fisher’s exact test, as appropriate. Correlations between 
continuous variables were tested with the Pearson correlation test. Inter- and 
intra-observer agreements for the measurement of LV GLS were evaluated 
calculating the intraclass correlation coefficients (ICC) including the lower 
and upper limits of the 95% confidence interval (CI). Good inter-observer 
(ICC 0.99, 95% CI 0.98-1.00) and intra-observer (ICC 0.95, 95% CI 0.85-0.98) 
agreement was found for pre-operative LV GLS strain values. The association 
between MR and LV GLS was evaluated using the multivariable regression 
analysis including as independent variables clinical and echocardiographic 
parameters associated in the univariable analysis with a p-value <0.10. 
P-values <0.05 were considered statistically significant. Statistical analysis 
was performed with SPSS version 20 (SPSS, Inc., Chicago, Illinois).
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RESULTS
In total, 150 patients with non-ischemic dilated cardiomyopathy were included in the current 
analysis (59±12 years old, male 58%): 75 with severe secondary MR matched with 75 patients 
with no/mild MR. Patients with severe MR were older, had higher prevalence of paroxysmal 
atrial fibrillation, diabetes, worse renal function and New York Heart Association functional class 
compared to patients with no/mild MR (Table 1).
Patients with severe MR (vena contracta 6.14±1.57 mm, effective regurgitant orifice area 
0.28±0.14cm2, regurgitant volume 32±10ml) had more dilated LV compared with patients with no/
mild MR (Table 2). However, both groups showed similar LV mass index, resulting in more eccentric 
LV hypertrophy in patients with severe MR compared with the no/mild MR group (Table 2). According 
to the inclusion criteria, there were no differences in LVEF between groups (31±10 vs. 31±10%, 
p=0.93). However, patients with severe MR had significantly lower forward ejection fraction (29±14 
vs. 40±18%, p<0.001) and more impaired GLS (-8.08±3.33 vs. -9.78±3.78%, p=0.004) compared to 
their counterparts (Table 2). The forward ejection fraction and GLS showed good correlation in the 
total population (r -0.632, p<0.001), in the severe MR group (r -0.523, p<0.005) and in the no/mild 
MR group (r -0.648, p<0.001). Figure 1 illustrates the examples of a patient with severe MR and a 
patient with trivial MR. Despite showing comparable LVEF, GLS was more impaired in the patient 
with severe MR. 
Table 1. Demographic and clinical characteristic of non-ischemic dilated cardiomyopathy patients 







Age, years 59±12 57±10 62±13 0.02
Male gender, n (%) 86 (58) 56 (75) 30 (41) <0.001
Body surface area, m2 1.95±0.23 2.00±0.23 1.89±0.22 0.004
Atrial fibrillation, n (%) 43 (31) 11 (17) 32 (43) 0.001
Hypertension, n (%) 70 (47) 33 (44) 37 (51) 0.42
Diabetes, n (%) 21 (14) 6 (8) 15 (20) 0.03
Glomerular filtration rate, ml/min/1.73m2 66±21 74±19 58±19 <0.001
Systolic blood pressure, mmHg 124±25 125±25 122±24 0.46
Diastolic blood pressure, mmHg 75±12 76±13 73±12 0.13
ACEi/ARBs, n (%) 128 (87) 66 (88) 62 (86) 0.73
Beta-blockers, n (%) 104 (71) 58 (77) 49 (65) 0.10
NYHA class I, n (%)
                    II, n (%)
                   III, n (%)














ACEi/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor blockers;  
DCM, dilated cardiomyopathy;  
MR, mitral regurgitation;  
NYHA, New-York Heart Association
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Table 2. Left ventricular systolic function and remodelling in non-ischemic dilated cardiomyopathy 







LV ejection fraction, % 31±10 31±10 31±10 0.93
Global longitudinal strain, % -8.93±3.65 -9.78±3.78 -8.08±3.33 0.004
Corrected global longitudinal strain for  
LV end-diastolic volume, %/10ml
-0.64±0.44 -0.73±0.50 -0.55±0.36 0.013
Corrected global longitudinal strain for  
LV end-systolic volume, %/10ml
-1.02±0.82 -1.16±0.92 -0.88±0.69 0.037
Stroke volume index, ml/m2 27±9 29±8 24±9 <0.001
Cardiac output, L/min 3.77±1.29 4.08±1.29 3.38±1.20 0.002
Cardiac index, L/min/m2 1.93±0.64 2.03±0.63 1.80±0.64 0.04
Forward ejection fraction, % 35±17 40±18 29±14 <0.001
LV end-diastolic volume index, ml/m2 90±34 83±30 96±37 0.02
LV end-systolic volume index, ml/m2 64±31 59±27 69±34 0.04
LV mass index, gr/m2 137±39 141±38 132±40 0.17
LV relative wall thickness, % 32±11 37±10 27±9 <0.001
LV mass/end-diastolic volume, gr/ml 1.64±0.51 1.81±0.51 1.48±0.46 <0.001
DCM, dilated cardiomyopathy;  
LV, left ventricular;  
MR, mitral regurgitation
Figure 1. Representative example of two patients with non-ischemic cardiomyopathy. Panel A: 
patient with trivial mitral regurgitation (MR). Panel B: patient with severe secondary MR. Despite 
showing comparable left ventricular ejection fraction (LVEF), the patient with severe MR had more 
impaired left ventricular global longitudinal strain. 
Independent 
association between 
MR grade and LV GLS
  Table 3 summarizes the results of the univariable and multivariable analyses. 
Severe MR was associated with an increase of 1.32% in the mean LV GLS 
(beta 1.32, 95% confidence interval 0.14 – 2.49, p=0.03) after adjusting for 
age and diabetes, The association remains significant although the effect of 
severe MR on LV GLS has been attenuated after the adjustment.  
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DISCUSSION
The present study demonstrates that LV GLS shows more deteriorated LV performance in patients 
with dilated cardiomyopathy and chronic severe secondary MR than LVEF.  
Assessment of LV 
inotropic state in 
chronic MR: GLS 
versus LVEF
  Assessment of LV myocardial performance in patients with chronic MR 
has been challenging. Initial cardiac catheterization studies demonstrated 
that the mean velocity of circumferential fibre shortening derived from LV 
angiograms was significantly reduced in patients with chronic MR compared 
with patients without MR despite having similar LVEF.3, 4 These findings 
suggested that the favourable unloading conditions of the left ventricle into 
the left atrium through the regurgitant jet may mask reduced LV inotropic 
state. The measurement of mean velocity of circumferential fibre shortening 
could be considered the precursor of current echocardiographic derived 
strain rate imaging since the circumference radius of the left ventricle at 
each frame is corrected for the end-diastolic circumference.12 However, this 
measurement is invasive and time consuming, limitations that have been 
overcome with current developments in non-invasive imaging enabling the 
assessment of myocardial velocities and deformation.8, 13  
  Speckle tracking derived LV GLS has been evaluated in patients with primary 
MR and preserved LVEF to detect the presence of subclinical LV myocardial 
dysfunction. In 59 patients with chronic severe primary MR and preserved 
Table 3. Parameters associated with global longitudinal strain in non-ischemic dilated 
cardiomyopathy patients
Univariable Multivariable
Beta 95% CI p-value Beta 95% CI p-value
Severe MR 1.70 0.55 – 2.85 0.004 1.32 0.14 – 2.49 0.03
Age, years 0.04 -0.006 – 0.09 0.09 0.02 -0.03 – 0.07 0.43
Male gender -0.08 -1.28 – 1.13 0.90
Atrial fibrillation 0.13 -1.18 – 1.44 0.85
Hypertension -0.01 -1.21 – 1.18 0.98
Diabetes 2.46 0.80 – 4.12 0.004 1.98 0.28 – 3.67 0.02
GFR, ml/min/1.73m2 0.001 -0.03 – 0.03 0.97
ACEi/ARBs 0.04 -1.75 – 1.84 0.96
Beta-blockers -1.09 -2.39 – 0.20 0.10
ACEi/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor blockers;  
CI, confidence interval;  
GFR, glomerular filtration rate;  
MR, mitral regurgitation  
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LVEF, Kim et al.7 demonstrated that speckle-tracking longitudinal strain was 
an earlier marker than LVEF of intrinsic LV systolic dysfunction due to MR 
induced LV remodelling. However, no studies have evaluated to date the 
use of speckle tracking echocardiography to detect LV systolic dysfunction 
beyond LVEF in patients with secondary MR.
GLS in severe 
secondary MR
  In contrast to primary MR, secondary MR is caused by LV dilatation and 
dysfunction which causes tethering of the mitral leaflets and reduced closing 
forces. In these patients, assessment of LV performance is crucial since the 
associated operative risks strongly depend on the LV inotropic status. LVEF is 
the parameter considered in current guidelines to select patients with severe 
secondary MR for surgical or transcatheter mitral valve repair/replacement.1,2 
However, similarly to patients with primary MR, LVEF may mask the true 
LV inotropic status. The present study provides further insight into this 
hypothesis. The two groups of patients with dilated cardiomyopathy had 
reduced LVEF and impaired LV GLS. Both groups of patients had comparable 
LVEF which indicates that the ratio of volume change was comparable. 
However, patients with severe MR had significantly lower forward flow, cardiac 
output and cardiac index compared with patients without MR. Similarly to 
the studies using invasive measurements, it could be hypothesized that in 
patients with severe MR a significant percentage of the regurgitant volume is 
emptied into the left atrium before the aortic valve opens.3 In addition, wall 
stress is lower during early and late systole and the reduced afterload results 
in increased total LV stroke volume.14 These pathophysiological mechanisms 
may mask a further reduced LV performance in patients with severe MR that 
LVEF cannot reflect. However, with the use of more sensitive measures such 
as LV GLS, this hypothesis is demonstrated. Indeed, patients with severe 
secondary MR had more impaired LV GLS than patients without significant 
MR despite having comparable LVEF.
Limitations   The current analysis is a retrospective observational study of prospectively 
collected data. The prognostic implications of LV GLS in patients with severe 
secondary MR have to be demonstrated in future prospective studies. The 
current study included only non-ischemic dilated cardiomyopathy patients 
in order to avoid the segmental LV dysfunction and local aneurysmal 
formation due to ischemic disease. Patients were matched according to 
LVEF and other factors that may influence LV GLS, such as age, gender, 
atrial fibrillation, diabetes, chronic kidney disease were not taken into 
consideration. However, after adjusting for these confounder factors, MR 
was independently associated with LV GLS. In addition, the presence of 
LV dyssynchrony, which has been associated with secondary MR, was not 
evaluated. Furthermore, direct measurement of LV contractility with the 
use of conductance catheters that quantify simultaneously LV volumes 
and pressure was not performed. Therefore, the question whether LV GLS 
represents an accurate measurement of LV contractility in this specific 
population needs to be elucidated in additional studies.
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CONCLUSION
In patients with severe secondary MR and reduced LVEF due to non-ischemic dilated cardiomyopathy, 
speckle-tracking LV GLS shows more impaired LV performance than LVEF. 
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ABSTRACT
 Aims   It remains unclear whether surgical or transcatheter mitral valve repair 
for secondary mitral regurgitation (MR) in patients with non-ischemic 
cardiomyopathy reverse the underlying left ventricular (LV) pathophysiology. 
The present study evaluated the effect of mitral valve repair on LV performance 
in this group of patients. 
 Methods and 
Results 
  Seventy-six patients (65±14 years old, 43% male) with non-ischemic 
cardiomyopathy and moderate to severe chronic secondary MR treated 
successfully with transcatheter or surgical mitral valve repair were evaluated. 
Transthoracic echocardiography was performed at baseline, discharge and 6 
months post-repair. After mitral valve repair, LVEF and LV global longitudinal 
strain (GLS) corrected for LV end-diastolic volume remained unchanged over 
time (p=0.90 and p=0.96 respectively). In contrast, LV forward flow increased 
significantly over time (stroke volume index: from 20±7 to 29±8 and 26±8 
ml/m2, p<0.001; cardiac index: from 1.50±0.44 to 2.36±0.60 and 2.01±0.48 
L/min/m2, p<0.001). In addition, LV end-diastolic and end-systolic volume 
index significantly reduced over time (from 87±42 to 70±33 and 75±39 
ml/ m2, p<0.001; and from 60±35 to 50±30 and 53±36 ml/ m2, p=0.004, 
respectively). These changes were independent of the type of repair. 
 Conclusion   Surgical and transcatheter mitral valve repair for secondary MR in patients 
with non-ischemic dilated cardiomyopathy improved LV forward flow and 
induced LV reverse remodeling but did not change LV systolic function.
 Keywords   Secondary mitral regurgitation; Dilated cardiomyopathy; MitraClip; Surgical 
mitral valve repair; Speckle tracking echocardiography 
 
Abbreviations   GLS, global longitudinal strain 
LV, left ventricular 




Secondary mitral regurgitation (MR) in patients with non-ischemic dilated cardiomyopathy is 
associated with poor survival.1 Despite optimal medical therapy and current device therapies, 
severe secondary MR confers worse prognosis and the outcomes of surgical mitral valve repair 
remain controversial. Accordingly, current European Society of Cardiology and American Heart 
Association/American College of Cardiology guidelines consider mitral valve repair in this group of 
patients as class IIb recommendation.2, 3  Advances in transcatheter mitral valve repair procedures 
have provided alternative therapy for patients with increased surgical risk such as patients with 
non-ischemic cardiomyopathy and depressed left ventricular ejection fraction (LVEF).4, 5
It remains unknown whether surgical or transcatheter mitral valve repair techniques may alter the 
underlying left ventricular (LV) pathophysiology in non-ischemic secondary MR and prevent further 
LV dilation and dysfunction. In non-ischemic cardiomyopathy, LV remodeling with displacement 
of the papillary muscles toward more apical positions and tethering of the mitral leaflets causes 
MR which leads to progressive LV remodeling which begets MR. It is logical to hypothesize that by 
restoring the mitral valve competence, LV remodeling may be halted and even reversed, improving 
LV systolic function and clinical prognosis. However, current data reporting on LV remodeling 
and functional recovery after mitral valve repair for secondary MR concern mainly ischemic 
cardiomyopathy patients and the results are controversial.5-7 Accordingly, the current study evaluated 
patients with non-ischemic dilated cardiomyopathy and secondary MR successfully corrected by 
transcatheter or surgical repair and analyzed subsequent LV remodeling and functional recovery. 
METHODS
Patients   Patients with non-ischemic heart failure and moderate to severe secondary 
MR who underwent surgical or transcatheter mitral valve repair were 
retrospectively identified from a clinical database (EPD-vision 8.3.3.6; 
Leiden University Medical Center, Leiden, The Netherlands). Patients who 
underwent concomitant aortic valve replacement or LV cardiac support 
device implantation (CorCap, Acorn Cardiovascular, St. Paul, Minnesota) were 
excluded. Successful mitral valve repair was defined as residual MR grade ≤2 
at discharge.8 None of the patients included in the current analysis was re-
operated for severe MR during the follow-up period.
  Demographics, clinical and procedural information and echocardiographic 
data were retrospectively analyzed from the departmental clinical (EPD-
vision 8.3.3.6; Leiden, The Netherlands) and echocardiographic (EchoPAC 




  The type of mitral valve repair (surgical restrictive annuloplasty or 
transcatheter MitraClip implantation [Abbott Vascular, Venlo, CA, USA]) was 
decided by the Heart Team, based on patient’s characteristics (symptoms, 
comorbidities, frailty), logistic EuroSCORE and the anatomical suitability for 
MitraClip implantation.9 Transcatheter mitral valve repair with the MitraClip 
device started in 2011 at the Leiden University Medical Center. 
  Surgical mitral valve repair was performed using restrictive mitral ring 
annuloplasty.10 Briefly, through a midline sternotomy approach and under 
normothermic cardiopulmonary bypass and intermittent antegrade warm 
blood cardioplegia, the mitral valve was exposed through a vertical trans-
septal incision of the interatrial septum. The mitral valve annulus was 
measured and the mitral ring (Carpentier Edwards Physioring, Edwards 
Lifesciences, Irvine, CA) was inserted, downsizing the ring by 2 sizes.10
  Transcatheter implantation of the MitraClip system uses a 24-F torqueable 
sheath which is introduced through the femoral vein into the right atrium 
passing to the left atrium through a trans-septal puncture.11,12 The MitraClip 
is advanced through the mitral valve into the LV and after aligning the arms 
of the clip perpendicular to the line of coaptation of the mitral leaflets, the 
device is pulled back to grasp the leaflets between the grippers and the arms of 
the clip at the level where the maximum regurgitation occurs. The procedure 
is performed under the guidance of 2- and 3- dimensional transesophageal 
echocardiography and the immediate reduction in MR is evaluated.9 More 
than one clip can be implanted in order to achieve adequate correction of 
MR without significant increase in diastolic transmitral gradient.13       
Echocardiography   Transthoracic echocardiography was performed at baseline, before discharge 
and at mid-term follow-up (6 month), using a commercially available 
ultrasound system (Vivid 7 and Vivid E9; GE Vingmed Ultrasound AS, Horten, 
Norway) equipped with 3.5-MHz or M5S transducers. Two-dimensional grey 
scale images and colour, continuous-wave and pulse-wave Doppler data 
were digitally stored and were analyzed offline (EchoPAC version 112.0.1; GE 
Vingmed Ultrasound, Norway).
Mitral regurgitation severity was assessed by an integrated approach as 
recommended, including measurement of the vena contracta and quantifi-
cation of the effective regurgitant orifice area and regurgitant volume with 
the proximal isovelocity surface area method.14 Severe secondary MR was 
defined by a vena contracta width of ≥0.4 cm, an effective regurgitant ori-
fice of ≥0.2 cm2 and a regurgitant volume of ≥30 ml/beat.14, 15 The residual 
MR post-repair was quantified in a semi-quantitative method as previously 
reported.8, 12 
LV remodeling was evaluated according to current recommendations.16 
LV end-diastolic and end-systolic volumes were evaluated by Simpsons’ 
biplane method and then indexed to body surface area. LV dimensions were 
measured on the parasternal long-axis view and the LV mass was calculated 
and indexed to body surface area, as previously described.16 In addition, the 
relative wall thickness ([2 x posterior wall thickness in diastole] / LV end-
diastolic diameter) and the ratio of LV mass to LV end-diastolic volume were 
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also assessed.16  
LVEF was measured using the Simpsons’ biplane method.16 Additionally, LV 
systolic function was assessed by 2-dimensional speckle tracking systolic 
global longitudinal strain (GLS).17 GLS was evaluated at the apical 3-, 4- 
and 2-chamber views after defining the aortic valve closure timing on the 
3-chamber view.17 Subsequently, GLS was corrected for LV end-diastolic 
volume (every 100ml) as previously reported.18 LV pressure and strain are 
affected by the LV myocardial fibers’ length, according to the Frank-Starling 
law,19 and as a result when the LV size changes due to MR reduction post-
repair, the GLS should be corrected for the LV size.18, 20 Furthermore, LV 
forward stroke volume was estimated by multiplying the LV outflow tract 
cross-sectional area by the velocity time integral derived from the pulse-
wave Doppler signal of the LV outflow tract and indexed to body surface 
area. The cardiac output was calculated from the stroke volume multiplied 
by the heart rate and the cardiac index by the cardiac output indexed to 
body surface area. The LV forward ejection fraction was estimated by 
dividing the stroke volume by the LV end-diastolic volume and expressed as 
a percentage.18    
Statistical 
analysis
  The continuous variables are presented as mean ± standard deviation and 
the categorical variables as frequencies and percentages. The continuous 
variables were compared with unpaired Students t-test or Mann-Whitney U 
test as appropriate. The categorical variables were compared with the chi-
square test.
  Changes over time in LV function variables (LVEF, GLS, corrected GLS), 
forward flow variables (stroke volume, stroke volume index, cardiac output, 
cardiac index, LV forward ejection fraction) and LV remodeling variables (LV 
end-diastolic volume, end-systolic volume, mass, relative wall thickness, ratio 
mass/end-diastolic volume) were assessed using linear mixed modelling 
analysis with all these variables as dependent variables. Time (baseline, pre-
discharge and 6 months) and type of repair (MitraClip or surgical repair) 
were introduced as main fixed effects. Main effects were compared and their 
interaction was tested using the Bonferroni confidence interval adjustment. 
Post-hoc analysis was performed with the Bonferroni test to determine 
the time points at which the dependent variables significantly differed. 
All statistical analyses were performed with the SPSS version 20 (SPSS, Inc, 
Chicago, IL) and p values <0.05 were considered statistically significant.   
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Age, years 65±14 62±14 72±10 0.002
Male, n (%) 33 (43) 22 (41) 11 (50) 0.46
Body surface area, m2 1.89±0.20 1.92±0.20 1.82±0.19 0.07
Hypertension, n (%) 46 (62) 38 (72) 8 (38) 0.007
Diabetes, n (%) 16 (22) 7 (14) 9 (43) 0.006
Atrial fibrillation, n (%) 39 (53) 29 (53) 10 (48) 0.64
eGFR, mL/min per 1.73 m2 60±25 65±22 50±30 0.02
NYHA class III-IV, n (%) 47 (63) 30 (56) 17 (77) 0.003
B-blockers, n (%) 52 (69) 37 (69) 15 (68) 0.59
ACEi/ARBs, n (%) 62 (82) 45 (83) 17 (77) 0.38
Diuretics, n (%) 61 (80) 45 (83) 16 (73) 0.23
Calcium antagonists, n (%) 8 (11) 4 (8) 4 (18) 0.16
Digoxin, n (%) 29 (38) 21 (39) 8 (36) 0.53
ACE-I, angiotensin-converting enzyme inhibitor;  
ARB, angiotensin-II receptor blocker;  
eGFR, estimated glomerular filtration rate;  
MR, mitral regurgitation;  
NYHA, New-York Heart Association







LV ejection fraction, % 34±10 35±10 32±11 0.20
Global longitudinal strain, % -9.63±4.11 -10.29±3.87 -8.09±4.32 0.04
Corrected global longitudinal strain, %/100ml -8.26±7.03 -9.10±7.38 -6.31±5.84 0.12
Stroke volume index, ml/m2 20±7 21±6 20±8 0.80
Cardiac index, L/min/m2 1.50±0.44 1.48±0.41 1.53±0.51 0.70
Forward ejection fraction, % 29±14 33±13 25±16 0.03
LVEDV index, ml/m2 87±42 81±36 105±56 0.03
LVESV index, ml/m2 60±35 55±31 75±46 0.04
LV mass index, gr/m2 128±42 121±41 148±41 0.01
29±10 29±10 30±9 0.94
LV mass/LVEDV, gr/ml 1.64±0.59 1.62±0.57 1.65±0.67 0.87
LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic 





  In total, 76 patients (65±14 years old, 43% male) with severe secondary 
MR and non-ischemic dilated cardiomyopathy with LVEF <50% who were 
successfully treated with mitral valve repair were evaluated. Baseline vena 
contracta, effective regurgitant orifice area and regurgitant volume were 
0.63±0.16 cm, 0.21±0.10 cm2 and 32±12 ml, respectively. Surgical mitral 
valve repair was performed in 54 (71%) patients whereas 22 (29%) were 
treated with transcatheter MitraClip implantation (Table 1). Patients treated 
with the MitraClip device were older and showed more advanced heart 
failure symptoms compared with patients treated surgically. The parameters 
characterizing LV function, LV forward flow and remodeling are presented 
in Table 2. Patients treated with the MitraClip device had more dilated and 
eccentrically hypertrophied LV but comparable systolic function and LV 
forward flow than patients treated with surgical repair.
MR change post-
repair
  Repeated echocardiography was performed pre-discharge (median of 5 
days; interquartile range 1-7) and at mid-term follow-up (median of 6 months; 
interquartile range 4-9). The MR grade at discharge was by definition ≤2, 
and although it increased at mid-term follow-up, it was still significantly less 
severe compared with baseline (p<0.001) (Figure 1). Specifically, at mid-term 
follow-up, in the surgical repair group 38% had no MR, 45% MR grade 1, and 
17% MR grade 2 and in the MitraClip group 5% had no MR, 47% MR grade 1, 
26% MR grade 2 and 21% MR grade 3. MR at follow-up was significantly less 
severe than pre-repair in both groups (p<0.001 in both groups).
LV functional 
recovery, forward 
flow and remodeling 
post-repair
  Over time after successful repair, LVEF and corrected GLS remained 
FU, follow-up; 





3=moderate to severe, 
4=severe.
Figure 1. Mitral regurgitation evolution post mitral valve repair in patients with non-ischemic 
secondary mitral regurgitation. 
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unchanged (p=0.90 and p=0.96 respectively) (Table 3). However, LV forward 
flow assessed by stroke volume index, cardiac output, cardiac index and LV 
forward ejection fraction increased over time (p<0.001 for all parameters). 
This increase was detected at discharge and although at mid-term follow-
up all these parameters were significantly reduced compared with discharge 
values, they still remained significantly better compared with baseline 
(follow-up versus baseline Bonferroni p<0.001 for all the forward flow 
parameters) (Table 3). 
  There were significant reductions in LV end-diastolic and end-systolic volumes 
over time after mitral valve repair (p<0.001 and p=0.005 respectively). This 
reduction occurred immediately after the MV repair at discharge and was 
sustained at mid-term follow-up (follow-up versus baseline Bonferroni 
p=0.001 and p=0.004 respectively) (Table 3).  
Impact of the 
type of repair 
on LV functional 
recovery, 
forward flow and 
remodeling
  Over time, the type of repair (MitraClip or surgical) had no impact on LVEF 
change (coefficient -3.50, 95% CI -8.61 – 1.54, p=0.17) and corrected GLS 
change (coefficient -1.48, 95% CI -4.64 – 1.67, p=0.35). Moreover, the type of 
Table 3. Left ventricular functional recovery and remodeling over time after mitral valve repair 
(n=76)
Baseline Discharge Mid-term FU p-value*
Left ventricular functional recovery
LV ejection fraction, % 34±10 35±12 34±12 0.94
Corrected global longitudinal strain, %/100ml -8.26±7.03 -8.76±6.20 -8.33±6.50 0.96
Left ventricular forward flow
Stroke volume, ml 39±12 55±18 † 50±17 ¥,§ <0.001
Stroke volume index, ml/m2 20±7 29±8 † 26±8 ¥,§ <0.001
Cardiac output, L/min 2.84±0.82 4.44±1.28 † 3.76±0.95 ¥,§ <0.001
Cardiac index, L/min/m2 1.51±0.44 2.36±0.60 † 2.01±0.48 ¥,§ <0.001
Forward ejection fraction, % 29±14 54±25 † 45±20 ¥,§ <0.001
Left ventricular remodeling 
LVEDV, ml 165±82 133±62 † 142±77 ¥ <0.001
LVEDV index, ml/m2 87±42 70±33 † 75±39 ¥ <0.001
LVESV, ml 114±69 93±56 † 100±60 ¥ 0.005
LVESV index, ml/m2 60±35 50±30 † 53±36 ¥ 0.004
Relative wall thickness,% 29±10 34±9 † 33±10 0.03
LV mass, gr 243±80 249±90 254±105 0.32 
LV mass index, gr/m2 128±42 132±46 134±53 0.39
LV mass/LVEDV, gr/ml 1.64±0.59 2.07±0.76 † 1.90±0.63 ¥ 0.004
LV, left ventricular;  
LVEDV, left ventricular end-diastolic volume;  
LVESV, left ventricular end-systolic volume;  
FU, follow-up 
*p-value for total change of the parameter over the total follow-up time period  
†p<0.05 for comparison of discharge vs. pre-repair with Bonferroni adjustment   
¥p<0.05  for comparison of mid-term follow-up vs. pre-repair with Bonferroni adjustment   
§p<0.05 for comparison of discharge vs. mid-term follow-up with Bonferroni adjustment   
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FU, follow-up;  
LV, left ventricular;  
LVEDV, left ventricular 
end-diastolic volume;  
LVESV, left ventricular 
end-systolic volume.
FU, follow-up;  
LV, left ventricular;  
LVEDV, left ventricular 
end-diastolic volume;  
LVESV, left ventricular 
end-systolic volume.
 
Figure 3. Left ventricular remodeling post mitral valve repair in patients with non-ischemic 
secondary mitral regurgitation.
Figure 2. Left ventricular functional recovery post mitral valve repair in patients with non-ischemic 
secondary mitral regurgitation.
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repair had no impact on stroke volume index change (coefficient -1.97, 95% 
CI -4.81 – 0.87, p=0.17) and cardiac index change over time (coefficient -0.13, 
95% CI -0.33 – 0.08, p=0.21). As a result the type of repair had no impact on 
LV functional recovery and forward flow change over time (Figure 2).
  Furthermore, patients treated with the MitraClip device had larger LV 
end-diastolic and end-systolic volume index (coefficient 29.38, 95% CI 
11.17 – 47.59, p=0.002 and coefficient 22.17, 95% CI 5.15 – 39.20, p=0.01, 
respectively) and LV mass index (coefficient 25.40, 95% CI 5.50 – 45.30, 
p=0.01) compared with the surgical repair group. However, LV reverse 
remodeling was comparable in both treatment groups (p for interaction 0.46 
and 0.65 respectively). In addition, the type of repair had no impact on the 
relative wall thickness change (coefficient 0.05, 95% CI -0.03 – 0.04, p=0.96) 
or reduction in LV mass (p for interaction 0.88) (Figure 3). This indicates that 
both therapies exerted similar LV reverse remodeling over time  (Figure 3).
 
DISCUSSION
The current study shows that successful correction of chronic moderate to severe secondary MR in 
non-ischemic dilated cardiomyopathy patients partly reverses the underlying LV pathophysiology, 
with significant increase of LV forward flow and LV reverse remodeling but without changes in LVEF 
and corrected GLS over time. The type of correction, MitraClip or surgical repair, had no significant 






  Despite the heterogeneous patient populations (ischemic versus non-
ischemic) and the different surgical repair techniques used (isolated mitral 
valve repair versus associated with coronary artery bypass grafting or 
LV reconstruction or passive containment with cardiac support devices), 
the majority of  the studies showed modest  but statistically significant 
improvements in LVEF after surgical mitral valve repair for secondary MR.21 
Among the studies including patients with non-ischemic secondary MR, the 
Acorn trial, where almost 78% of patients had non-ischemic cardiomyopathy, 
showed significant and sustained improvements in LVEF at 12 months after 
restrictive mitral valve annnuloplasty.22 In contrast, a study including 69 
patients with non-ischemic cardiomyopathy undergoing restrictive mitral 
valve annuloplasty showed no significant improvement in LVEF (from 26±8 
to 29±11% at 2-year follow-up).23 Using MitraClip device several series 
have reported conflicting results in terms of LVEF improvement during 
follow-up.5, 24 The Real World Expanded Multicenter Study of the MitraClip 
System (REALISM) study including 379 patients with secondary MR (12.2% 
non-ischemic aetiology) showed stable LVEF at 12 months follow-up after 
MitraClip (44±11 vs. 44±11%).5 In contrast, the sub-analysis of the Getting 
Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) 
registry, including 78 patients (about 62% non-ischemic) with secondary 
MR, reported significant improvement of the LVEF 12-months post-MitraClip 
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(from 40.72±11.62 to 46.23±9.03%).24 In these studies, disparities in patient 
populations may explain in part the controversial results in terms of LVEF 
improvement. 
  However, LVEF may not be the best reflector of improvement in LV systolic 
function after mitral valve repair. In 24 patients with secondary MR (54% 
non-ischemic cardiomyopathy) who underwent cine multi-detector row 
computed tomography prior to and 2 months after restrictive mitral 
annuloplasty, Takeda et al showed an 11% decrease in global LV end-systolic 
wall stress along with significant improvement in LVEF (from 27±8% to 
33±13%; p=0.0007) and LV reverse remodeling (21% and 13% reductions 
in LV end-systolic and end-diastolic volumes, respectively).25 This reduction 
in LV end-systolic volume would lead to a reduction in LV end-systolic wall 
stress favoring further reduction in LV systolic volume and exceeding the 
reduction in LV end-diastolic volume which eventually results in increase 
in LVEF. In addition, a modest improvement in LV end-systolic wall stress 
corrected for LV end-systolic volume (a relatively load-independent 
measure of myocardial contractility) was observed but was weakly 
correlated with the increase in LVEF suggesting that the improvement in 
LV ejection performance is most probably related to afterload reduction 
rather than intrinsic improvement in LV contractility. Similarly, the present 
study showed no changes in LV GLS corrected for end-diastolic volume. 
In contrast, improvement in LV forward ejection fraction was observed 
suggesting that restrictive mitral annuloplasty is not associated with 





  The prevalence of LV reverse remodeling, defined as 15% reduction in LV 
end-systolic volume, after surgical mitral valve repair for secondary MR 
ranges between 50% and 73%.23, 26, 27 In studies including patients in whom 
passive restraint devices were used (i.e. CorCap Acorn CV, St Paul, Minn), the 
magnitude of LV volumes reduction was higher compared with series where 
these devices were not used.22, 23 The Acorn trial showed significant and 
sustained reductions in LV end-systolic and end-diastolic volumes at 5 years 
after restrictive mitral annuloplasty.22 Using the MitraClip device, Glower 
et al reported the 12-month echocardiographic outcomes of 351 patients 
enrolled in the EVEREST-II (Endovascular Valve Edge-to-Edge REpair Study) 
High-Risk registry and the REALISM Continued Access Study High-Risk 
Arm:4 the LV end-diastolic volume reduced from 161±56 ml to 143±53 ml 
(p<0.001) and end-systolic volume from 87±47 ml to 79±44 ml (p<0.001). In 
the present study, both LV end-diastolic and end-systolic volume decreased 
significantly at follow-up. Interestingly, patients treated with the MitraClip 
device showed larger LV volumes during follow-up as compared with patients 
who underwent surgical mitral valve repair. It has been described that the 
presence of significant residual MR or recurrent MR is associated with less LV 
reverse remodeling.5 In line with previous studies,28, 29 the present study also 
showed that the prevalence of moderate MR in this study was significantly 
higher in the MitraClip group at discharge (MR grade 2: 27% vs. 0%, p<0.001) 
and at follow-up (MR grade 2-3: 47% vs. 17%, p=0.02) compared with the 
surgical repair group. However, the type of treatment was not associated 
with the occurrence of LV reverse remodeling. Probably other confounding 
parameters, apart from the gradual MR increase, may influence this finding.5 
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Clinical implications: 






  The current analysis demonstrated that LV reverse remodeling and LV 
forward flow increased after mitral valve repair in patients with non-ischemic 
secondary MR and these improvements were independent of the type of 
repair (surgical or transcatheter). Current guidelines indicate that mitral 
valve repair/replacement may be considered in non-ischemic heart failure 
patients with symptomatic severe secondary MR despite optimal medical 
treatment (including cardiac resynchronization therapy) (Class IIbC) due 
to the limited evidence and the inconsistent results in terms of clinical and 
echocardiographic outcomes across the various studies.2, 3 The present study 
provides further insights into the question on the effects of mitral valve 
repair on the underlying pathophysiology of non-ischemic secondary MR 
by showing that, despite no changes in LVEF or GLS corrected for LV end-
diastolic volume, LV reverse remodeling occurs and LV forward ejection 
fraction improves. The fact that these findings were independent of type of 
repair emphasizes the relevance of role of the Heart team which is able to 
personalize the treatment according to the surgical risk. 
Limitations   The current analysis included a relatively small number of patients which 
precluded us to perform survival analyses. However the cohort was very 
homogeneous including only patients with non-ischemic secondary MR. 
Longer follow-up would have strengthened the results by showing whether 
changes in LV structure and function were sustained. 
CONCLUSIONS
Successful correction of chronic moderate to severe secondary MR in non-ischemic dilated cardio-
myopathy patients partly reverses the underlying LV pathophysiology, with significant increase of 





1. R Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, et al. Independent prognostic 
value of functional mitral regurgitation in patients with heart failure. A quantitative 
analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. 
Heart 2011;97:1675-80.
2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, et al. 2014 
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A 
Report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation 2014;129:e521-643.
3. Joint Task Force on the Management of Valvular Heart Disease of the European Society of 
C, European Association for Cardio-Thoracic S, Vahanian A, Alfieri O, Andreotti F, Antunes 
MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular 
heart disease (version 2012). Eur Heart J 2012;33:2451-2496.
4. Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, et al. Percutaneous mitral valve 
repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am 
Coll Cardiol 2014;64:172-81.
5. Grayburn PA, Foster E, Sangli C, Weissman NJ, Massaro J, Glower DG, et al. Relationship 
between the magnitude of reduction in mitral regurgitation severity and left ventricular 
and left atrial reverse remodeling after MitraClip therapy. Circulation 2013;128:1667-74.
6. Taramasso M, Maisano F, Latib A, Denti P, Buzzatti N, Cioni M, et al. Clinical outcomes 
of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention 
2014;10:746-52.
7. Franzen O, van der Heyden J, Baldus S, Schluter M, Schillinger W, Butter C, et al. MitraClip(R) 
therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 2011;13:569-76.
8. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or 
surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406.
9. Debonnaire P, Delgado V, Bax JJ and Marsan NA. Tools & Techniques - Clinical: 3D 
transoesophageal echocardiography for selecting and guiding in percutaneous mitral 
valve repair using MitraClip. EuroIntervention 2014;10:884-6.
10. Ciarka A, Braun J, Delgado V, Versteegh M, Boersma E, Klautz R, et al. Predictors of 
mitral regurgitation recurrence in patients with heart failure undergoing mitral valve 
annuloplasty. Am J Cardiol 2010;106:395-401.
11. Beigel R, Wunderlich NC, Kar S and Siegel RJ. The evolution of percutaneous mitral valve 
repair therapy: lessons learned and implications for patient selection. J Am Coll Cardiol 
2014;64:2688-700.
12. Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, Luscher TF, et 
al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-
up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol 
2014;64:875-84.
13. Alegria-Barrero E, Chan PH, Foin N, Syrseloudis D, Tavazzi G, Price S, et al. Concept of the 
central clip: when to use one or two MitraClips(R). EuroIntervention 2014;9:1217-24.
14. Grayburn PA, Carabello B, Hung J, Gillam LD, Liang D, Mack MJ, et al. Defining “Severe” 
Secondary Mitral Regurgitation: Emphasizing an Integrated Approach. J Am Coll Cardiol 
2014;64:2792-801.
15. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. 
134 CHAPTER 7
Recommendations for the echocardiographic assessment of native valvular regurgitation: 
an executive summary from the European Association of Cardiovascular Imaging. Eur 
Heart J Cardiovasc Imaging 2013;14:611-44.
16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations 
for cardiac chamber quantification by echocardiography in adults: an update from the 
american society of echocardiography and the European association of cardiovascular 
imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-71.
17. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current 
and evolving echocardiographic techniques for the quantitative evaluation of cardiac 
mechanics: ASE/EAE consensus statement on methodology and indications endorsed by 
the Japanese Society of Echocardiography. Eur J Echocardiogr 2011;12:167-205.
18. Witkowski TG, Thomas JD, Delgado V, van Rijnsoever E, Ng AC, Hoke U, et al. Changes in 
left ventricular function after mitral valve repair for severe organic mitral regurgitation. 
Ann Thorac Surg 2012;93:754-60.
19. Shiels HA and White E. The Frank-Starling mechanism in vertebrate cardiac myocytes. J 
Exp Biol 2008;211:2005-13.
20. Marciniak A, Claus P, Sutherland GR, Marciniak M, Karu T, Baltabaeva A, et al. Changes 
in systolic left ventricular function in isolated mitral regurgitation. A strain rate imaging 
study. Eur Heart J 2007;28:2627-36.
21. Di Salvo TG, Acker MA, Dec GW and Byrne JG. Mitral valve surgery in advanced heart 
failure. J Am Coll Cardiol 2010;55:271-82.
22. Acker MA, Jessup M, Bolling SF, Oh J, Starling RC, Mann DL, et al. Mitral valve repair in 
heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn 
randomized trial. J Thorac Cardiovasc Surg 2011;142:569-74.
23. Braun J, Ciarka A, Versteegh MI, Delgado V, Boersma E, Verwey HF, et al. Cardiac support 
device, restrictive mitral valve annuloplasty, and optimized medical treatment: a 
multimodality approach to nonischemic cardiomyopathy. J Thorac Cardiovasc Surg 
2011;142:e93-100.
24. Attizzani GF, Ohno Y, Capodanno D, Cannata S, Dipasqua F, Imme S, et al. Extended use 
of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve 
Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic 
outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous 
Clip Implantation) registry. JACC Cardiovasc Interventions 2015;8:74-82.
25. Takeda K, Taniguchi K, Shudo Y, Kainuma S, Hamada S, Matsue H, et al. Mechanism of 
beneficial effects of restrictive mitral annuloplasty in patients with dilated cardiomyopathy 
and functional mitral regurgitation. Circulation 2010;122:S3-9.
26. Westenberg JJ, van der Geest RJ, Lamb HJ, Versteegh MI, Braun J, Doornbos J, et al. MRI to 
evaluate left atrial and ventricular reverse remodeling after restrictive mitral annuloplasty 
in dilated cardiomyopathy. Circulation 2005;112:I437-42.
27. De Bonis M, Lapenna E, Verzini A, La Canna G, Grimaldi A, Torracca L, et al. Recurrence 
of mitral regurgitation parallels the absence of left ventricular reverse remodeling after 
mitral repair in advanced dilated cardiomyopathy. Ann Thorac Surg 2008;85:932-9.
28. Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, et al. 4-year 
results of a randomized controlled trial of percutaneous repair versus surgery for mitral 
regurgitation. J Am Coll Cardiol 2013;62:317-28.
29. Taramasso M, Denti P, Buzzatti N, De Bonis M, La Canna G, Colombo A, et al. Mitraclip 
therapy and surgical mitral repair in patients with moderate to severe left ventricular 
failure causing functional mitral regurgitation: a single-centre experience. Eur J 
Cardiothorac Surg 2012;42:920-6.
PART III





Prognostic Value of Aortic and Mitral Valve 
Calcium Detected by Contrast Cardiac 
Computed Tomography Angiography in 
Patients with Suspicion of Coronary Artery 
Disease
Vasileios Kamperidis, MD, MSc, Michiel A. de Graaf, Alexander Broersen, 
PhD, Wehab Ahmed, Georgios Sianos, MD, PhD, Victoria Delgado, MD, 
PhD, Jouke Dijkstra, PhD, Jeroen J. Bax, MD, PhD, and Arthur J. Scholte, 
MD, PhD
Am J Cardiol. 2014;113(5):772-8.
138 CHAPTER 8
ABSTRACT
Aortic valve calcium (VC) detected on non-contrast cardiac computed tomography angiography 
(CCTA) is known to be associated with all-cause mortality in asymptomatic and primary prevention 
population. However, the clinical significance of aortic and mitral VC remains unknown in symp-
tomatic patients with suspected coronary artery disease (CAD). The aim of the present study was to 
assess whether aortic and mitral VC is independently associated with cardiac events and all-cause 
mortality in symptomatic patients with suspected CAD. A total of 369 symptomatic patients (mean 
age 55 ± 11 years, 60% male) who were referred for CCTA because of suspected CAD were included 
in the study. Aortic and mitral VC was detected and quantified by volume on contrast CCTA. Median 
follow-up (FU) for events (coronary-events and all-cause mortality) was 2.8 (interquartile range: 1.6 
to 4.0) with a maximum of 5.5 years. A total of 39 (11%) patients had VC. Increased age, hyperten-
sion and increased Agatston coronary artery calcium (CAC) score were associated with VC. During 
the FU, patients with VC had higher risk for a coronary event (38.8 vs. 11%, log-rank p<0.001) and 
worse survival (92.3 vs. 99.1%, log-rank p=0.002) compared to those without VC.  Volume of VC 
was independently associated with outcome, after adjusting for clinical variables (hazard ratio 1.88, 
p<0.001), Agatston CAC score (hazard ratio 1.47, p=0.03) and significant CAD (hazard ratio 1.81, 
p=0.001). In conclusion, aortic and mitral VC volume quantified on contrast CCTA was independent-
ly associated with coronary events and all-cause mortality in patients with suspected CAD. 
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INTRODUCTION
Contrast enhanced cardiac computed tomography angiography (CCTA) is nowadays used for the 
anatomic evaluation of coronary artery disease (CAD) in symptomatic patients with chest pain and 
low to intermediate probability of CAD.1,2 Besides CAD, valve calcium (VC) can be detected by con-
trast enhanced CCTA.3,4 Aortic and mitral VC detected by CCTA has been associated with increased 
prevalence of CAD, cardiovascular events and all-cause mortality in asymptomatic patients.5-8 How-
ever, little is known about the prognostic value of aortic and mitral VC detected by CCTA in symp-
tomatic patients. Moreover, the value of VC quantification on contrast enhanced CCTA has never 
been explored. Therefore, the aim of the current study was to assess the independent association 
between VC, detected and quantified on contrast CCTA, and prognosis in symptomatic patients 
with suspected CAD.
METHODS
We included all symptomatic patients who underwent a clinically indicated 
contrast enhanced CCTA for the evaluation of CAD from November 2007 till 
April 2010. Patients with previous diagnosis of CAD, congenital heart dis-
ease, mechanical valve prosthesis and poor CCTA diagnostic image quality 
were excluded. 
All scans were performed using a 64-detector row computed tomography 
scanner or a 320-row scanner according established guidelines and local 
protocol.9,10 Scan parameters were: 120kV, 300mA (depending on BMI and 
thoracic anatomy) and collimation of 64x0.5mm; and 120kV, 400-580mA (de-
pending on BMI and thoracic anatomy) and collimation of 320x0.5mm for 
64- and 320-row scanners, respectively. Contrast-enhanced CCTAs were re-
constructed at 75% of the R-R interval with a slice thickness of 0.3mm for the 
64- and 0.5mm, increment 0.25mm for the 320-detector scanner. Non-en-
hanced CCTAs were also reconstructed at the 75% of the R-R interval but 
with a slice thickness of 3mm non-overlapping. Reconstructed images were 
transferred to a remote workstation (Vital Images, Plymouth, Minnesota) for 
post-processing with dedicated software. 
The non-contrast scans were used to evaluate the total coronary artery calci-
um (CAC) score as described by Agatston et al. applying a threshold of ≥130 
Hounsfield units (HU)11 with commercially available software (Vitrea 2, Vital 
Images, Plymouth, Minnesota).
To quantify VC on contrast-enhanced CCTA, novel automated data post-pro-
cessing software (customized research version of CalcScore V11.1 by Medis 
specials b.v.) was used. Since both calcium and contrast medium have a ra-
dio density of >130 HU, a cut-off value of >130 HU as used for non-contrast 
scans, is not suitable to quantify calcium on contrast enhanced CCTA imag-
es.12 Therefore, in the present study we applied a predefined threshold of 800 
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HU to quantify calcium on the aortic and mitral valve.3 An example of both 
thresholds is depicted in Figure 1. Because the Agatston score is only suit-
able for assessing coronary artery calcium,11 VC was quantified by assessing 
the volume (mm3) of calcium on contrast-enhanced CCTA.3,4 
To quantify VC we performed the following steps: because the aortic valve is 
depicted obliquely on the standard axial view,3 the first step was to reorient 
the image based on the aortic valve. By using three multi-planar reformation 
planes (Figure 2.A1&A2), a double oblique transverse view was created. In 
this plane the aortic cusps were equally bisected allowing concomitant vi-
sualization of the insertion point of the aortic cusps (Figure 2.B1). Secondly, 
scrolling through sequential axial images below the aortic annulus, the mi-
tral valve can be visualized in this view (Figure 2.C1). Next, 3mm slabs were 
created to facilitate accurate VC quantification. Subsequently, the aortic (Fig-
Figure 1. Aortic valve calcium 
assessed on contrast cardiac computed 
tomography angiography at the double 
oblique transverse view. A. Using a 
threshold of 130 HU detects all contrast, 
B. Using a threshold of 800 HU detects 
calcium on the aortic valve. AV=Aortic 
Valve, HU=Hounsfield Units, LA=Left 
Atrium, RV=Right Ventricle
Figure 2. Aortic and mitral valve calcium assessed on contrast cardiac computed tomography 
angiography with the threshold of ≥800HU. By adjusting the 3 orthogonal multi-planar reformation 
planes (red, yellow and green dotted lines), based on aortic valve orientation, in the coronal (A1) 
and single oblique sagittal (A2) views, the double oblique transverse view depicting the real aortic 
valve short axis (B1) was created. By using the sequential axial images below the aortic annulus, 
the mitral valve could also be visualized in this view (C1). B2 demonstrates the calcium detected on 
the aortic valve. Blue arrows point the aortic valve calcium colored yellow after selecting it. Orange 
arrows point the coronary artery calcium colored pink (not selected). C2 demonstrates the calcium 
detected on the mitral valve. Red arrow points mitral valve calcium colored green after selecting it.
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ure 2.B2) and mitral VC (Figure 2.C2) were manually selected. The aortic VC 
included all calcium within the level of the aortic annulus till the level of the 
coronary ostia. Mitral VC was defined as calcium of the mitral annulus and 
leaflets. Finally, the volume of the selected aortic and mitral VC was calculat-
ed automatically by the software.
Presence of significant CAD was evaluated from the contrast CCTA as previ-
ously described.13 Significant CAD was defined as ≥50% stenosis. 
Cardiovascular risk factors  evaluated for this study were: hypertension, de-
fined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure 
≥90 mm Hg and/or the use of antihypertensive medication; hypercholes-
terolemia, defined as serum total cholesterol ≥230 mg/dl and/or serum tri-
glycerides ≥200 mg/dl and/or treatment with lipid lowering drugs; diabetes, 
defined as fasting glucose ≥ 126mg/dl and/or on blood glucose lowering 
treatment; smoking, as current; obesity, as BMI ≥ 30 Kg/m2 and family histo-
ry: defined as the presence of CAD in first-degree family members diagnosed 
at the age of <55 years in men and <65 years in women. 
Clinical information were recorded prospectively into the departmental Car-
diology Information System (EPD, Vision, version 8.3.3.6, Leiden, The Neth-
erlands) and analyzed retrospectively. Follow up was completed till January 
2013. Patient follow-up data were gathered using clinical visits or standard-
ized telephone interviews. The primary outcome was all-cause mortality. The 
secondary end-point was coronary events, including a composite of myo-
cardial infarction (MI) and revascularization (percutaneous coronary inter-
vention (PCI) and coronary artery by-pass grafting (CABG)). The combined 
(primary and secondary) end-point is described as events.    
Statistical analysis was performed with the SPSS software version 20 (SPSS, 
Chicago, IL). Categorical variables are presented as number and percentages 
and continuous variables as mean ± standard deviation. Based on the distri-
bution, continuous variables were compared with the Student t-test or the 
Mann-Whitney U-test. Categorical variables were compared with the x2 test. 
Logistic regression analysis was used to evaluate the association between 
each cardiovascular risk factor and valve calcium as a categorical variable. 
In the multivariate adjusted analysis only the covariates with a p <0.10 in 
the univariate analysis were included. CAC Agatston score was introduced 
in the regression analysis as log(CAC Agatston score + 1). Cumulative event 
rates from the time of CCTA scanning were calculated using the Kaplan-Mei-
er method. The log-rank test for time to event data with respect to the pri-
mary (all-cause mortality) and secondary end point (composite endpoint of 
MI and revascularization) were used for statistical comparison between the 
patient groups (VC group vs. the no-VC group). In addition, the Kaplan-Meier 
estimates of the primary and the secondary endpoints were calculated for 
patients included in the VC group divided according to the median value of 
calcium volume. Cox regression analysis was conducted for the evaluation of 
univariate and multivariate hazard ratios (HRs) for the occurrence of events. 
CAC Agatston score and valve calcium volume were both introduced in the 
Cox regression analysis as log(CAC Agatston score + 1) and log(valve calcium 
volume + 1). HRs were reported with 95% confidence interval (CI). Statistical 
significance was considered for p value < 0.05. 
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RESULTS
Of the 384 consecutive symptomatic patients referred for CCTA to detect and evaluate CAD, 369 
patients (mean age 55 ± 11 years, 60% men) were finally included in the current analysis. Fifteen pa-
tients were excluded because of: mechanical aortic valve prosthesis (N=3, 0.8%) and adult congen-
ital heart disease (N=12, 3%). VC was observed in 39 (10.7%) patients; 34 (9.3%) had aortic VC, 10 
(2.8%) had mitral VC and 5 (1.4%) had calcium on both valves. Baseline characteristics are presented 
in table 1. Patients with VC were older, were more likely to have hypertension and had a higher 
CAC score. In addition, patients with hypertension and those with Agatston CAC score >1006,14 had 
higher VC volumes compared to patients without hypertension and those with Agatston of ≤100, 
respectively (Table 2). 
  Table 3 demonstrates the univariate and multivariate analysis for the associa-
tion of classical cardiovascular risk factors with the presence of VC. Increasing 
age and Agatston CAC score were the only factors independently associated 
with the presence of VC. 
  The median follow-up after the CCTA was 2.8 years (interquartile range 1.6 
to 4.0) with a maximum of 5.5 years. During this follow-up period, the com-
bined end-point was observed in 56 (15%) patients; 6 (1%) patients died, 
11 (3%) suffered acute coronary syndrome, 32 (9%) underwent PCI, 4 (1%) 
underwent CABG and 3 (1%) suffered a myocardial infarction during the fol-
low-up period after CCTA. Event-free survival was significantly worse for pa-
tients with VC in comparison to those without VC (event rate: 44% vs. 12% 
respectively, log-rank p<0.001) (Figure 3.A).  Patients with higher VC volume 
had worse event-free survival (event rate: 12% for no VC patients vs. 33% for 
subgroup of patients with VC volume below the median value of 14 mm3 
[interquartile range 5 to 49] vs. 56% for subgroup of patients with VC vol-
ume above this median, log-rank p<0.001) (Figure 3.B). Focusing on the cor-
onary-event-free survival, patients with VC had statistically significant more 
coronary events than those without VC (coronary-event rate: 39% vs. 11% 
respectively, log-rank p<0.001) (Figure 3.C). Focusing on all-cause mortality, 
the survival was significantly worse for those with versus those without VC 
(survival rate: 92% vs. 99% respectively, log-rank p=0.002) (Figure 3.D).  
  Table 4 presents the HRs of the univariate analysis for the association of car-
diovascular risk factors and VC volume with events. Increasing age, signifi-
cant CAD, Agatston CAC score and VC volume were significantly associated 
with events in the univariate cox-regression analysis. VC volume remained 
independently associated with the endpoint, after adjusting for age, hyper-
tension, smoking and Agatston CAC score or significant CAD (Table 5).
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Table 1. Baseline Demographics and Risk Factors According to the Presence of Valve Calcium.
Variable
All subjects Valve Calcium
p* value
N=369 (100%) NO (N= 330) YES (N=39)
Age (years) 55 ± 11 54 ± 11 66 ± 9 <0.001
Men 221 (60%) 198 (60%) 23 (59%) 0.90
Body Mass Index (Kg/m2) 26 ± 4.2 26 ± 4.1 26 ± 4.5 0.72
Diabetes Mellitus 103 (30%) 89 (29%) 14 (36%) 0.37
Hypertension 139 (40%) 117 (38%) 22 (56%) 0.02
Hypercholesterolemia 123 (35%) 105 (34%) 18 (46%) 0.13
Smoker 58 (17%) 50 (16%) 8 (21%) 0.50
Family History of CAD 144 (41%) 133 (43%) 11 (28%) 0.07
Obesity 70 (20%) 63 (20%) 7 (18%) 0.74
Agatston CAC Score 175 ± 478 114 ± 291 666 ± 1059 <0.001
Values are mean ± SD or n (%).
*p value for the comparison of Valve Calcium YES to NO.
Hypertension, defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the 
use of antihypertensive medication. Hypercholesterolemia, defined as serum total cholesterol ≥230 mg/dl and/or serum 
triglycerldes ≥200 mg/dl and/or treatment with lipid lowering drugs. Obesity, defined as BMI ≥30Kg/m2. CAC= Coronary 
Artery Calcium, CAD= Coronary Artery Disease
Table 2.  Risk Factors according to Quantified Valve Calcium.
Variable Valve Calcium Volume p value
Diabetes Mellitus
+ 44.5 ± 394.1
0.18
0 8.79 ± 78.6
Hypertension
+ 45.6 ± 353.6
0.02
0 1.8 ± 8.4
Hypercholesterolemia
+ 35.9 ± 360.6
0.18
0 10.2 ± 82.2
Smoker
+ 21.8 ± 148.4
0.49
0 18.9 ± 237.4
Family History of CAD
+ 3.6 ± 25.1
0.07
0 30.4 ± 291.7
Obesity
+ 21.4 ± 137.6
0.65
0 18.9 ± 242.0
Agatston CAC Score
>100 74.2 ± 445.4
<0.001
≤100 1.0 ± 8.1
All values are mean ± SD in mm3.   +=Yes, 0=No, CAC= Coronary Artery Calcium, CAD= Coronary Artery Disease
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Table 4.  Univariate Cox Regression Analyses of factors associated with the Combined End Point.
Variable Univariate
HR 95% CI p value
Age (years) 1.06 1.03 - 1.08 <0.001
Diabetes Mellitus 1.20 0.69 - 2.09 0.52
Hypercholesterolemia 1.20 0.70 - 2.05 0.51
Hypertension 1.60 0.94 - 2.71 0.08
Family History of CAD 1.45 0.85 - 2.45 0.17
Smoking 1.73 0.93 - 3.23 0.08
Obesity 1.33 0.72 - 2.48 0.36
CA stenosis ≥50% 2.63 1.55 - 4.45 <0.001
Agatston CAC score 2.58 1.98 - 3.38 <0.001
Valve Calcium Volume 2.26 1.71 - 2.99 <0.001
Agatston CAC score has been introduced as log(Agatston CAC score + 1)
Valve Calcium Volume has been introduced as log(Valve Calcium Volume + 1)
CA= Coronary Artery, CAC= Coronary Artery Calcium, CAD= Coronary Artery Disease, CI= Confidence Interval, HR= 
Hazard Ratio
Table 3.  Univariate and Multivariate Analysis of Risk Factors associated with Valve Calcium.
Variable Univariate Multivariate 
OR 95% CI p value OR 95% CI p value
Age (years) 1.14 1.09 - 1.20 <0.001 1.11 1.06 - 1.17 <0.001
Diabetes Mellitus 1.37 0.68 - 2.76 0.37
Hypercholesterolemia 1.66 0.85 - 3.25 0.14
Hypertension 2.10 1.07 - 4.12 0.03 1.01 0.46 - 2.21 0.98
Family History of CAD 0.52 0.25 - 1.08 0.08 0.68 0.30 – 1.53 0.35
Smoking 1.33 0.58 - 3.06 0.50
Obesity 0.87 0.37 - 2.05 0.74
Agatston CAC Score 2.74 1.91 - 3.89 <0.001 1.88 1.28 - 2.76 0.001
Agatston CAC score has been introduced as log(Agatston CAC score + 1)
CAC= Coronary Artery Calcium, CAD= Coronary Artery Disease, CI= Confidence Interval, OR= Odds Ratio
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Figure 3. Kaplan-Meier curves for combined end-point (events), coronary-events and all-cause 
mortality in patients with and without VC. Patients with VC had worse outcome; A. event-free 
survival was significantly worse for the patients with VC (event rate: 11.8% in no-VC vs. 43.5% 
in VC, p<0.001). B. event-free survival was significantly worse for the patients with higher VC 
volume (event rate: 11.8% in no VC vs. 33.3% in 1st subgroup of VC with calcium volume below the 
median VC volume vs. 55.5% in 2nd subgroup of VC with calcium volume above the median VC 
volume, p<0.001). C. coronary-event-free survival was significantly worse for the patients with VC 
(coronary-event rate: 11% in no VC vs. 38.8% in VC, p<0.001). D. survival was significantly worse 
for the patients with VC (survival rate: 99.1% in no VC vs. 92.3% in VC, p=0.002). VC= valve calcium, 
vs.=versus  
Table 5. Multivariate Cox-Regression Analyses for Valve Calcium Volume association to Combined 
End Point.
Variable Baseline model Baseline model + 
Agatston CAC score
Baseline model + 
CA stenosis ≥50%
HR (95% CI) 
p-value
HR (95% CI) 
p-value
HR (95% CI) 
p-value
Valve Calcium Volume 1.88 (1.35 - 2.62)
<0.001
1.47 (1.04 - 2.08)
0.03
1.81 (1.27 - 2.56)
0.001
Baseline Model: included Age, Hypertension, Smoking and Valve Calcium Volume 
Agatston CAC score has been introduced as log(Agatston CAC score + 1) 
Valve Calcium Volume has been introduced as log(Valve Calcium Volume + 1) 
CA= Coronary Artery, CAC= Coronary Artery Calcium, CAD= Coronary Artery Disease, CI= 
Confidence Interval, HR= Hazard Ratio
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DISCUSSION
The current study sought to investigate the prognostic value of aortic and 
mitral VC quantified on contrast CCTA in symptomatic patients with suspect-
ed CAD. The main findings are: 1) Increased age and CAC score were inde-
pendently associated with VC. 2) Patients with VC had more events in com-
parison to those without; and those with higher VC volume, had even more 
events. 3) VC volume was independently associated with the study endpoint. 
Furthermore, the current study showed that quantification of VC volume on 
contrast CCTA   was associated with all-cause mortality and cardiovascular 
events in symptomatic patients with clinical suspicion of CAD.
Non-contrast multi-detector computed tomography (MDCT) is a well-es-
tablished method for identifying aortic and/or mitral VC.5-8,15-18 In addition 
to identifying VC, a few studies focused on quantification of aortic VC.5,15,19-21 
Recently, aortic VC has been identified and quantified on contrast enhanced 
MDCT in patients with severe aortic valve stenosis undergoing transcatheter 
aortic valve implantation (TAVI).3,4 Contrast-enhanced CT allows also accu-
rate discrimination between calcium of the circumflex coronary artery and 
the mitral annulus, permitting more accurate evaluation of the mitral VC vol-
ume.22 
Echocardiography is an imaging modality that is widely used for identify-
ing aortic and/or mitral VC.22-27 However, echocardiography can provide 
semi-quantification of VC and cannot provide absolute quantification of the 
VC volume.22 Moreover, with echocardiography  the discrimination between 
calcium and dense fibrosis is difficult, leading to an overestimation of VC 
in comparison to the reference standard MDCT.16,19 Cardiac magnetic reso-
nance imaging is an excellent modality for differentiating between mitral an-
nulus VC and caseous calcification, but has not been used for VC assessment 
in large cohorts of patients.28
Aortic and mitral VC are known to be an expression of generalized athero-
sclerosis as demonstrated by several studies proving strong clinical associa-
tion of cardiovascular risk factors with the presence of VC on MDCT.15-17,21,29,30 
Advanced age is the risk factor that has been recognized by all studies con-
ducted so far as an independent predictor of VC in the asymptomatic popu-
lation.16,17,21,29,30 The other risk factors associated with  mitral and/or aortic VC 
in the asymptomatic population were hypertension, type 2 diabetes, smok-
ing, dyslipidemia and obesity.16,17,21,29,30 Moreover, quantitative assessment 
of  aortic VC, demonstrated higher VC volumes in hypertensive, diabetic and 
dyslipidemic patients.15 The Agatston CAC score, as an expression of the ath-
erosclerotic plaque burden, has been associated with VC, but only recently it 
was demonstrated to be an independent predictor of mitral VC. 5,17,21,29    
The current study quantified both aortic and mitral VC on contrast CCTA 
and showed that VC volume was significantly higher in patients with hyper-
tension and in those with Agatston CAC score >100 (table 2). Furthermore, 
advanced age and Agatston CAC score were independently associated with 
aortic and mitral VC (table 3) which is in concordance with previous studies, 
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although the present study focused on symptomatic patients.16,17,21,29,30 
In addition to the association with clinical risk factors, the prognostic value 
of VC has been widely studied. Wong et al. studied aortic VC and thoracic 
aorta calcium on non-contrast cardiac electron beam computed tomogra-
phy (EBCT) and MDCT in self-referred or physician-referred patients without 
known CAD and demonstrated the incremental value of VC over the Agat-
ston CAC score for predicting the 10-year risk of CAD estimated by the Fram-
ingham risk score.29 In a similar way, Gondrie et al. studied aortic and mitral 
VC on chest MDCT in the population of the PROgnostic Value of incidental 
Information in Diagnostic Imaging (PROVIDI) study and observed that pa-
tients with VC had a higher incidence of CAD, heart failure, peripheral artery 
disease, aortic aneurysm or cerebrovascular disease.7 The prognostic value 
of VC on mortality has been studied in the primary prevention Multi-Ethnic 
Study of Atherosclerosis (MESA) population by Blaha et al.6 In this study aortic 
VC on non-contrast cardiac EBCT was an independent predictor of all-cause 
mortality even after adjusting for the classical cardiovascular risk factors and 
Agatston CAC score.6 Analyzing the same MESA study population, Owens 
et al. concluded that aortic VC detected on non-contrast cardiac MDCT was 
independently associated with cardiovascular and coronary events and that 
the risk of cardiac death increased in parallel to increasing VC severity, even 
after adjusting for the Agatston CAC score.5 
In contrast to previous studies that assessed the association between aor-
tic VC (assessed with non-contrast MDCT) and mortality, the current study 
focused on the association of aortic and mitral VC with all-cause mortality 
quantifying VC on contrast cardiac MDCT. Moreover, our study focused on 
the quantification of VC in a symptomatic population. Since symptomatic 
patients are increasingly undergoing contrast CCTA,   additional prognostic 
information can be extracted by quantifying the VC.1,2,5-7 
Some limitations have to be acknowledged. In the current study, CCTAs were 
not performed primarily for VC quantification, but for the assessment of 
CAD. As a result, VC assessment was performed retrospectively. Moreover, 
CCTA can overestimate coronary artery stenosis leading to referral for inva-
sive coronary angiography and subsequent revascularization. In addition, 
C-reactive protein was not available for all patients included in the study and 
its association to VC was not studied. Finally, the cause of death was not sys-
tematically available. 
Aortic and mitral VC identified on clinically indicated contrast CCTA in symp-
tomatic patients with suspected CAD is associated with worse survival and 
more coronary events. The volume of VC can be used as an additional and 
independent predictor of cardiac events.
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ABSTRACT
The prognostic implications of flow, assessed by stroke volume index (SVi), and left ventricular 
(LV) global longitudinal strain on survival of patients with low gradient severe aortic stenosis (AS) 
and preserved left ventricular ejection fraction (LVEF) are debated. The aim of this study was to 
evaluate the impact of flow and LV global longitudinal strain on survival of these patients treated 
with aortic valve replacement (AVR). Low gradient severe AS patients with preserved LVEF treated 
with AVR (N=134, age 76±10 years, 50% men) were included in the current study. Aortic valve 
hemodynamics and LV function were assessed with 2-dimensional, Doppler and speckle-tracking 
echocardiography pre AVR. Patients were dichotomized based on low (SVi≤35ml/m2) or normal 
(SVi>35ml/m2) flow and impaired (>-15%) or more preserved (≤-15%) global longitudinal strain. 
The end-point was all-cause mortality. During a median follow-up of 1.8 years (interquartile range 
0.5-3 years) after AVR, 26 (19.4%) patients died. Survival was better for patients with SVi>35ml/
m2 or global longitudinal strain ≤-15% as compared with patients with SVi≤35ml/m2 or global 
longitudinal strain >-15% (log-rank p=0.01). Atrial fibrillation (hazard ratio 5.40, 95% confidence 
interval 1.81-16.07, p=0.002) and chronic kidney disease (hazard ratio 3.67, 95% confidence interval 
1.49-9.06, p=0.005) were the clinical variables independently associated with all-cause mortality. 
The addition of global longitudinal strain (X2 19.87, p=0.029 and C-statistics 0.74) or SVi (X2 29.62, 
p<0.001 and C-statistics 0.80) to a baseline model including atrial fibrillation and chronic kidney 
disease (X2 14.52, C-statistics 0.68) improved risk stratification of these patients. In conclusion, 
flow and LV global longitudinal strain are independently associated with survival after AVR in low 
gradient severe AS patients with preserved LVEF. 
Keywords   Low gradient severe aortic stenosis;  





The decision making of patients with low gradient (mean pressure gradient ≤40mmHg) severe aortic 
stenosis (AS) (aortic valve area index, AVAi ≤0.6cm2/m2) with preserved left ventricular (LV) ejection 
fraction (EF) (≥50%) has been source of debate.1, 2 While some studies have reported better survival 
of these patients after aortic valve replacement (AVR),3, 4 others have suggested that these patients 
have comparable prognosis to that of patients with moderate AS.5 The underlying mechanisms 
influencing the outcome of these patients remain unclear. Despite having preserved LVEF, these 
patients have impaired LV mechanics as assessed with LV global longitudinal strain speckle tracking 
echocardiography and may have normal or low forward flow evaluated by stroke volume index 
(SVi).3, 6 The influence of flow and LV global longitudinal strain on the prognosis of patients with 
preserved LVEF low gradient severe AS remains unexplored. The present evaluation assessed the 
relative merits of flow and LV global longitudinal strain to predict the outcome of patients with 
severe AS, low gradient and preserved LVEF who underwent AVR. 
METHODS
Patients with symptomatic low gradient severe AS and preserved LVEF who 
underwent AVR were identified from an ongoing registry and were included 
in the current analysis (Figure 1).7 
Patients were clinically evaluated and data were collected on a dedicated 
departmental Cardiology Information System (EPD-Vision®, Leiden University 
Medical Center, Leiden, The Netherlands) and analyzed retrospectively. 
Demographics, clinical symptoms (New York Heart Association (NYHA) 
functional class), cardiovascular risk factors, medications and presence of 
atrial fibrillation, chronic kidney disease (defined as moderately to severely 
decreased creatinine clearance <45ml/min)8 and chronic pulmonary 
obstructive disease were collected. The Institutional Review Board approved 
this retrospective analysis of clinically acquired data and waived the need for 
written patient informed consent.
All patients underwent a complete transthoracic echocardiogram using 
commercially available ultrasound systems (Vivid-7 and E9, General 
Electric, Horten, Norway) equipped with 3.5MHz or M5S transducers. Two-
dimensional, colour-, pulsed-wave and continuous-wave Doppler data were 
acquired in the parasternal and apical views and were stored digitally and 
analyzed offline on a dedicated workstation (EchoPac 112.0.1, GE Medical 
Systems, Horten, Norway). LV dimensions and wall thickness were measured 
from the parasternal long-axis view according to current recommendations.9 
LV mass was estimated according to the formula by Devereux et al.9 Relative 
wall thickness and the ratio of LV mass to LV end-diastolic volume were 
calculated as previously described.10 LV end-diastolic and end-systolic 
volumes were measured in the apical 4- and 2-chamber views and indexed 
to body surface area and LVEF was derived using the Simpson’s biplane 
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method.9 SVi was estimated by multiplying LV outflow tract area by LV 
outflow tract velocity time integral on pulse-wave Doppler recordings and 
then indexed to body surface area. Cardiac output was calculated as the 
product of stroke volume and heart rate. Stroke work was calculated by 
the formula (mean arterial pressure + mean peak gradient) x stroke volume 
x 0.0136 and indexed to LV mass.11 Peak and mean pressure transaortic 
gradients were measured in the 3- or 5-chamber apical views according to 
the simplified Bernoulli equation. AVA was calculated with the continuity 
equation and then indexed to body surface area. In addition, energy loss 
index, valvulo-arterial impedance, systemic vascular resistance and systemic 
arterial compliance were calculated as previously described.12
For further evaluation of LV systolic function, offline 2-dimensional speckle 
tracking longitudinal strain analysis was performed at a workstation with 
commercially available software (EchoPac 112.0.1, GE Medical Systems, 
Horten, Norway). From the apical 3-, 4- and 2- chamber views, global 
longitudinal strain was measured and averaged. Transmitral pulsed-wave 
Doppler was used for assessment of LV diastolic function. Additionally, left 
atrial volume was evaluated according to the biplane area-length method 
and then indexed to body surface area.9 Co-existing valvular dysfunction 
was assessed based on the European Association of Echocardiography and 
the American Society of Echocardiography recommendations.12      
Based on SVi patients were divided into two categories: low flow was defined 
as SVi≤35ml/m2 and normal flow as SVi>35ml/m2.6, 13, 14 Patients were also 
categorized as having an LV global longitudinal strain ≤-15% or >-15%.7, 15-17
Figure 1. Patient population. AVAi, aortic valve area index;  
AVR, aortic valve replacement;  
LVEF, left ventricular ejection fraction;  
MPG, mean pressure gradient.  
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The end-point of the study was all-cause mortality. All patients were followed-
up after AVR. Survival data were collected either from the departmental 
Cardiology Information System (EPD-Vision®, Leiden University Medical 
Center, Leiden, the Netherlands), or by telephone interview or by the Social 
Security death index and were complete for all subjects included in the study.
Categorical variables are expressed as counts (frequency) and continuous 
variables as mean ± standard deviation. Continuous variables were 
compared between the 2 groups (survivors versus non-survivors) with 
the Student-t test or Mann-Whitney U test, as appropriate and categorical 
variables with the Chi-square test or Fisher exact test, as appropriate. The 
intra- and interobserver reproducibility of LV global longitudinal strain and 
SVi measurements were assessed by the intraclass correlation coefficient. 
The cumulative event rates were calculated based on Kaplan-Meier method 
and comparisons between groups were assessed by log-rank test. Cox 
proportional hazard ratio regression analyses were performed to investigate 
univariate and multivariate correlates of all-cause mortality. Hazard ratios 
and 95% confidence intervals were reported. Variables with univariate 
p<0.10 were entered in the multivariate analysis. The incremental value of 
flow and LV global longitudinal strain category over a baseline clinical model 
was estimated by the significant change in chi-square of the baseline model. 
The relative fit of each model was calculated with the −2 log likelihood. 
Moreover, C-statistics was used for model comparison. Statistical significance 
was considered for p value <0.05. Statistical analysis was performed with the 
SPSS software version 20 (SPSS, Chicago, IL). 
Figure 2. Impact of flow on survival of patients with low gradient severe aortic stenosis and 
preserved ejection fraction after aortic valve replacement. After adjusting for age, atrial fibrillation, 
chronic obstructive pulmonary disease, chronic kidney disease, New York Heart Association 
functional class and left ventricular systolic function assessed by global longitudinal strain, normal 
flow (stroke volume index>35ml/m2) patients had better outcome than patients with low flow 
(stroke volume index≤35ml/m2). CI, confidence interval; HR, hazard ratio. 
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Figure 3. Impact of left ventricular global longitudinal strain (GLS) on survival of patients with low 
gradient severe aortic stenosis and preserved ejection fraction after aortic valve replacement. After 
adjusting for age, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, 
New York Heart Association functional class and flow expressed as stroke volume index, patients 
with better GLS (≤-15%) had better outcome than patients with GLS >-15%. CI, confidence interval; 
HR, hazard ratio.
 
Figure 4. Impact of flow and left ventricular global longitudinal strain (GLS) on survival of 
patients with low gradient severe aortic stenosis and preserved ejection fraction after aortic 
valve replacement. Patients with low flow and more impaired GLS (>-15%) had significantly worse 
outcome compared with the other groups.
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RESULTS 
The baseline characteristics of 134 patients (75.5±9.9 years old, 50% male) 
are summarized in Table 1. Surgical AVR was performed in 71 (53%) patients 
and transcatheter AVR in the remaining 63 (47%). Echocardiographic data 
are summarized in Table 2. Low flow was identified in 48 (36%) patients 
and normal flow in 86 (64%) whereas an LV global longitudinal strain 
>-15% was observed in 67 (51%) patients and ≤-15% in 65 (49%). LV global 
longitudinal strain measurement was feasible in 132 (98%) patients. The 
intraclass correlation coefficients for intra and interobserver reprodcubility 
were 0.95 (95% confidence interval 0.69–0.99) and 0.87 (95% confidence 
interval 0.50-0.97)  for LV global longitudinal strain, respectively, and 0.90 
(95% confidence interval 0.60-0.97) and 0.88 (95% confidence interval 0.55-
0.97) for SVi, respectively. 
During a median follow-up of 1.8 years (interquartile range 0.5-3 years) 
after AVR, 26 (19.4%) patients died. There were no patients lost at follow-
up. At baseline, patients who died exhibited more frequently associated 
co-morbidities (atrial fibrillation, chronic kidney disease, chronic pulmonary 
obstructive disease), previous cardiac surgery and worse NYHA functional 
class as compared with survivors (Table 1). Aortic valve hemodynamics were 
comparable between non-survivors and survivors. However, non-survivors 
had a higher LV global afterload, more concentrically remodelled LV, lower 
flow and more impaired LV global longitudinal strain than survivors (Table 2). 
When dichotomizing the population based on low flow and normal flow, 
patients with low flow had higher mortality rates at 1, 2 and 3 years follow-up 
after AVR than patients with normal flow (16.7%, 25.0% and 33.3% vs. 2.3%, 
3.5% and 4.6%, respectively, log-rank p<0.001). This difference remained 
significant after adjusting for age, atrial fibrillation, chronic pulmonary 
obstructive disease, chronic kidney disease, NYHA functional class and LV 
global longitudinal strain; patients with normal flow had significantly better 
outcome than low flow patients (Figure 2). When dividing the population 
according to the pre-specified LV global longitudinal strain cut-off value, 
patients with more impaired global longitudinal strain (>-15%) had 
significantly increased mortality at 1, 2 and 3 years after AVR in comparison 
with patients with more preserved global longitudinal strain (≤-15%) 
(mortality rate 13.4%, 19.4% and 22.4% vs. 1.5%, 3.1% and 7.7%, respectively, 
log-rank p=0.01). Survival remained significantly higher in the cohort of 
patients with global longitudinal strain ≤-15% after adjusting for age, atrial 
fibrillation, chronic pulmonary obstructive disease, chronic kidney disease, 
NYHA functional class and SVi (Figure 3). Figure 4 shows the cumulative 
survival for patients grouped according to global longitudinal strain and 
flow. Patients with a global longitudinal strain >-15% and SVi≤35ml/m2 had 
the worse prognosis. There were 6 patients who died within 30 days post AVR 
(50% had TAVR). All of them (100%) had impaired global longitudinal strain 
(>-15%) and 5 (83%) had low-flow. Perioperative mortality was significantly 
higher in the group with more impaired global longitudinal strain (>-15%) 
compared with the group with ≤-15% (log rank p=0.015) and in the low-flow 
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compared to the normal-flow group (log rank p=0.014).
The univariate Cox-regression analysis demonstrated that the presence of 
atrial fibrillation, chronic pulmonary obstructive disease, chronic kidney 
disease, previous myocardial infarction and previous cardiac surgery were 
associated with increased all-cause mortality risk in this population (Table 
3). From the echocardiographic variables, lower valvulo-arterial impedance 
and LV mass/LV end-diastolic volume ratio were associated with improved 
survival after AVR. Atrial fibrillation and chronic kidney disease were 






Age (years) 76 ± 10 75 ± 11 76 ± 5 0.24
Male 67 (50%) 53 (49%) 14 (54%) 0.66
Body mass index (Kg/m2) 26 ± 4 26 ± 4 26 ± 4 0.92
Body surface area (m2) 1.9 ± 0.2 1.8 ± 0.2 1.9 ± 0.2 0.64
Atrial fibrillation 10 (8%) 5 (5%) 5 (21%) 0.008
Chronic kidney disease 28 (21%) 16 (15%) 12 (46%) 0.001
Hypertension 98 (74%) 76 (71%) 22 (85%) 0.16
Diabetes mellitus 34 (25%) 24 (22%) 10 (39%) 0.09
Hyperlipidemia 69 (52%) 59 (56%) 10 (39%) 0.12
Smoker 44 (34%) 35 (33%) 9 (36%) 0.77
Family history of CAD 34 (27%) 28 (27%) 6 (24%) 0.75
Coronary artery disease 83 (69%) 67 (69%) 16 (67%) 0.76
Previous cardiac surgery 33 (25%) 22 (20%) 11 (42%) 0.02
Myocardial infarction 19 (14%) 13 (12%) 6 (23%) 0.15
Stroke 16 (12%) 11 (10%) 5 (20%) 0.17
Chronic obstructive pulmonary disease 35 (26%) 24 (22%) 11 (42%) 0.04
Logistic EuroSCORE (%) 14 ± 12 13 ± 11 18 ± 13 0.08
ACEi / ARB 66 (50%) 49 (46%) 17 (65%) 0.07
Beta-blocker 77 (58%) 64 (60%) 13 (50%) 0.36
Calcium channel blocker 39 (30%) 28 (26%) 11 (42%) 0.12
Statin 79 (59%) 64 (60%) 15 (58%) 0.84
Diuretics 62 (47%) 47 (44%) 15 (58%) 0.21
NYHA class I 40 (30%) 36 (33%) 4 (15%)
0.04
                    II 46 (34%) 37 (34%) 9 (35%)
                    III 38 (28%) 30 (28%) 8 (31%)
                    IV 10 (8%) 5 (5%) 5 (19%)
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary 
artery disease; NYHA, New York Heart Association. 
Hyperlipidemia, defined as serum total cholesterol ≥230 mg/dl and/or serum triglycerides ≥200 
mg/dl and/or treatment with lipid lowering drugs. Family history of CAD, defined as first degree 
relatives of <55 years in men and <65 years in women who had a cardiac event. Coronary artery 
disease, defined as previous coronary artery bypass grafting or percutaneous coronary intervention 
or more than 50% stenosis at the coronary angiography.
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independently associated to mortality after AVR and were selected to build 
a baseline clinical model to test the independent association between flow 
and global longitudinal strain with survival (Table 3). Global longitudinal 
strain >-15% and each 1% impairment in global longitudinal strain were 
independently associated with all-cause mortality (Table 4). In addition, SVi 
≤35ml/m2 and each 5ml/m2 decrease in SVi were independently associated 
with all-cause mortality (Table 4). 







Aortic valve area (cm
2
) 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 0.13




) 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.12
Peak velocity (m/s) 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.4 0.74
Mean gradient (mmHg) 32 ± 6 32 ± 6 32 ± 7 0.93




) 0.5 ± 0.1 0.5 ± 0.1 0.4 ±  0.1 0.09
Valvulo-arterial impedance  (mmHg/ml/m
2
) 4.9 ± 1.5 4.7 ± 1.4 5.6 ± 1.5 0.004
Systemic vascular resistance (mmHg.min/l) 1741 ± 504 1695 ± 500 1932 ± 485 0.03
Systemic arterial compliance (ml/mmHg/m
2
) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.1 0.16
Septal wall thickness in diastole (cm) 1.3 ± 0.2 1.3 ± 0.2 1.4 ± 0.3 0.11
Posterior wall thickness in diastole (cm) 1.2 ± 0.2 1.2 ± 0.2 1.3 ± 0.2 0.08
LVEDDi (cm/m2) 2.5 ± 0.3 2.5 ± 0.3 2.5 ± 0.3 0.69
LVESDi (cm/m2) 1.5 ± 0.4 1.5 ± 0.3 1.5 ± 0.4 0.62
Left ventricular mass index (g/m2) 121 ± 32 118 ± 32 131 ± 31 0.06
Relative wall thickness (%) 56 ± 13 55 ± 13 58 ± 17 0.31
LVEDVi (ml/m2) 49 ± 17 49 ± 17 47 ± 19 0.49
LVESVi (ml/m2) 20 ± 8 20 ± 8 19 ± 8 0.85
Left ventricular mass / LVEDV ratio (g/ml) 2.7 ± 1.2 2.6 ± 1.1 3.2 ± 1.3 0.03
Ejection fraction (%) 61 ± 6 62 ± 6 59 ± 5 0.08
Stroke volume index (ml/m2) 38 ± 10 39 ± 9 33 ± 10 0.001
Cardiac Output (l/min) 4.8 ± 1.1 4.9 ± 1.1 4.4 ± 0.9 0.03
Cardiac Index (l/min/m2) 2.6 ± 0.6 2.6 ± 0.6 2.3 ± 0.5 0.02
Stroke Work (g.m) 124 ± 35 127 ± 34 110 ± 16 0.02
Stroke Work /100g (g.m) 60 ± 26 62 ± 25 48 ± 25 0.01
Global longitudinal strain (%) -15 ± 3 -15 ± 3 -13 ± 3 0.005
E wave velocity (cm/s) 77 ± 28 76 ± 29 81 ± 25 0.39
Deceleration time (msec) 257 ± 100 263 ± 98 232 ± 106 0.15
Left atrial volume index (ml/m2) 37 ± 15 37 ± 16 37 ± 15 0.95
Aortic regurgitation no/mild/moderate, n 56/66/12 42/54/12 14/12/0 0.13
Mitral regurgitation no/mild/moderate, n 67/53/14 55/41/12 12/12/2 0.71
LVEDDi, left ventricular end-diastolic diameter index;  
LVEDVi, left ventricular end-diastolic volume index;  
LVESDi, left ventricular end-systolic diameter index;  
LVESVi, left ventricular end-systolic volume index.
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Table 3 Univariate and multivariate Cox regression analysis to identify determinants of all-cause 
mortality in patients with low gradient, preserved ejection fraction severe aortic stenosis after 
aortic valve replacement
Univariate Analysis Multivariate Analysis
HR 95% CI p-value HR 95% CI p-value
Clinical Variables
Age (years) 1.04 0.99-1.09 0.08 1.01 0.93-1.09 0.78
Male gender 1.49 0.68-3.29 0.32
Body mass index (Kg/m2) 1.01 0.91-1.13 0.81
Transcatheter aortic valve replacement 1.69 0.74-3.89 0.21
Logistic EuroScore (%) 1.03 1.00-1.06 0.03 0.98 0.92-1.06 0.69
Coronary artery disease 0.96 0.40-2.27 0.92
Chronic kidney disease 2.60 1.18-5.74 0.02 3.20 1.10-9.31 0.03
Atrial fibrillation 3.45 1.26-9.40 0.02 4.63 1.22-17.62 0.02
Hypertension 2.28 0.78-6.69 0.13
Diabetes 1.64 0.72-3.71 0.24
Hyperlipidemia 0.63 0.28-1.43 0.23
Previous cardiac surgery 2.37 1.06-5.29 0.04 0.97 0.20-4.71 0.97
Myocardial infarction 2.96 1.16-7.55 0.02 2.57 0.55-12.04 0.23
Stroke 2.08 0.76-5.65 0.15
Chronic obstructive pulmonary disease 2.57 1.15-5.77 0.02 1.45 0.49-4.25 0.50
New York Heart Association class I Ref 0.08 0.62
class II 3.20 0.96-10.47 0.06 1.75 0.45-6.80 0.42
class III 2.72 0.77-9.27 0.10 2.07 0.51-8.33 0.31
class IV 5.63 1.49-21.15 0.01 2.82 0.55-14.26 0.21
Echocardiographic Variables
Aortic valve area index (cm2/m2) 0.06 0.001-5.18 0.21
Mean pressure gradient (mmHg) 0.98 0.93-1.05 0.61
Valvulo-arterial impedance (mmHg/ml/m2) 1.26 1.02-1.57 0.03 1.08 0.80-1.49 0.66
Left ventricular mass index (g/m2) 1.01 0.99-1.02 0.23
Relative wall thickness (%) 1.02 0.99-1.05 0.12
Left ventricular mass / LVEDV ratio (g/ml) 1.63 1.27-2.10 0.001 1.44 0.95-2.17 0.08
Left ventricular ejection fraction (%) 0.94 0.87-1.00 0.07 0.97 0.89-1.06 0.56
Left atrium volume index (ml/m
2
) 0.99 0.97-1.02 0.71
CI, confidence interval; HR, hazard ratio; LVEDV, left ventricular end-diastolic volume.
161VASILEIOS KAMPERIDIS
Table 4. Multivariate Cox regression analysis and c-statistics to test the value of flow (stroke volume 
index category > and ≤35ml/m2 or increase per 5ml/m2) and left ventricular systolic function (global 
longitudinal strain category > and ≤-15% or increase per +1%) on baseline model (please look at 
table 3) predicting mortality in low gradient, preserved ejection fraction severe aortic stenosis after 
aortic valve replacement
Multivariate Analysis Model Comparison






Baseline model 173.34 14.52 - 0.68
Atrial fibrillation 5.40 1.81-16.07 0.002
Chronic kidney disease 3.67 1.49-9.06 0.005
Baseline model + GLS category 166.80 19.87 0.029 0.74
Atrial fibrillation 4.03 1.33-12.18 0.014
Chronic kidney disease 3.95 1.61-9.69 0.003
Global longitudinal strain 
≤-15%
0.37 0.14-0.94 0.036
Baseline model + SVi category 158.06 29.62 <0.001 0.80
Atrial fibrillation 3.18 1.00-10.07 0.050
Chronic kidney disease 3.59 1.41-9.11 0.007
Stroke volume index 
>35ml/m2
0.16 0.06-0.44 <0.001
Baseline model + GLS 1% increase 164.09 22.29 0.006 0.78
Atrial fibrillation 3.49 1.11-10.92 0.03
Chronic kidney disease 3.74 1.50-9.31 0.005
Global longitudinal strain 1.21 1.05-1.39 0.007
Baseline model + SVi 5ml/m2 increase 167.86 19.77 0.019 0.77
Atrial fibrillation 3.16 0.93-10.45 0.07
Chronic kidney disease 3.57 1.44-8.99 0.006
Stroke volume index 0.77 0.61-0.97 0.03
*p-value by multivariate Cox regression analysis
†p-value by likelihood ratio test vs. baseline model
CI, confidence interval; GLS, Global longitudinal strain; HR, hazard ratio; SVi, Stroke volume index.  
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DISCUSSION
The present evaluation showed that patients with preserved LVEF, low 
gradient severe AS and normal flow or LV global longitudinal strain ≤-15% 
have better survival after AVR compared to their counterparts with low 
flow or global longitudinal strain >-15%. The addition of flow and LV global 
longitudinal strain to a clinical model improved the risk stratification of 
patients with preserved LVEF, low gradient severe AS treated with AVR.   
Severe aortic stenosis based on AVAi calculation but with low gradient is 
observed in almost 35% of patients with preserved LVEF.4-6, 10, 18, 19 Decision 
making in this subgroup of patients remains controversial. While several 
series have shown that surgical AVR in patients with severe AS with low 
gradient and preserved LVEF portends better prognosis compared with 
medical treatment,11, 14, 20-22 other studies have shown that the prognosis of 
these patients medically treated is similar to that of patients with moderate 
aortic stenosis.5, 10 The study by Hachicha et al. including 512 patients with 
severe AS and preserved LVEF, 62% of them with low gradient, showed that 
patients undergoing surgical AVR had better survival than patients treated 
medically.3 Similarly, Ozkan et al. confirmed that patients with symptomatic 
severe AS, low gradient and preserved LVEF had better prognosis compared 
to medically treated patients (26% versus 40% mortality after 28 months of 
mean follow-up).11 In contrast, Jander et al. demonstrated that patients with 
asymptomatic severe AS, low gradient and preserved LVEF had comparable 
outcome to patients with moderate aortic stenosis (major cardiovascular 
events 14.8±1.0% versus 14.1±1.5%, respectively; p=0.59).5 Accordingly, the 
authors considered that patients with low gradient, preserved LVEF severe 
AS do not represent a true severe AS group and the progression of the 
disease is similar to moderate aortic stenosis.5, 10
These apparently conflicting results may be explained by differences within 
the group of patients with low gradient, preserved LVEF severe AS. Based on 
LV stroke volume, patients with preserved LVEF, low gradient severe AS can 
be further divided into low flow (≤35 ml/m2) or normal flow (>35ml/m2) and 
these two subgroups of patients have distinct clinical and echocardiographic 
characteristics: the former are more frequently female and older, have 
higher systemic vascular resistance, lower systemic compliance and higher 
LV global afterload than the normal flow patients.4, 6, 21 In addition, low flow 
patients show smaller LV outflow tract and LV cavity dimensions, increased 
concentric remodelling and lower LVEF (although within the normal range) 
than normal flow patients.4, 10 The increased concentric LV remodelling may 
have a significant impact on the LV mechanics that cannot be unmasked by 
LVEF alone. Two-dimensional speckle tracking longitudinal strain analysis 
can discriminate between these two groups of patients. Lancellotti et al 
showed that patients with preserved LVEF, low flow-low gradient severe AS 
had more impaired global longitudinal strain as compared with patients with 
normal flow-low gradient severe AS (-13.6±4.3% vs. -16.7±2.6%, p<0.001).23 
Therefore, low flow-low gradient severe AS may represent a more progressed 
disease status and the assessment of LV remodelling and global longitudinal 
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strain may help distinguishing these two subgroups. 
While the prognostic implications of flow (SVi) in patients with low gradient 
severe AS and preserved LVEF remains debated, the impact of LV global 
longitudinal strain on the outcome of these patients has not been evaluated. 
In the sub-study of the Simvastatin and Ezetimibe in Aortic Stenosis trial 
(including 435 patients with asymptomatic low gradient severe AS) Jander et 
al.5 proposed that patients with low flow and patients with normal flow had 
comparable outcomes in terms of aortic valve and cardiovascular events and 
cardiovascular death. However, the outcome after AVR was not evaluated. 
In contrast, the studies by Hachicha et al.4 and Ozkan et al.11 suggested that 
survival after AVR is comparable between low flow and normal flow severe 
AS patients. Mehrotra et al.10 provided further evidence to the association 
between flow and survival in patients with low gradient severe AS and 
suggested that patients with low flow severe AS had worse survival than 
normal flow severe AS and patients with moderate aortic stenosis. However, 
flow was not independently associated with survival of patients with 
low gradient severe AS. Similarly, Mohty et al.21 reported an independent 
association between flow and survival in patients with severe AS and after 
correcting for AVR (as time-dependent covariate), low flow-low gradient 
severe AS was associated with increased all-cause mortality risk (hazard 
ratio 1.84, p=0.014). The present study is in line with the results by Mohty et 
al.21 demonstrating that flow status is independently associated with long-
term outcome of patients with low gradient severe AS and preserved LVEF 
treated with AVR. However, the present study provides also incremental 
value by demonstrating the independent association between LV global 
longitudinal strain and outcome in this group of patients. After correcting 
for SVi, LV global longitudinal strain was associated with all-cause mortality. 
LV global longitudinal strain may be impaired in patients with low gradient 
severe AS and preserved LVEF possibly due to subendocardial ischemia, 
myocardial fibrosis, concentric remodelling or increased afterload.6, 16, 24 LV 
global longitudinal strain can detect the subtle intrinsic myocardial systolic 
dysfunction and its impairment precedes LVEF reduction.16, 25 However, 
randomized studies would be preferable to confirm the benefits of AVR in 
this subgroup of patients and impact on current practice guidelines.1
Several limitations should be acknowledged. Outcome and echocardiographic 
data were retrospectively analysed. In addition, patients underwent surgical 
or transcatheter AVR, introducing a important prognostic bias. We did not 
use a propensity score to account for this difference. Finally, we did not 
include a comparator group who were medically treated. However, the 
comparison of prognostic implications of medical treatment vs. AVR in this 
group of patients was beyond the scope of the present evaluation.  
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 Background   Surgical mitral valve repair for severe secondary mitral regurgitation (MR) 
remains controversial. The association of MR reduction and changes in 
left ventricular (LV) hemodynamics with postoperative survival has not 
been investigated. The aim of the present study was to investigate the 
independent associates of all-cause mortality in heart failure patients with 
severe secondary MR who underwent surgical mitral valve repair.
 Methods   In total, 130 patients (62±12 years old, 55% male) with chronic severe 
secondary MR and impaired LV ejection fraction (<50%, mean 31±10%) who 
underwent surgical mitral valve repair were included. Echocardiography was 
performed at baseline and post-repair at discharge. LV forward flow was 
assessed by LV forward stroke volume and LV forward ejection fraction. All-
cause mortality was the primary endpoint and the secondary endpoint was 
the combination of major adverse cardiac events and all-cause mortality. 
 Results   At hospital discharge, 77% of patients showed no residual MR and 23% mild 
MR. LV end-diastolic and end-systolic volumes reduced significantly while LV 
ejection fraction remained unchanged. In contrast, LV forward stoke volume 
(53±24 vs. 64±22ml, p<0.001) and LV forward ejection fraction (0.32±0.16 
vs. 0.48±0.24, p<0.001) significantly increased at discharge. During a median 
follow-up of 3.44 years, 33 (29%) patients died and 40 had major adverse 
cardiac events. On multivariable analysis, LV forward stroke volume post-
repair was independently associated with all-cause mortality (hazard ratio 
0.98, 95% confidence interval 0.95-1.00; p=0.047) and with the combined 
endpoint (hazard ratio 0.98, 95% confidence interval 0.96-1.00; p=0.045) 
after correcting for other baseline, procedural and post-repair characteristics. 
 Conclusions   In patients with severe secondary MR treated with surgical repair, LV forward 
flow was independently associated with better survival and lower risk of the 
combined endpoint. 
Keywords   Secondary mitral regurgitation,  
surgical mitral valve repair,  




It has been demonstrated that severe secondary mitral regurgitation (MR) has 
deleterious influence on survival of patients with ischemic and non-ischemic 
left ventricular (LV) systolic dysfunction.1-3 Surgical correction of MR has been 
associated with reduction in LV volumes and improvement in LV systolic 
function.4 However, it has not been demonstrated that surgical mitral valve 
repair for secondary MR is associated with better prognosis compared with 
optimal medical treatment (including cardiac resynchronization therapy).4-6 
Current guidelines on management of valvular heart disease consider 
surgical mitral valve repair in ischemic and non-ischemic secondary MR with 
a recommendation level IIa and IIb, respectively, due to the lack of robust 
data on survival benefit.7, 8
Surgical mitral valve repair for secondary MR uses frequently undersized 
annuloplasty rings to improve the coaptation of the mitral leaflets, resulting 
in reduction of the volume overload. Reduction in LV preload may lead to 
falsely reduced LV systolic function, based on LV ejection fraction, which 
merely represents a change in total LV volumes, without taking into account 
if the direction of the blood flow is regurgitant or forward. After mitral valve 
repair, the LV volume pumped into the low-pressure left atrium is significantly 
reduced and as a result the LV ejection fraction may be reduced (less total 
volume shifted). However, other parameters that more precisely reflect LV 
forward flow such as LV forward stroke volume, evaluating the blood volume 
pumped only into the aorta, and LV forward ejection fraction, evaluating the 
percentage of LV end-diastolic volume pumped into the aorta, may better 
reflect the remaining LV systolic function after surgical mitral valve repair. The 
prognostic value of LV forward flow, assessed by LV forward stroke volume 
and LV forward ejection fraction in patients with secondary MR treated 
with surgical restrictive mitral annuloplasty has not been evaluated so far. 
Accordingly, the current analysis evaluated the prognostic implications of 




Patients with severe secondary MR, and LV ejection fraction <50%, treated 
successfully with surgical repair were included in the current analysis. 
Successful mitral valve repair was defined as the presence of residual MR less 
than moderate at discharge. The demographic and clinical characteristics 
of the population were prospectively collected in the departmental clinical 
database (EPD-vision 8.3.3.6; Leiden University Medical Center, Leiden, The 
Netherlands). The institutional ethical committee approved this retrospective 
analysis of prospectively collected clinical data and waived the need for 
patient written informed consent.
All patients included in the current analysis were treated with surgical mitral 
valve repair, consisting of restrictive mitral ring annuloplasty. The mitral ring 
(Carpentier Edwards Physioring, Edwards Lifesciences, Irvine, CA) implanted 
was selected downsizing the native annulus by 2 sizes, i.e. if the native ring was 
estimated 30 the implanted one was 26, as previously described.9 Whenever 
necessary, coronary artery bypass grafting, tricuspid valve annuloplasty, 
cardiac support device implantation (CorCap, Acorn Cardiovascular, St. 
Paul, Minnesota), LV reconstruction, atrial fibrillation ablation and LV lead 
implantation for cardiac resynchronization therapy were performed.  
Comprehensive transthoracic echocardiography was performed in allpatients 
at baseline and after surgical mitral valve repair before hospital discharge. 
Patients were hemodynamically stable during echocardiography which was 
performed with a commercially available ultrasound system (Vivid 7 and Vivid 
E9; GE Vingmed Ultrasound AS, Horten, Norway) equipped with 3.5-MHz or 
M5S transducers. Grey scale images and Doppler data (colour, continuous 
and pulsed wave) were digitally stored for off-line analysis (EchoPAC version 
112.0.1; GE Vingmed Ultrasound, Norway).
Secondary MR severity was assessed with a multiparametric integrated 
approach.10 Vena contracta width was measured on a zoomed parasternal 
long-axis view. Effective regurgitant orifice area and regurgitant volume were 
evaluated with the proximal isovelocity surface area method. Vena contracta 
width >4mm, effective regurgitant orifice area ≥0.2cm2 or regurgitant volume 
≥30ml defined severe secondary MR.10 Residual MR severity at discharge was 
assessed by colour Doppler as previously described.11, 12
LV hemodynamics at baseline and after surgical mitral valve repair were 
assessed with echocardiography according to current recommendations.13 
Simpson’s biplane method was used to measure LV end-diastolic and end-
systolic volumes, from which LV ejection fraction was calculated. LV forward 
stroke volume was estimated on pulsed-wave Doppler spectral recordings 
obtained at the LV outflow tract, multiplying the velocity time integral of 
the LV outflow tract by the cross-sectional area of the LV outflow tract. The 
cardiac output was derived from the product of stroke volume and the heart 
rate. LV forward ejection fraction was estimated as the ratio of forward stroke 
volume by the LV end-diastolic volume.14 
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Left atrial volume was assessed by tracing the endocardial borders at end-
systole in both four- and two-chamber apical views using the disk summation 
algorithm.13 Moreover, right ventricular systolic pressure was evaluated from 
the summation of the right atrial pressure to the peak pressure gradient 
between the ventricle and the atrium.15 Additionally, LV mass and relative 
wall thickness were estimated according to current recommendations on LV 
chamber quantification and the ratio of LV mass to LV end-diastolic volume 
was calculated.13 
The patients were followed-up after surgical mitral valve repair for the 
occurrence of major adverse cardiac events (heart failure hospitalization, 
redo surgery due to repair failure, endocarditis, left ventricular assist device 
implantation or heart transplant) and all-cause mortality. The primary 
endpoint of the study was all-cause mortality and the secondary endpoint 
was the combination of major adverse cardiac events and all-cause mortality. 
The data were collected from the departmental clinical database (EPD-vision 
8.3.3.6; Leiden University Medical Center, Leiden, The Netherlands) or from 
the Social Security Death Index.
Continuous variables are presented as mean±standard deviation and 
categorical variables as frequencies and percentages. Continuous variables 
were compared with paired sample Students t-test or Mann-Whitney U-test 
as appropriate.
The cumulative survival rates at 1, 2, and 3 years follow-up were estimated 
according to the Kaplan-Meier method. Comparison of all-cause mortality and 
the combined endpoint between two groups of patients divided according 
to the median value of LV forward stroke volume at discharge was performed 
by the log-rank test. Univariable Cox proportional-hazards ratio regression 
analysis was performed to investigate baseline, procedural and post-surgical 
mitral valve repair parameters associated with all-cause mortality and the 
combined endpoint. A stepwise multivariable approach was followed to 
avoid model overfit, by including 4 variables in each multivariable model. 
Those variables were the most clinically relevant and most significant within 
the subgroup. In the first model only baseline parameters were introduced. 
The variables independently associated to the outcome were introduced 
in the second model which included the procedural parameters. The third 
model included the variables independently associated with the endpoint 
and the post-surgical repair parameters. Hazard ratios and 95% confidence 
intervals were reported. P-values <0.05 were considered statistically 
significant. All statistical analyses were performed with the SPSS version 20 
(SPSS, Inc, Chicago, IL).
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RESULTS
The characteristics of the overall population (62±12 years old, 55% male) with 
chronic secondary MR are summarized in Table 1. Baseline mitral regurgitant 
jet vena contracta was 6.36±1.73 mm, effective orifice area 0.26±0.13 cm2 and 
regurgitant volume 38.10±17.40 ml/beat. All patients underwent surgical 
mitral valve repair and 23 (18%) had concomitant coronary artery bypasss 
grafting, 91 (70%) tricuspid valve repair, 5 (4%) LV reconstruction, 55 (42%) 
CorCap cardiac support device implantation, 48 (37%) LV lead implantation 
for cardiac resynchronization therapy and 20 (15%) atrial fibrillation ablation. 
The hemodynamic changes after surgical mitral valve repair are shown in 
Table 2. At discharge, 30 (23%) patients had mild MR while the remaining 
100 (77%) had no MR. LV end-diastolic and end-systolic volumes were 
significantly reduced and LV mass was unchanged. Although LV ejection 
fraction remained stable (31±10 vs. 30±12%, p=0.18), LV forward stoke 
volume (53±24 vs. 64±22 ml, p<0.001) and LV forward ejection fraction 
(0.32±0.16 vs. 0.48±0.24, p<0.001) were significantly improved at discharge. 
Moreover, left atrial volume and right ventricular systolic pressure were 
significantly reduced at discharge (Table 2).
The study cohort was followed-up for a median period of 3.44 years 
(interquartile range 1.34 – 8.64 years) after the surgical procedure. The total 
follow-up time for the entire study population was 662.62 patient-years. 
The post-surgery survival rates at 1, 2 and 3 years of follow-up were 86%, 
79% and 71%, respectively (Figure 1A). The combined endpoint free-survival 
rates for the combined endpoint were 81%, 72% and 60% at 1, 2 and 3 years, 
respectively (Figure 1B).  
The median value of LV forward stroke volume at discharge was 58.6 ml. 
Patients with forward stroke volume ≥58.6 ml had better survival and 
Figure 1. Kaplan-Meier analysis of (A) 3-year survival and (B) combined endpoint free-survival 
after successful surgical mitral valve repair of patients with chronic severe secondary mitral 
regurgitation. (A) The survival rate at 1-year was 86% (18 events), at 2-years 79% (26 events) and at 
3-years 71% (33 events). (B) The combined endpoint free-survival rate at 1-year was 81% (21 events), 
at 2-years 72% (31 events) and at 3-years 60% (40 events).  
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Male, n (%) 72 (55)
Log EuroScore I, % 12±11
Non-ischemic cardiomyopathy, n (%) 102 (78)
Hypertension, n (%) 63 (48)
Diabetes mellitus, n (%) 26 (20)
Chronic kidney disease, n (%) 46 (36)
Atrial fibrillation, n (%) 54 (42)
B-blocker use, n (%) 76 (59)
ACEi/ARB use, n (%) 98 (75)
Previous CRT/D, n (%) 13 (10)
NYHA functional class III-IV, n (%) 78 (61)
ACEi, angiotensin converting enzyme inhibitor; 
ARBs, angiotensin receptor blockers; 
CRT/D, cardiac resynchronization therapy/defibrillator; 
NYHA, New-York heart association
Table 2. Hemodynamic changes post successful surgical mitral valve repair in patients with 
secondary mitral regurgitation. 
Pre-repair Post-repair p-value
LV end-diastolic volume, ml 188±74 155±65 <0.001
LV end-systolic volume, ml 134±65 114±60 <0.001
LV ejection fraction, % 31±10 30±12 0.18
LV forward stroke volume, ml 53±24 64±22 <0.001
Cardiac output, ml/min 3.85±1.60 5.43±1.93 <0.001
LV forward ejection fraction 0.32±0.16 0.48±0.24 <0.001
LV mass, gr 261±83 257±92 0.57
LV mass/LV volume 1.51±0.50 1.82±0.76 <0.001
Relative wall thickness, % 28±9 34±9 <0.001
Left atrial volume, ml 108±55 89±38 <0.001
RV systolic pressure, mmHg 37±12 29±11 <0.001
LV, left ventricular;  
RV, right ventricular
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Table 3. Univariable Cox-regression analysis to identify baseline, procedural and post-repair 
determinants of all-cause mortality and the combined endpoint after successful surgical mitral 
valve repair in patients with secondary mitral regurgitation.
All-cause mortality Combined endpoint
HR 95% CI p-value HR 95% CI p-value
Baseline Clinical Characteristics
Age, years 1.04 1.00-1.08 0.03 1.03 1.00-1.07 0.04
Male gender 1.26 0.63-2.52 0.51 1.17 0.63-2.17 0.63
Log EuroScore I, % 1.04 1.02-1.07 <0.001 1.04 1.02-1.06 <0.001
Non-ischemic cardiomyopathy 0.68 0.29-1.59 0.37 0.61 0.28-1.35 0.22
Hypertension 1.09 0.55-2.16 0.80 0.97 0.52-1.82 0.93
Diabetes mellitus 1.50 0.68-3.34 0.32 2.12 1.05-4.25 0.04
Chronic kidney disease 2.93 1.46-5.84 0.002 2.54 1.35-4.79 0.004
Atrial fibrillation 1.71 0.82-3.60 0.16 1.17 0.62-2.22 0.63
B-blocker use 0.82 0.42-1.61 0.56 0.86 0.46-1.60 0.63
ACEi/ARB use 1.06 0.48-2.35 0.89 0.95 0.47-1.89 0.88
Previous CRT/D 1.13 0.39-3.21 0.82 0.83 0.29-2.33 0.72
NYHA functional class III-IV 1.42 0.68-2.99 0.35 1.32 0.37-4.68 0.67
Baseline Hemodynamics
LV end-diastolic volume, ml 1.00 0.99-1.00 0.22 1.00 0.99-1.01 0.27
LV end-systolic volume, ml 1.00 0.99-1.01 0.24 1.00 0.99-1.01 0.29
LV ejection fraction, % 0.98 0.95-1.02 0.30 0.99 0.96-1.02 0.61
LV forward stroke volume, ml 1.00 0.99-1.02 0.66 0.99 0.98-1.01 0.83
Cardiac output, ml/min 1.07 0.98-1.31 0.53 0.98 0.81-1.19 0.87
LV forward ejection fraction 0.52 0.04-7.34 0.63 0.38 0.04-4.10 0.43
LV mass, gr 1.00 0.99-1.00 0.23 1.00 0.99-1.01 0.13
LV mass/LV volume 1.14 0.57-2.27 0.72 1.23 0.66-2.29 0.50
Relative wall thickness, % 0.99 0.96-1.04 0.83 1.01 0.97-1.04 0.75
Left atrial volume, ml 1.00 0.99-1.01 0.34 1.00 0.99-1.01 0.43
RV systolic pressure, mmHg 1.00 0.97-1.03 0.94 1.01 0.98-1.04 0.64
Procedural Characteristics
CABG 1.75 0.75-4.06 0.19 2.05 0.94-4.49 0.07
Maze procedure 0.48 0.15-1.56 0.22 0.54 0.19-1.53 0.25
CorCap device 1.65 0.83-3.31 0.16 1.27 0.68-2.37 0.46
CRT/D 1.47 0.74-2.94 0.28 1.71 0.91-3.19 0.09
Post-repair hemodynamics
LV end-diastolic volume, ml 1.00 0.99-1.01 0.21 1.00 0.99-1.01 0.26
LV end-systolic volume, ml 1.00 0.99-1.01 0.13 1.00 0.99-1.01 0.19
LV ejection fraction, % 0.97 0.94-1.01 0.13 0.99 0.96-1.02 0.40
LV forward stroke volume, ml 0.98 0.96-0.99 0.03 0.98 0.96-0.99 0.04
Cardiac output, ml/min 0.83 0.65-1.07 0.15 0.88 0.70-1.09 0.25
LV forward ejection fraction 0.13 0.02-1.04 0.05 0.15 0.02-1.15 0.07
LV mass, gr 1.00 0.99-1.00 0.64 1.00 0.99-1.00 0.48
LV mass/LV volume 0.69 0.38-1.27 0.24 0.86 0.53-1.42 0.56
Relative wall thickness, % 0.97 0.93-1.01 0.16 0.98 0.95-1.02 0.28
Left atrial volume, ml 0.10 0.98-1.01 0.70 0.99 0.99-1.01 0.45
RV systolic pressure, mmHg 1.00 0.96-1.04 0.96 1.00 0.97-1.04 0.75











HR, hazard ratio; 
LV, left ventricular;
MPG, mean pressure 
gradient; MR, mitral 
regurgitation; 
NYHA, New-York Heart 
Association; 
RV, right ventricular.  
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Table 4. Multivariate Cox-regression models to identify baseline, procedural and post-repair 
determinants of all-cause mortality and combined endpoint after successful surgical mitral valve 
repair in patients with secondary mitral regurgitation in a stepwise approach.
All-cause mortality Combined endpoint
HR 95% CI p-value HR 95% CI p-value
Baseline Model
   Age, years 1.04 1.00-1.09 0.04 1.02 0.98-1.05 0.34
   Log EuroScore I, % 1.03 0.99-1.05 0.07 1.03 1.00-1.05 0.03
   Chronic kidney disease 2.90 1.42-5.91 0.003 2.21 1.16-4.22 0.02
   Atrial fibrillation 2.15 0.99-4.67 0.054 - - -
   Diabetes mellitus - - - 1.65 0.78-3.51 0.19
Baseline + Procedural Model
   Age, years 1.05 1.00-1.09 0.03 - - -
   Log EuroScore I, % - - - 1.03 1.00-1.06 0.006
   Chronic kidney disease 2.95 1.46-5.98 0.003 2.18 1.15-4.15 0.02
   CorCap device 1.50 0.74-3.02 0.26 - - -
   CABG 1.34 0.57-3.18 0.50 1.75 0.79-3.87 0.17
   CRT/D - - - 1.24 0.64-2.41 0.52
Baseline + Post-repair Model
   Age, years 1.03 0.99-1.07 0.17 - - -
   Chronic kidney disease 2.33 1.04-5.24 0.041 1.96 0.95-4.02 0.07
   Log EuroScore I, % - - - 1.03 1.00-1.05 0.053
   LV forward stroke volume, ml 0.98 0.95-1.00 0.047 0.98 0.96-1.00 0.045
   Mitral valve MPG, mmHg 0.86 0.66-1.11 0.24 - - -
CABG, coronary artery bypass grafting;  
CI, confidence interval;  
CRT/D, cardiac resynchronization therapy/defibrillation;  
HR, hazard ratio; LV, left ventricular;  
MPG, mean pressure gradient.  
Figure 2. Kaplan-Meier analysis of (A) survival and (B) combined endpoint free-survival according 
to left ventricular (LV) forward stroke volume at discharge after successful surgical mitral valve 
repair. Patients with LV forward stroke volume ≥58.6ml (median value) have significantly better 
3-year survival (A) and combined endpoint free-survival (B) compared to those with LV forward 
stroke volume <58.6ml at discharge.  
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combined endpoint free-survival compared to those with <58.6 ml (log-
rank p= 0.018 and 0.045, respectively) (Figure 2). Table 3 summarizes the 
univariable determinants of mid-term all-cause mortality and the combined 
endpoint in patients with secondary MR treated successfully with surgical 
mitral valve repair. In the univariable analysis, age, logistic EuroSCORE I 
and chronic kidney disease at baseline were associated with worse survival 
and combined endpoint free-survival along with lower LV forward stroke 
volume post-repair. In contrast, none of the procedural characteristics 
were significantly associated with the primary and secondary endpoints. 
On multivariable analysis, lower LV forward stroke volume post-repair was 
independently associated with all-cause mortality (hazard ratio 0.98, 95% 
confidence interval 0.95-1.00, p=0.047) and the combined endpoint (hazard 
ratio 0.98, 95% confidence interval 0.96-1.00, p=0.045) (Table 4). Each 10 ml 
increase in LV forward stroke volume was independently associated with 21% 
decrease in all-cause mortality and 21% decrease in the combined endpoint.
COMMENT
Successful surgical mitral valve repair for secondary MR improves the LV 
hemodynamics with increased LV forward flow and reduced pulmonary 
arterial systolic pressure at discharge. LV forward flow, evaluated by LV 
forward stroke volume, at discharge was the only hemodynamic parameter 
that was independently associated with overall survival and combined 
endpoint free-survival. 
Successful mitral valve repair eliminates the LV volume overload caused 
by significant MR and results in acute reductions in LV end-diastolic and 
end-systolic volumes. Similarly to previous studies in similar groups of 
patients,16,17  the present study also showed significant reductions in LV 
volumes. In contrast, LV ejection fraction remained unchanged. This has been 
also reported by Acker and coworkers in a study including 155 patients with 
ischemic and non-ischemic secondary MR treated with surgical mitral valve 
repair.11 These findings suggest no significant benefit from surgical mitral 
valve repair in terms of LV systolic function. However, it may well be that LV 
ejection fraction does not reflect appropriately the residual LV contractile 
function. The LV forward flow is a hemodynamic parameter that reflects 
both the MR reduction post-surgical repair and the LV systolic function. The 
forward flow improvement after restrictive mitral annuloplasty has been 
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demonstrated previously using cardiac magnetic resonance in 22 patients 
with dilated cardiomyopathy and secondary MR treated successfully with 
mitral valve repair.18 The current study confirmed the increase in forward 
flow after successful mitral valve repair in patients with severe secondary 
MR as an indicator of LV functional recovery although LV ejection fraction 
remained unchanged.
LV ejection fraction at baseline is a hemodynamic parameter that has not been 
consistently associated with survival after surgical mitral valve repair. Magne 
et al. studied 370 patients with ischemic MR treated with surgical mitral valve 
repair or replacement and reported that baseline LV ejection fraction was 
independently associated with survival.19 Moreover, in a study including 54 
patients with non-ischemic MR treated with surgical mitral valve repair, LV 
ejection fraction was independently associated with survival.4 In contrast, 
these results were not corroborated in 76 patients with secondary MR of 
ischemic (34%) and non-ischemic (65%) etiology treated successfully with 
surgical repair; 93.4% of them had MR grade <2 at discharge and baseline 
LV ejection fraction was not a predictor of 30-day survival.20 Similarly, the 
current study demonstrated that baseline LV ejection fraction was not 
associated with survival after successful mitral valve repair.
It has been demonstrated that LV ejection fraction does not completely 
reflect the contractile properties of the left ventricle in patients with 
secondary MR.14 By unloading the LV after successful mitral valve repair, 
the LV volumes reduce acutely and the LV ejection fraction may remain 
unchanged or even decrease. However, LV forward flow increases resulting 
in a hemodynamic improvement that may have consequences on the clinical 
outcome. The present study showed that the improvement in LV forward 
flow was independently associated with better clinical outcome. Each 10 
ml increase in LV forward stroke volume was independently associated with 
21% decrease in all-cause mortality and 21% decrease in combined endpoint 
of major adverse cardiac events and mortality. 
The present study has several limitations. The study design is retrospective 
and may lead to patient selection bias. The study population is relatively 
small. There was not a comparable group treated medically, to investigate 
whether surgical mitral valve repair in this group of patients portends better 
prognosis. 
In conclusion, in chronic severe secondary MR, surgical repair is associated 
with LV hemodynamic improvement at discharge. LV forward flow is 
independently associated with survival and combined endpoint free-
survival whereas conventional parameters of LV systolic function such as LV 
ejection fraction were not.  
 Disclosures   The Department of Cardiology received grants from Biotronik, Medtronic, 
Boston Scientific Corporation. Victoria Delgado received speaker fees from 
Abbott Vascular. The remaining authors have nothing to disclose.
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Chapter 1 of this thesis is the introduction that describes the prevalence of aortic stenosis (AS) and 
mitral regurgitation (MR) which are the most common valvular heart disease. The types of these 
diseases are described; AS types are based on flow, gradient and left ventricular ejection fraction 
(LVEF) categories, making the exact diagnosis of severe AS challenging. MR types are primary, sec-
ondary and mixed based on whether they stem from structural valvular disease, left ventricular/
atrial disease or a combination of both, respectively. Since several types of the disease exist several 
types of surgical and transcatheter treatments have been developed. Subsequently, the role of mul-
timodality imaging based on advanced echocardiography and multidetector row computed to-
mography is discussed for the accurate evaluation of the grade and pathophysiology of the valvular 
disease, either AS or MR. However, the assessment of the valvular component only is not enough, 
considering that the left ventricle is one of the main structures affected by the pressure and volume 
overload, and may impact on the diagnostic accuracy and the prognosis of the disease, especially 
in low-flow low-gradient AS and in functional MR. Thus, the clinical value of left ventricular global 
longitudinal strain (GLS) and forward stroke volume are reviewed in the introduction. 





  Part I of the thesis includes original research on calcified AS which is the most 
frequent degenerative valvular heart disease in Western countries and its 
prevalence increases in parallel to the ageing process of the population. The 
four chapters (Chapters 2 to 5) included in Part I discuss the most appropri-
ate imaging modalities to establish the diagnosis and the proper manage-
ment of this degenerative disease.  
Chapter 2 refers on the accurate AS diagnosis in discordant patients with 
low-gradient severe AS with aortic valve area index <0.6cm2/m2 and LVEF 
≥50% who are also called paradoxical low-gradient severe AS. So far, there 
were no standards to distinguish between true moderate or true severe ste-
nosis in this group of patients. This chapter suggests the use of cardiac mul-
tidetector row computed tomography-derived planimetered left ventricular 
outflow tract area in the continuity equation alongside with the Doppler 
hemodynamics in order to evaluate the fusion aortic valve area. In patients 
with low gradient severe AS with echocardiographic aortic valve area index 
<0.6cm2/m2 and preserved LVEF, fusion aortic valve area index evaluation 
permits reclassification to true moderate AS in 52% of the normal flow and 
12% of the low flow patients.
Chapter 3 reviews the diagnosis and treatment of patients with the other 
type of discordant AS met in heart failure patients, called classical low-flow, 
low-gradient AS. Heart failure may be present in up to a quarter of patients 
with severe AS posing significant diagnostic and management challenges. 
These patients have low-gradient with aortic valve area index <0.6cm2/m2 
and low LVEF <50% that differentiates them from the paradoxical low-gradi-
ent AS discussed in the previous chapter. This chapter reviews the prevalence 
of HF in severe AS patients, discusses the diagnostic challenges, proposes 
a diagnostic algorithm for the accurate assessment of the disease severity, 
describes the advances in multimodality imaging to identify the patients 
that may benefit from surgical or transcatheter aortic valve replacement and 
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summarizes the current evidence on management for this group of patients.
Since the accurate diagnosis of severe AS in patients with discordant low-gra-
dient and preserved or reduced LVEF has been studied in chapters 2 and 
3, Chapter 4 focuses on the treatment of these patients. The low-gradient 
severe AS patients are usually of high surgical risk and frequently referred 
to transcatheter aortic valve replacement (TAVR). In chapter 4, patients with 
low-flow low-gradient severe AS treated with TAVR have been proved to 
have left ventricular functional recovery and reverse remodelling post-TAVR, 
regardless of baseline LVEF category. This improvement occurred during the 
first 6 months post – TAVR, remained stable for the subsequent 6 months and 
was detected by left ventricular (LV) GLS but not by LVEF change, especially 
in the preserved LVEF group. Changes in LV global longitudinal strain were 
independent of LVEF at baseline, LV mass index and procedural approach 
(transfemoral or transapical), among other relevant clinical variables. In ad-
dition, absolute and relative wall thickness decreased in both groups of pa-
tients, but only those with low LVEF had a reduction in LV chamber volumes. 
Overall, TAVR had a positive impact on the low-flow low-gradient severe AS 
patients, providing LV functional recovery and reverse remodeling.
Apart from TAVR that has been evolved as a treatment of high surgical risk 
patients with severe AS, new minimal invasive surgical replacement options 
have emerged, such as the surgical sutureless prosthesis. Chapter 5 studied 
these two different options of treating severe AS in propensity-score matched 
high-risk patients and compared their haemodynamic performance and the 
clinical outcomes. In high operative risk patients with severe AS undergoing 
aortic valve replacement, TAVR prostheses have better hemodynamic 
profile at discharge, in terms of higher effective orifice area index, lower 
mean transvalvular pressure gradient, lower prevalence of forward low-flow 
and prosthesis-patient-mismatch, compared to the sutureless 3f Enable 
valve. However, the incidence of aortic regurgitation is significantly higher 
among patients treated with TAVR than patients submitted to a sutureless 
bioprosthesis. Nevertheless, these differences did not have prognostic 
implications since patients treated with sutureless aortic valve replacement 
had comparable mid-term survival with those treated with TAVR.





  The second part of the thesis consists of two chapters focused on MR, which 
is the second most common valvular heart disease after AS, and evaluates 
the role of the LV GLS in the diagnosis and treatment of MR disease. MR can 
be primary or secondary and Part II focuses on patients with significant MR, 
secondary to non-ischemic cardiomyopathy. 
In patients with MR, LVEF is currently considered for the decision making of 
the management. However, LVEF does not characterize the intrinsic func-
tion of the myocardium, which is merely done by GLS. Chapter 6 showed 
that patients with non-ischemic dilated cardiomyopathy and severe MR had 
significantly worse left ventricular GLS compared to those without MR and 
comparable LVEF. Additionally, the presence of severe secondary MR was 
independently associated with worse left ventricular GLS. Thus, in patients 
with severe secondary MR and reduced LVEF due to non-ischemic dilated 
cardiomyopathy, speckle-tracking LV GLS is more sensitive to uncover even 
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more impaired LV performance than LVEF does. 
In Chapter 7 patients with non-ischemic dilated cardiomyopathy and severe 
secondary MR were successfully treated with surgical or transcatheter mitral 
valve repair and were studied at medium term follow-up. The study conclud-
ed that successful correction of chronic severe secondary MR in non-isch-
emic dilated cardiomyopathy patients partly reverses the underlying LV 
pathophysiology at medium-term follow-up; the LV forward flow (stroke vol-
ume index and cardiac index) significantly increased and LV reverse remod-
eling occurred with reduction of LV end-diastolic and end-systolic volume 
index. However, LV myocardial functional recovery did not ensue, without 
any changes in LVEF and corrected GLS for LV end-diastolic volume over 
time. The type of correction, transcatheter MitraClip or surgical mitral valve 
repair, had no significant impact on changes in LV forward flow or the extent 
of LV reverse remodeling over time. 





  Part III focuses on the prognosis of AS and MR either as combined valvular 
heart disease or isolated.
The article in Chapter 8 studied patients with co-existing aortic and mi-
tral valve disease and focused on the prognostic value of detecting aortic 
and mitral valve calcification on multidetector row cardiac computed to-
mography in patients with suspected coronary artery disease. This study 
demonstrated that increased age and coronary artery calcium score were 
independently associated with valve calcification. Moreover, patients with 
valve calcification had more cardiac events in comparison to those without; 
and those with higher valve calcium volume, had even more cardiac events. 
The aortic and mitral valve calcium volume were independently associated 
with all-cause mortality and cardiovascular events in symptomatic patients 
with clinical suspicion of coronary artery disease. Thus, the volume of valve 
calcium is indicative of poorer prognosis and is an additional independent 
predictor of cardiac events.
Chapter 9 refers to the prognosis of patients with severe AS, discordant 
low-gradient and preserved LVEF treated with surgical or transcatheter aor-
tic valve replacement. This original evaluation showed that patients with pre-
served LVEF, low gradient severe AS and normal flow or LV GLS ≤-15% have 
better survival after aortic valve replacement compared to their counterparts 
with low flow or global longitudinal strain >-15%, respectively. Furthermore, 
patients with low flow (stroke volume index <35ml/m2) and concomitantly 
more impaired intrinsic myocardial function expressed by GLS >-15%, de-
spite the preserved LVEF, had significantly worse survival compared with all 
the other combinations-groups. The addition of forward flow and LV GLS to 
a clinical model including atrial fibrillation and chronic kidney disease im-
proved the risk stratification of patients with preserved LVEF, low gradient 
severe AS treated with aortic valve replacement.   
Chapter 10 studied the prognosis of patients with severe secondary MR 
and heart failure reduced ejection fraction due to non-ischemic dilated car-
diomyopathy treated with surgical restrictive mitral valve annuloplasty. The 
analysis concluded that post surgical repair, the pulmonary arterial systolic 
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pressure reduced, the LV end-diastolic and end-systolic volumes reduced 
significantly while LVEF remained unchanged. However, LV forward stroke 
volume was significantly increased at discharge and was the only hemody-
namic parameter independently associated with all-cause mortality at 3.44 
years follow-up. Thus, successful surgical mitral valve repair for secondary 
MR in heart failure patients with reduced LVEF, improves the LV hemody-
namics by increasing the LV forward flow that defines their prognosis.
Conclusions and Future Perspectives
This thesis explored the diagnosis, management and prognosis of the most common valvular heart 
diseases: AS and MR. It enlightened the most challenging conditions of each disease: the discor-
dant low-gradient severe AS and the secondary MR in non-ischemic cardiomyopathy. This thesis 
provides new insights into the use of fusion aortic valve area index, by  incorporating the measure-
ment of left ventricular outflow tract area on cardiac multidetector row computed tomography in 
the continuity equation, for the diagnosis of low-gradient AS. For the treatment of low-gradient AS, 
TAVR is shown to result in reverse LV remodeling and functional recovery. In comparison to other 
minimal invasive surgical methods it results in less prosthesis-patient-mismatch although paraval-
vular aortic regurgitation is a caveat. Regarding the diagnostic assessment of secondary MR due to 
LV dysfunction this thesis concluded that LV GLS reflects the real LV dysfunction while LVEF overes-
timates LV function without accounting for the forward LV flow. Mitral valve repair offers LV reverse 
remodeling and increase in forward flow when used for the treatment of this challenging condition. 
Regarding the prognostication of low-gradient AS and secondary MR this thesis advocates for the 
evaluation of the valvular calcium on cardiac computed tomography and the evaluation of LV GLS 
and forward flow that are associated with survival.
The current thesis leads the way for further research in low-gradient AS and in secondary MR so 
as the findings of the research conducted for the purpose of this thesis are further validated and 
appropriately positioned in the treatment algorithm of these conditions. Testing the fusion aortic 
valve area index in prospective studies would facilitate the identification of the optimal cut-off val-
ue that detects the worst clinical outcomes in low-gradient AS patients and dictates the need for 
treatment. A prospective study using the GLS in the decision making process of the management 
of secondary MR with patients randomized based on LVEF or based on GLS to surgical treatment 
would prove which is the best marker for intervention. Real life longitudinal studies of clinical out-
comes such as the changes in NYHA class, renal function, brain function and survival among pa-
tients with secondary MR would lead to the better understanding of the value of increased forward 
stroke volume after mitral valve repair.  
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Samenvatting
In de introductie van dit proefschrift, Hoofdstuk 1, wordt de prevalentie beschreven van de twee 
meest voorkomende hartklep ziekten, namelijk aortaklep stenose en mitralisklep insufficiëntie. 
Beide klepvitia zijn verder in groepen onder te verdelen. Zo kan voor aortaklepstenose o.b.v. de 
flow en de druk gradiënt door (en over) de aortaklep en o.b.v. de ejectiefractie van de linker ven-
trikel (LV) een patiënt verder worden gekarakteriseerd. Mitralisklep insufficiëntie wordt verder 
gecategoriseerd als primair indien de klepinsufficiëntie door een intrinsieke beschadiging van de 
klep zelf komt, en als secundair indien de klep niet goed sluit als gevolg van een gedilateerde of 
disfunctionerende LV. Door specifieker onderscheid te maken in de verschillende categorieën van 
deze twee hartklepziekten kan beter worden bepaald welke behandeling het meest geschikt voor 
de patiënt is. 
Voor het verkrijgen van een nauwkeuriger inzicht in het specifieke type van klepdysfunctie speelt 
beeldvorming met o.a. echocardiografie en computed tomografie (CT) een belangrijke rol. Niet 
alleen visualisatie van de hartklep, maar juist ook van de extra-valvulaire structuren zoals de hart-
kamers en grote vaten, kan veel pathofysiologisch inzicht geven.  Met de beeldvorming van hart-
kleppen en kamers kan een indruk worden gekregen van wat nu juist de oorzaak danwel gevolg is. 
Zo wordt bij een aortaklepstenose en bij mitralisklep insufficiëntie het functioneren van de LV sterk 
beïnvloed door de ernst van het klepprobleem maar wordt daarentegen de hemodynamiek van 
het klepprobleem dan weer door de functie en het volume van de LV functie bepaald. 
Voor een, van het klepprobleem, onafhankelijkere bepaling van de intrinsieke LV functie kan het 
meten van de contractiele verkorting van het myocard in longitudinale richting door het meten 
van de globale longitudinale strain een rol spelen. De globale longitudinale myocardiale verkor-
ting (global longitudinal strain [GLS]) kan als maat voor LV functie aanvullende inzichten geven. De 
klinische toegevoegde waarde van het op deze manier meten van de LV functie, met ook tevens 
het bepalen van het antegrade slagvolume (in tegenstelling tot de LV ejectiefractie) wordt ook be-
schreven in de introductie. 





  In deel 1 van het proefschrift is er onderzoek gedaan naar gecalcificeerde 
aortaklep stenose. In Westerse landen is dit de meest voorkomende hart-
klep afwijking en de incidentie hiervan stijgt in parallel met het verouderen 
van de populatie. In hoofdstuk 2 tot 5 is onderzocht hoe, en welke, beeld-
vormingstechnieken gebruikt kunnen worden voor het vast stellen van de 
diagnose en op wat voor manier beeldvorming de (keuze voor) behandeling 
verder kan ondersteunen.
In Hoofdstuk 2 wordt ingegaan op het accuraat vast stellen van de daad-
werkelijke ernst van de aortaklep stenose in patiënten bij wie verschillende 
echografische parameters die de ernst beschrijven discordant met elkaar 
zijn. Dit hoofdstuk gaat specifiek over patiënten bij wie er een lage gradiënt 
over de aortaklep wordt gemeten ondanks dat het berekende aortaklep op-
pervlakte kleiner is dan <0.6cm2/m2 maar de LV ejectiefractie wel ≥50% is. 
Deze patiënten hebben een zo geheten paradoxale low-gradiënt aortaklep 
stenose. Tot dusver was er in deze patiëntengroep geen goede standaard 
om onderscheid te maken tussen een matige of een daadwerkelijk ernstige 
graad van aortaklep stenose. In dit hoofdstuk wordt onderzocht of het met 
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CT planimetrisch meten van de oppervlakte van de LV uitflow verwerkt kan 
worden in de (met name in de echocardiografie gebruikte) continuïteitsfor-
mule van Bernouilli. Op deze manier kan de nauwkeurig te meten anatomie 
van CT worden gefuseerd met de echografische schattingen van drukken en 
snelheden. In dit hoofdstuk bleek met door het gebruik van deze CT-echo 
fusie parameter 52% van de patiënten met een low gradiënt ernstige aortak-
lep stenose, een echografisch aortaklep oppervlakte van <0.6cm2/m2 bij een 
toch behouden LV ejectiefractie te kunnen worden geclassificeerd tot een 
matige aortaklep stenose bij een normale flow. Bij een lage flow werd 12% 
van deze patiënten geclassificeerd. 
Hoofdstuk 3 is een review over de diagnose en behandeling van patiënten 
met hartfalen en een discordante aortaklep stenose. Dit zijn de patiënten 
met een klassieke lage flow, lage gradiënt, ernstige aortaklepstenose. Hartfa-
len is aanwezig in tot ruim 25% van de patiënten met een ernstige aortaklep 
stenose en dit bemoeilijkt de diagnose en ook het besluit voor de optimale 
behandeling. Deze patiënten hebben een lage gradiënt over de aortaklep, 
het berekende aortaklep oppervlakte is klein, <0.6cm2/m2, en de LV ejec-
tiefractie is <50% en dit laatste differentieert deze patiënten van de eerder 
genoemde patiënten met een paradoxaal lage gradiënt aortaklepstenose. 
Naast het beschrijven van de prevalentie van hartfalen in patiënten met een 
ernstige aortaklep stenose beschrijft dit artikel de specifieke diagnostische 
moeilijkheden in deze groep en wordt er een algoritme voorgesteld voor het 
bepalen van de ernst van de ziekte en het met beeldvorming bepalen welke 
patiënten het meest baat zouden hebben bij een chirurgische danwel trans-
catheter aortaklepvervanging. Hoofdstuk 4 bediscussieert specifiek de be-
handeling van deze groep patiënten. Een ernstige aortaklep stenose waarin 
er een lage gradiënt is, karakteriseert deze patiënten als een groep waarin 
het chirurgisch risico hoog is.  Omdat het risico van langdurende, open hart 
chirurgie in deze patiënten verhoogd is, worden ze eerder voor minimaal in-
vasievere transcatheter vervanging/implantatie van de aortaklep (TAVI) wor-
den verwezen. In hoofdstuk 4 blijkt dat er herstel/verbetering is van de LV 
functie in patiënten met een lage flow, lage gradiënt ernstige aortaklep ste-
nose die met TAVI worden behandeld. Dit ongeacht de LV ejectiefractie van 
de patiënten. Deze verbetering vindt plaats in de eerste 6 maanden na TAVI 
en bleek de hierop volgende 6 maanden stabiel te zijn. Deze verbetering 
van LV functie was slechts detecteerbaar met het bepalen van de intrinsieke 
longitudinale verkortingsfunctie van de LV d.m.v. GLS, en was niet detecteer-
baar indien er alleen naar de LV ejectiefractie werd gekeken. Verbeteringen 
in de longitudinale LV contractiele functie gebeurden onafhankelijk van ver-
schillende baseline karakterisieken, waaronder de LV ejectiefractie, LV mas-
sa, en de manier waarop de TAVI verricht was (transfemoraal of transapicaal). 
Verder bleken ook de absolute en relatieve wanddikten van de patiënten na 
TAVI te verminderen, maar was er alleen een verkleining van de LV volumina 
in de patiënten wiens ejectiefractie ook verlaagd was.  Al met al bleek het 
behandelen van patiënten met een lage gradiënt, lage flow ernstige aortak-
lep stenose een positieve invloed te hebben op het functioneel herstel van 
de LV functie.  
Naast de TAVI zijn er ook andere, minimaal invasievere thorax chirurgische 
methoden voor het vervangen van de aortaklep ontwikkeld, waaronder 
de chirurgische “hechtingloze” aortaklep prothese. In Hoofdstuk 5 werden 
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deze twee manieren van behandeling, TAVI vs. de chirurgisch “hechtingloze” 
aortaklep prothese met elkaar vergeleken in een cohort waarin de patiënten 
van beide behandelingen d.m.v. propensity score aan elkaar werden gemat-
ched. Er werd zowel gekeken naar de hemodynamische als klinische uitkom-
sten van beide behandelingen. In chirurgisch hoog risico patiënten met een 
ernstige aortaklep stenose bleken de TAVI prothesen qua hemodynamiek 
op een aantal parameters bij het ontslag gunstigere waarden op te leveren 
dan de “hechtingloze”  chirurgische kleppen. Bij de TAVI prothesen was het 
geïndexeerde, effectieve openings oppervlakte van de klep groter, was er 
een lager percentage patient-prothese mismatch en bleek de transvalvulai-
re drukgradient over de prothese lager te zijn. De incidentie van kunstklep 
lekkage was echter wel groter in de patiënten die een TAVI hadden gekregen 
vs. de patiënten die met een “hechtingloze” kunstklep waren behandeld. Op 
de middellange overleving was er echter geen verschil tussen beide typen 
van behandeling. 
DEEL II – MITRALIS 
KLEP LEKKAGE 
– DIAGNOSE EN 
BEHANDELING 
  Het tweede deel van het proefschrift bestaat uit 2 hoofdstukken die zich rich-
ten op mitralisklep insufficiëntie, de tweede meest voorkomende hartklep 
ziekte. Er wordt specifiek gekeken naar de rol die de longitudinale contrac-
tiele LV functie speelt bij de diagnose en behandeling van patiënten met een 
mitralisklep insufficiëntie. In tegenstelling tot primaire klepschade, wordt bij 
secundaire mitralisklep insufficiëntie de lekkage met name veroorzaakt door 
dysfunctie en remodeling van de LV.  
In de huidige besluitvorming in deze patiënten speelt de ejectiefractie van 
de LV een grote rol in zowel de diagnostiek als behandeling. Echter, met de LV 
ejectiefractie wordt niet de intrinsieke contractiele functie van het myocard 
bestudeerd, en dit gebeurt wel met bepalen van de eerder genoemde GLS. 
In Hoofdstuk 6 wordt aangetoond dat in patiënten met een non-ischemi-
sche, gedilateerde cardiomyopathie en een ernstige miltralisklep insufficiën-
tie, de GLS verminderd is t.o.v. patiënten met een vergelijkbare ejectiefractie 
maar zonder ernstige mitralisklep insufficiëntie. Verder was ook omgekeerd 
de aanwezigheid van een ernstige mitralisklep insufficiëntie onafhankelijk 
geassocieerd met een verminderde GLS. Speckle tracking van de LV voor het 
bepalen van de GLS blijkt dus een sensitievere maat voor het detecteren van 
een verminderde LV performance dan de LV ejectiefractie. In Hoofdstuk 7 
werd de chirurgische en transcatheter behandeling van een ernstige secun-
daire mitralisklep insufficiëntie in patiënten met een non-ischemische gedi-
lateerde cardiomyopathie bestudeerd. Na een middellange follow-up bleek 
een succesvolle correctie van de chronische, ernstige secundaire mitralis-
klep insufficiëntie een deel de LV dysfunctie en geometrische remodeling te 
kunnen herstellen. Het antegrade LV slagvolume werd groter en de eind-dia-
stolische en eind-systolische LV volumina verminderden. De mitralisklep cor-
rectie resulteerde niet in een verbetering van de LV ejectie of van de LV GLS. 
Het type van interventie, de transcatheter MitraClip of volledige chirurgie 
had geen invloed op de veranderingen in antegraad LV slagvolume of de 
mate van LV reverse remodeling. 
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  In deel III lag de focus op de prognose van patiënten met een aortaklep ste-
nose en mitralisklep insufficiëntie en dit werd nader onderzocht als aparte 
ziekten en gecombineerd.  
In Hoofdstuk 8 zijn patiënten met verkalking van zowel de aorta- als de 
mitralisklep onderzocht. Er werd specifiek gekeken naar de prognostische 
waarde van het met CT detecteren van calcium op beide kleppen in patiën-
ten die gescand zijn met de verdenking op coronairlijden. Calcificatie van 
beide kleppen bleek geassocieerd te zijn met een toenemende leeftijd en 
ook met de calciumscore van de coronairen. In patiënten met valvulair calci-
um ontstond er vaker een cardiaal event dan patiënten die dit niet hadden; 
verder bleek ook dat hoe hoger het valvulair calcium volume was, hoe meer 
cardiale events er optraden. In deze patiënten met de verdenking op coro-
nair lijden, was het calcium volume van de aorta- en mitralisklep onafhanke-
lijk geassocieerd met een hogere, algehele mortaliteit en met het optreden 
van cardiovasculaire events.  Hieruit blijkt dat het valvulaire calcium volume 
een additieve indicator is voor toekomstige cardiale events. 
In Hoofdstuk 9 werd onderzocht wat de prognose is van patiënten met een 
ernstige aortaklepstenose en een discordant lage gradiënt bij een behou-
den LV ejectiefractie die behandeld werden met een chirurgische of transca-
theter vervanging van de aortaklep. In deze groep van patiënten hadden de 
patiënten met een normale flow of een behouden GLS van ≤-15% een bete-
re overleving na aortaklepvervanging in vergelijking met de patiënten met 
een low flow of GLS >-15%. De groep van patiënten met een lage flow en 
(slag volume index <35ml/m2) en tevens een matige LV functie (GLS >-15%) 
had de slechtste prognose t.o.v. de andere groepen. Het toevoegen van de 
voorwaartse flow en van de GLS aan een klinisch model met atriumfibril-
leren en chronisch nierfalen bleek van toegevoegde waarde voor de risico 
stratificatie van patiënten met een lage gradiënt, ernstige aortaklepstenose 
en behouden LV ejectiefractie die een aortaklep vervanging ondergaan. 
In Hoofdstuk 10 werd de prognose bestudeerd van patiënten met systo-
lisch hartfalen o.b.v. een non-ischemische gedilateerde cardiomyopathie 
en hierbij een ernstige secundaire mitralisklep insufficiëntie die chirurgisch 
werden behandeld met een restrictieve mitralisklep annuloplastiek. Uit de 
analyse bleek dat na reparatie van  de mitralisklep de pulmonaaldrukken wa-
ren verlaagd en dat de eind-diastolische en systolische LV volumina waren 
verminderd. De LV ejectiefractie bleef onveranderd. Het antegrade LV slag-
volume steeg significant bij ontslag en dit was de enige hemodynamische 
parameter die geassocieerd bleek met de algehele mortaliteit na 3.44 jaar 
follow-up. Een succesvolle, chirurgische reparatie van de mitralisklep in pa-
tiënten met een non-ischemische cardiomyopathie, verminderde LV ejectie-
fractie en een secundaire mitralisklep insufficiëntie leidt tot een betere LV 
hemodynamiek door het verbeteren van het antegrade slagvolume en dit 
beïnvloedt de prognose. 
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Conclusie en Toekomst Perspectieven 
In dit proefschrift werd onderzoek gedaan naar de diagnose, behandeling en prognose van de 
twee meest voorkomende hartklep ziekten: aortaklep stenose en mitralisklep insufficiëntie. In-
gewikkelde situaties waarin deze ziekten kunnen voorkomen werden nader onderzocht: ernstige 
aortaklepstenose met een discordant lage gradiënt en secundaire mitralisklep insufficiëntie in een 
non-ischemische cardiomyopathie.  
Met het gebruiken van een fusie parameter waarin de anatomische oppervlakte van de aortaklep 
opening werd gemeten op CT en waarbij deze waarde werd geïncorporeerd in de continuïteitsfor-
mule met hemodynamische, echocardiografisch parameters kunnen er nieuwe inzichten worden 
verkregen in de diagnostiek van een aortaklepstenose met een lage gradiënt. Wat betreft de be-
handeling van een lage gradiënt aortaklepstenose toonde dit proefschrift dat TAVI voor reverse 
remodeling en functioneel herstel van de LV kan leiden. In vergelijking met andere, minimaal inva-
sieve chirurgische methoden resulteerde TAVI tot minder patiënt-prosthese mismatch maar blijft 
paravalvulaire lekkage een punt van aandacht.  
Voor secundaire mitralisklep insufficiëntie bleek in patiënten met LV dysfunctie o.b.v. een non-ische-
mische cardiomyopathie dat GLS een betere detectie maat voor LV dysfunctie was dan de LV ejec-
tiefractie welke geen onderscheid kan maken tussen antegrade en retrograde flow. In deze groep 
blijkt het chirurgisch repareren van de mitralisklep tot reverse remodeling van de LV te leiden met 
ook een verbetering van de antegrade flow.  
Voor prognose bleek verder uit dit proefschrift dat het met CT bepalen van het valvulair calcium vo-
lume en het echografisch meten van de LV GLS en antegrade flow van prognostisch belang kan zijn 
met een impact op de overleving. Na aanleiding van dit proefschrift kan verder onderzoek worden 
verricht naar de aortaklepstenose met een lage gradiënt, en naar secundaire mitralisklep insuffici-
entie zodat dan de huidige resultaten en voorstellen voor behandelingsalgoritmen kunnen worden 
gevalideerd. Voor het definiëren van de optimale afkapwaarden voor de CT-echo gefuseerde aort-
aklep oppervlakte index voor het bepalen of patiënten baat zouden kunnen hebben bij een inter-
ventie zijn er prospectieve studies nodig. Ook wat betreft het gebruik van GLS in de besluitvorming 
voor chirurgie in patiënten met een secundaire mitralisklep insuffiëntie zijn prospectieve studies 
nodig waarin patiënten worden gerandomiseerd voor chirurgie o.b.v. GLS vs. LV ejectiefractie. Lon-
gitudinale uitkomst studies na mitralisklep chirurgie waarin gekeken wordt naar veranderingen in 
hartfalen-klasse, nierfunctie, hersenfunctie en overleving zijn nodig voor het beter op waarde kun-
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